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Invasive pests impact the environment, economy and society. Current control methods 
are costly and largely inadequate, and they often lead to unwanted suffering in target and 
non-target species. Gene drives that enable super-mendelian inheritance of a transgene 
may offer a more cost-effective, humane and species-specific alternative to current 
methods. By harnessing gene drives to distort the sex-ratio of the breeding population it 
may be possible to control a population’s reproductive success. Using CRISPR-Cas gene 
editing technology, this PhD project aimed to design, model and engineer a safeguard 
gene drive, known as a split gene drive, in mice that could spread female infertility through 
a laboratory-contained mouse population. Three gene drive strategies were designed 
and in silico modelled in wild mouse populations. Reagents were generated to engineer 
two of the three split gene drive strategies using mouse embryonic stem cell technology. 
Both these approaches aim to disrupt an essential female fertility gene (OOEP) to confer 
a recessive female-infertility phenotype. Split gene drive harbouring mouse embryonic 
stem cells were engineered using plasmid donor-DNA and a combination of SpCas9 
ribonucleoprotein or plasmid-based AsCas12a endonuclease. Engineered cells were 
screened through a pipeline, which included analyses by PCR, droplet digital PCR, 
Sanger sequencing and functional testing of the integrated transgenic systems. These 
validated split gene drive embryonic stem cells and the corresponding regulatory approval 
for animal testing now allows for two split gene drive mouse models to be generated by 
blastocyst injection of the engineered cells. It is hoped that the findings from this PhD 







Invasive pests are a global concern that impact our environment, economy and society. 
Examples of damaging invasive pests include rabbits and feral cats in Australia, mink and 
grey squirrel in the United Kingdom, wild boar in the United States, and the widespread 
infestation of rats and mice around the globe. It is estimated that in the United States 
alone, introduced rats cost the economy more than US$27 billion per year. To counter the 
impact of invasive pests, control measures are used, such as shooting, trapping and 
poisoning, which are brutal, costly and often lead to unwanted animal suffering in both 
targeted pests and non-targeted native animals. Gene drive technology may offer a 
humane, cost-effective and species-specific alternative. In most cases a particular gene 
has a 50% chance of being transmitted from parent to offspring. Gene drives are genes 
that beat the odds by being passed on to more than 50% of the offspring – that could be 
50.01% or 100% – and this advantage enables them to spread through a population. 
Using a gene editing technology, known as CRISPR, scientists can now develop gene 
drives that can spread beneficial traits through wild populations. This PhD project set out 
to design, model and engineer a safe version of a gene drive, as a proof-of-concept, that 
could spread female infertility through a laboratory-contained population of mice. By 
spreading female infertility through a population, it is possible to reduce the population 
size due to the lack of fertile females available for breeding. If most females in the 
population are infertile, the population will reduce in size but if all females are infertile the 
population will collapse. This approach could be used as a humane pest management 
tool. Within this PhD project, gene drive strategies for this purpose were designed and 
computationally simulated in mouse populations. Two safeguarded gene drive 
approaches were selected for further development. These two safeguarded strategies will 
only work in laboratory mice and not in wild mice, protecting wild mice from unintentional 
release. CRISPR gene editing tools were developed and used to introduce the gene 
drives into the DNA of mouse cells. These modified mouse cells that carry the gene drives 
in their DNA can now be used to generate two gene drive mouse models for further study 
in laboratory-contained mouse populations. The results from this PhD project will help 
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1.1 Invasive vertebrate pests 
In agriculture and wildlife, invasive vertebrate species are well known around the globe. 
Although their spread can have beneficial aspects, invasive species can disrupt 
ecosystems, impede biodiversity and threaten livelihoods. Damaging invasive species are 
classified as invasive pests and examples include: rabbits (Oryctolagus cuniculus) and 
feral cats (Felis catus) in Australia, American mink (Neovison vison) and grey squirrel 
(Sciurus carolinensis) in the United Kingdom (UK), European starling (Sturnus vulgaris), 
Burmese pythons (Python bivittatus) and wild boar (Sus scrofa) in the United States of 
America (USA), and the omni-present infestation of rats and mice around the globe (Krull 
et al., 2014; Robertson et al., 2017; Witmer & Fuller, 2011). The burden of invasive pests 
has been worsened in recent times by the increases in global trade, travel and climate 
change (Early et al., 2016). Current pest management tools for vertebrate pests are crude, 
costly, inhumane and often inadequate to cope with the scale of the problem. The ability 
to humanely control damaging invasive pests has long been a goal of scientists. 
Of the numerous invasive vertebrate pests, mice and rats (Muridae) are recognised as 
some of the most prolific. At an economic level, the worldwide losses caused by mice and 
rats are enormous. It has been conservatively estimated that in Asia, each year, rats 
consume over 30 million tons of rice. That is enough rice to feed 180 million people per 
year (Singleton, 2003). In outbreaks years, domestic damage to Australian wheat reduced 
the country’s total agricultural production by 3 to 4% (Singleton, 1997). It is estimated that 
in the US alone, introduced rats cost the economy more than US$27 billion per year 
(Pimentel, 2007). In addition to agricultural impacts, a number of mice and rats serve as 
reservoirs of disease of humans and livestock. For example, in North America the white-
footed mouse (Permomyscus leucopus) is a major reservoir for Lyme disease (Snow, 
2019). In many countries and oceanic islands, rodents are also a major cause of reduction 
in bird populations due to their predation of native bird eggs (Howal et al., 2007; Towns, 




Current efforts to eradicate rats and mice include the use of traps, poisons, and biological 
controls, such as the introduction of predators or diseases (Figure 1.1). Application of 
rodenticides can be expensive due to costs associated with regulation compliance, 
dispersal methods, size of the treated area, and the toxicant itself (Meerburg, Brom, & 
Kijlstra, 2008). Mechanical traps are often considered more humane than rodenticides 
because they do not involve the use of chemicals that could adversely affect non-target 
animals, humans or overall ecosystem health (Lorvelec & Pascal, 2005; Witmer & Fuller, 
2011). However, placing traps and collecting the caught animals is labour intensive, traps 
do not discriminate between target and non-target organisms, and traps are insufficient 
to fully eradicate a rodent population without the use of other methods (Lorvelec & Pascal, 
2005). Scientists may now be able to utilise the growing body of knowledge on selfish 
genetic elements and recent advances in genome engineering technologies to develop 
species-specific, humane and cost-effective genetic pest management tools. 
 
 
Figure 1.1 Invasive vertebrate pests are a global concern that impacts the 
environment, economy and society. As a result, control measures are deployed, which 
are considered to be inhumane, costly, and often inadequate to deal with the scope of the 
problem. Image from McFarlane, Whitelaw, and Lillico (2018). 
 
1.2 Selfish genetic elements 
Selfish genetic elements are described as an exception to the conventional rules of 
inheritance. First described in 1866 by a monk named Gregor Mendel, the conventional 
rules of inheritance, also known as Mendelian inheritance, dictate offspring have a 50% 
chance of inheriting a gene from one of their parents. With Mendelian inheritance, not all 
offspring will inherit the gene, and so the frequency of that gene in future generations will 
be similar to the frequency of that gene in the parents’ generation. With selfish genetic 
elements, offspring have more than a 50% chance of inheriting a genetic element from a 
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parent, and so a specific genotype will increase in the population over time. Such an 
element is said to ‘drive’ within a population (Burt & Trivers, 2006; Esvelt et al., 2014). 
Scientists have known about selfish genetic elements that violate Mendel’s rules since 
the late 1880s. At a molecular level, they are sequences of DNA, such as genes or their 
fragments, all or parts of chromosomes, or noncoding DNA, for which inheritance is 
biased in their favour (Burt & Trivers, 2006). These elements achieve drive through one 
or more of three key mechanisms (Figure 1.2): 1. Interference: with this strategy a gene 
gains an advantage by disrupting the transmission of an alternative gene. An example of 
a selfish element that operates by interference is the t-haplotype in mice (see section 
1.2.2). 2. Over-replication: these elements bias their transmission to the next generation 
by being replicated more than other genes in an animal. A good example is transposable 
elements. 3. Gonotaxis: where genetic elements bias movement towards the germ line. 
Some B-chromosomes, which are accessory chromosomes that are not essential for the 
life of a species, act selfishly by replicating themselves and moving to the germline and 
avoiding the somatic cells. (Burt and Trivers, 2006). 
 
 
Figure 1.2 Examples of the three known primary mechanisms by which selfish 
genetic elements achieve ‘drive’. Interference. A killer gene (K) is able to kill non-K 
bearing sperm. This would benefit the K gene’s chance of fertilising an egg. b. Over-
replication. A transposable element (T) makes a second copy of itself and one daughter 
cell inherits one copy while the other inherits two copies. c. Gonotaxis. A B-chromosome 
replicates itself and both copies move to the germline and avoid the somatic cells. Image 
adapted from Burt and Trivers (2006). 
 
One important particularity of selfish genetic elements is that they do not need to make 
any contribution to the reproductive success of the host organism in order to drive 
successfully (Burt & Trivers, 2006). In addition to the examples highlighted in Figure 1.2, 
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homing endonuclease genes and meiotic drivers represent two important examples of 
natural selfish genetic elements, having evolved several times in different taxa. Due to the 
significance of meiotic drives and homing endonuclease genes in the development of 
engineered selfish gene elements, I have briefly described these elements below. 
1.2.1 Homing endonuclease genes 
Homing endonuclease genes (HEGs) achieve drive through an over-replication 
mechanism. These genes are situated on a chromosome within a specific DNA sequence 
that they recognise and cut. They encode an endonuclease that cuts the recognition 
sequence on the chromosome that is homologous to the one originally containing the 
HEG. After the sequence is cut, homologous recombination (HR) is used to copy the HEG 
into the cut in the homologous sequence. When this process occurs in the germline, the 
proportion of gametes that contain the HEG is greater than 50% and therefore the HEG 
can drive itself through the population (Fraser, 2012). HEGs are present in eukaryotic 
organisms, archaea, and bacteria, where their recognition sequences are found at low 
frequencies in the genome (Jasin, 1996). Well characterised examples of HEGs include, 
the fungal homing endonuclease I-PpoI from Physarum polycephaleum and I-SceI from 
Saccharomyces cerevisiae, which target 15 bp and 18 bp DNA motifs, respectively 
(Belfort & Bonocora, 2014; Windbichler et al., 2007).  
1.2.2 Meiotic drive 
Meiotic drive is a method by which a selfish genetic element can achieve drive through 
an interference mechanism (McDermott & Noor, 2010). In vertebrates, the most studied 
natural meiotic drive is the t-haplotype in the house mouse (Mus musculus; Ardlie, 1998; 
Silver, 1993). The t-haplotype consists of a series of linked, independent T-complex 
distorter genes and a T-complex responder gene that are inherited together. When 
present in the heterozygous (Tt) condition in the male, the wild-type sperm show motility 
defects and are functionally inactive, so more than 90% of the progeny receive the t-
haplotype. This requires the combined action of the distorter genes, which attacks 
gametes, and a responder gene, which protects gametes carrying the t-haplotype. This 
action leads to morphological defects in spermatozoa that do not carry a t-haplotype due 
to excessive activation of the chromosome 17 gene SMOK (Bauer et al., 2012; Bauer et 





1.3 Harnessing evolution 
Although selfish genetic elements have been recognised by the scientific community since 
the late 19th century, the idea to using these elements as a means to control natural 
populations did not surface until the mid-20th century (Burt & Trivers, 2006). In 1960, 
Craig, Hickey & Vandehey suggested using a breeding program in which a “male-
producing factor” that is naturally present in some male mosquitoes could be harnessed 
to control mosquito populations. Hickey and Craig (1966) went on to identify the genomic 
region responsible for this phenomenon. Their logic behind this control strategy was that 
when male mosquitoes with this male producing factor breed, most of their offspring then 
develop as males. Environmental releases of mosquitoes carrying this male-producing 
factor could potentially “reduce the number of females below the level required for efficient 
disease transmission” (Craig, Hickey, & Vandehey, 1960).  
In the 1960s, Craig, Hickey and the other early pioneers did not yet have the molecular 
tools to engineer animals harbouring desirable genes. More than 30 years of basic 
biological research in genetics and molecular biology took place before potential genetic 
engineering tools became available. In 2003, Austin Burt proposed using HEGs to drive 
modified genes through a population (Burt, 2003). It was Burt’s seminal work describing 
his idea, in combination with advanced knowledge about genetics and modern molecular 
tools that bolstered the field of inquiry into synthetic ‘gene drives’.  
1.4 What are gene drives? 
There is a growing acceptance that the term ‘gene drives’ simply refers to engineered 
selfish genetic elements. As noted above, since the 1960’s researchers have imagined 
that selfish genetic elements “might serve as the basis for ‘gene drives’ capable of 
spreading engineered traits through wild populations” (Esvelt et al., 2014). However, the 
terms ‘gene drive’ and ‘selfish genetic element’ are still used interchangeably. In a recent 
report by the National Academies of Sciences (2016), they defined gene drives as 
systems of biased inheritance in which the ability of a genetic element to pass from a 
parent to its offspring through sexual reproduction is enhanced. Therefore, the result of a 
gene drive is the preferential increase of a specific genotype from one generation to the 
next, and potentially spread throughout the population. Figure 1.3 illustrates an idealised 





Figure 1.3 Mendelian and gene drive inheritance. Left: Mendelian inheritance of an 
altered gene. Right: Inheritance of a gene drive. Image from McFarlane et al. (2018). 
 
Although this thesis concentrates on gene drives for controlling populations of invasive 
vertebrate pests, these elements have been proposed for numerous applications; perhaps 
the most prominent of these is to reduce populations of malaria-transmitting mosquitoes 
(Adelman & Tu, 2016; Galizi et al., 2014; Hammond et al., 2016). In this context, gene 
drives could provide a new means of tackling a disease that still infects 200 million people 
and causes 400,000 deaths each year (World Health Organization, 2019). Other potential 
applications outside pest control include genetically immunising populations of animals 
against disease and improving the sustainability of agriculture by reducing the need for 
and toxicity of pesticides and herbicides (Esvelt et al., 2014). Synthetic gene drives could 
have remarkable benefits for the environment, society and the economy. 
1.5 Classical genetic engineering 
In order to develop synthetic gene drives scientist required precision genetic engineering 
technologies. Precision genetic engineering focuses on generating site-specific 
modifications to the genome. Initial successes in the mid 1980’s with precision genetic 
engineering were accomplished by microinjecting DNA sequences with high homology to 
the targeted genomic sequence into cells (Smithies et al., 1985). These experiments 
utilised a homologous recombination (HR) dependent approach, which took advantage of 
the cell’s own DNA repair machinery to replace a targeted genetic locus with an introduced 
DNA sequence. However, the targeted engineering events occurred at very low rates 
(around 1 in 3x104 cells, but this varied between cell types; Capecchi, 1989)  
1.6 Nuclease-assisted genetic engineering 
A key breakthrough in the field of genetic engineering was the realisation that double-
stranded DNA breaks (DSBs) greatly stimulated cellular DNA repair mechanisms (Rouet, 
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Smih, & Jasin, 1994; Smih et al., 1995). All eukaryotic cells efficiently repair DSBs using 
one of three primary pathways: non-homologous end-joining (NHEJ), microhomology-
mediated end-joining (MMEJ) or a via a form of HR, known as homology directed repair 
(HDR). NHEJ simply joins the broken ends of the DNA, often creating small insertion or 
deletion mutations (indels); MMEJ can occur when short microhomologies exist, both 
upstream and downstream of the DSB, the two microhomologies can be annealed, often 
resulting in deletions of the intervening sequence; HDR uses a homologous DNA template 
to replace the broken region with high fidelity (Liu, Rehman, et al., 2019; Sakuma et al., 
2016; Yanik et al., 2018). Thus, the induction of directed DSBs at a genomic locus of 
interest can greatly stimulate HDR-based genetic engineering efficiency (Figure 1.4). As 
targeted DSBs in the genome could be introduced by nucleases, this method has become 
known as nuclease-assisted genetic engineering. It is the same premise that HEGs have 
naturally evolved to use and the logic behind Austin Burt’s idea of applying HEGs for 
developing synthetic gene drives. 
 
 
Figure 1.4 Nuclease-assisted gene targeting. A double strand DNA breaks (DSB) from 
a site-specific nuclease could lead to precise modification through homology directed 
repair (HDR) in the presence of a DNA repair template, in the form of double stranded 
DNA or a single strand DNA oligonucleotide, both of which must contain homology arms. 
DSBs can also be repaired through non-homologous end joining (NHEJ), which frequently 
leads to small insertions and deletions (indels), or microhomology-mediated end-joining 




Early nuclease-assisted genetic engineering experiments using HEGs demonstrated that 
DSBs increased the frequency of template integration (Rouet et al., 1994). Working with 
Austin Burt, Windbichler et al. (2011) did go on to describe the use of a HEG in the creation 
of a gene drive in mosquitoes. In this instance, a transgenic mosquito was created with a 
cleavage site near a fluorescence gene, and, upon expression of the HEG from a donor 
DNA plasmid, the site was cut, allowing for copying of the HEG into the target site through 
HDR. The increased transmission of the HEG demonstrated these nucleases have 
potential for developing gene drives. However, the practical utility of HEGs to target any 
genomic loci at will was limited by the long and highly-specific DNA recognition sequences 
(14 to 40 bp) of these enzymes. Furthermore, the engineering of HEGs was extremely 
challenging for the majority of researchers because the DNA recognition sites and 
cleavage functions of these enzymes are intertwined in a single domain (Burt & 
Koufopanou, 2004; Rocha-Martins et al., 2015; Sander & Joung, 2014). 
Fortunately, the possibility of manipulating genomes at will captivated scientist’s attention 
from all corners of biology and the initial challenges posed by early genetic engineering 
tools were soon overcome by the development of a new genre of truly programmable 
nucleases. 
1.7 ZFNs and TALENs 
Programmable nucleases have transformed the field of genetic engineering. This class of 
nucleases can be engineered to bind to a specific nucleotide sequence in the genome 
and subsequently generate a DSB at a user defined site. ZFNs and TALENs were the first 
classes of programmable nuclease to be developed. 
Both these nucleases are engineered DNA binding proteins that facilitate targeted cutting 
of the genome much like a HEG (Pratt et al., 2012). ZFNs combine a nuclease domain 
derived from a specific restriction enzyme (typically FokI) with a DNA binding domain 
mediated by zinc fingers and can be used to target user-defined DNA sequences. Each 
zinc finger typically binds 3 nt with contact to a fourth. Specificity of each zinc finger is 
influenced by the neighbouring zinc fingers, which are set in an array of 3-4 for each arm 
of a ZFN (Figure 1.5). Each arm is targeted against a DNA strand in a tail-to-tail 
orientation. The ZFNs function as pairs because the enzymatic domains must form dimers 





Figure 1.5 A schematic representation of zinc finger nuclease (ZFN) structure. Each 
ZFN is composed of a zinc-finger protein (ZFP) DNA binding domain and a FokI nuclease 
domain. Image adapted from Kim and Kim (2014). 
 
Like ZFNs, Transcription Activator-Like Effector Nucleases (TALENs) typical utilise the 
same nuclease domain from FokI and so function as dimers. In place of the zinc finger, 
TALENs use an alternative DNA binding domain called a Transcription Activator-Like 
effector (TALE), derived from the plant pathogenic bacterium Xanthomonas (Boch & 
Bonas, 2010). Each TALE contains a series of 33-35 amino acid repeat domains where 
each repeat recognises a single base. The specificity of each TALE is conferred by the 
repeat-variable di-residue (RVDs), which are two hypervariable amino acids that interact 
with the nucleotide sequence (Figure 1.6). Like ZFNs, each arm of a TALEN is targeted 
against a DNA strand in a tail-to-tail orientation, to dimerize the FokI nuclease in order to 
induce a DSB at the target sequence (Kim & Kim, 2014; Nemudryi et al., 2014). 
 
 
Figure 1.6 A schematic representation of transcription activator-like effector 
nuclease (TALEN) structure. Each TALEN is composed of DNA binding Transcription 
Activator-Like effector (TALE) domain and a FokI nuclease domain. Each TALE repeat is 
comprised of 33–35 amino acids and recognizes a single base pair through the amino 
acids at positions 12 and 13, which is called the repeat-variable di-residue (RVD; shown 




Although both ZFNs and TALENs are highly specific genome editors that have 
successfully modified the genome of many species, including,  mice, rats, zebrafish, fruit 
flies, nematodes, rats, livestock and even monarch butterflies, their creation can be time-
consuming and labour-intensive; requiring a new protein pair to be created for every DNA 
sequence to be edited (Gaj, Gersbach, & Barbas, 2013; Mao et al., 2013). Simoni et al. 
(2014) showed that ZFNs and TALENs could be used to develop gene drives much like 
HEGs, with homing frequencies of 34% and 49% to available target loci, respectively, in 
Drosphila melanogaster. In many instances, though, these systems are not transmitted 
faithfully due to the number of repetitive elements within their design and their subsequent 
tendency to recombine, leading to their loss of function. 
Then, CRISPR arrived (Cong et al., 2013; Jinek et al., 2012; Lander, 2016). 
1.8 CRISPR-Cas 
The arrival of the RNA-guided CRISPR-Cas (Clustered regularly-interspaced short 
palindromic repeats-CRISPR associated protein) system has been game changing. The 
system was first observed in Escherichia coli in 1987 by its striking genomic structure 
(Ishino et al., 1987). Evolved as an adaptive immune system in bacteria and archaea, the 
system uses a set of Cas genes to incorporate exogenous DNA into the CRISPR locus, 
and subsequently transcribe them as RNA templates that guide the Cas proteins to cleave 
invasive DNA or RNA (Horvath & Barrangou, 2010). However, the system was not 
repurposed into a genome editing tool until 2012 when Jinek et al. published their seminal 
paper. Three major types of CRISPR-Cas systems have been identified, differing in their 
targets as well as mechanisms of action. Type I and III CRISPR systems employ an 
ensemble of Cas genes to carry out RNA processing, targeting and target site cleavage. 
By contrast, the type II CRISPR-Cas systems uses a single nuclease to cleave target 
DNA. Among the three types of CRISPR-Cas systems, the type II CRISPR-SpCas9, 
derived from Streptococcus pyogenes and CRISPR-AsCas12a (formerly AsCpf1) from 
Acidaminococcus sp. are presently the most suitable and widely used as a genome 
editing tools (Mojica & Montoliu, 2016; Yao et al., 2018).  
1.8.1 SpCas9 
The S. pyogenes type II CRISPR-Cas system consists of a SpCas9 nuclease and two 
RNAs; CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA). The crRNA 
and tracrRNA hybridise to form a guide RNA (gRNA) before complexing with SpCas9 
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(Deltcheva et al., 2011). SpCas9 is directed to the target site by 20 nt of the crRNA by 
Watson-Crick base-pairing with the target DNA sequence (Cong et al., 2013). However, 
crRNA and tracrRNA can be fused to form a 102 nt single guide RNA (Jinek et al., 2012), 
which is also referred to as a gRNA within this thesis. Once the gRNA guides the SpCas9 
to the target site, cleavage of the target site only occurs if a protospacer adjacent motif 
(PAM), a defined 3 nt sequence at the 3’ end of the crRNA sequence is present. For 
SpCas9, the PAM sequence is 5’-NGG, although it can recognise other noncanonical 5’-
NAG and 5’-NGA PAMs to a lesser extent (Hsu et al., 2013). At an overall structural level, 
SpCas9 contains two nuclease domains, HNH and RuvC, each of which cleaves one 
strand of the target DNA (Figure 1.7). In SpCas9, these domains cleave 3 bp upstream 
from the PAM sequence, leaving blunt ends (Anzalone, Koblan, & Liu, 2020; Garneau et 
al., 2010; Hsu et al., 2013). 
 
 
Figure 1.7 A schematic representation of Streptococcus pyogenes Cas9 (SpCas9). 
SpCas9 is programmed here with a single guide RNA (gRNA; purple). The gRNA in this 
case is a single gRNA comprising a site specific CRISPR RNA (crRNA) and an auxiliary 
trans-activating crRNA (tracrRNA). Two nuclease domains (RuvC and HNH) both cut one 
DNA strand 3 bp upstream from the protospacer adjacent motif (PAM; 5’-NGG) to 







Unlike SpCas9, the Acidaminococcus sp. Cas12a (AsCas12a) endonuclease only 
requires a short 42–44 nt crRNA and no tracrRNA. As AsCas12a does not require a 
tracrRNA, the crRNA is often referred to as the gRNA. The first 19-20 nt corresponding to 
the repeat sequence and the remaining 21-25 nt to the spacer sequence. AsCas12a 
recognises a T-rich PAM (5′-TTTN) which is situated upstream of the 5' end of the non-
target strand and generates dsDNA breaks with staggered 5′ ends at the 19 and 23 nt 
relative to the PAM sequence (Figure 1.8; Zetsche et al., 2015). It has been shown that 
AsCas12a processes its own pre-crRNA into mature crRNAs, without the requirement of 
a tracrRNA, making it a unique effector protein with both endoribonuclease and 
endonuclease activities (Zetsche et al., 2017). AsCas12a’s ability to process crRNA 
makes it an attractive option for expression of multiple crRNAs from a single transcript. 
The DNase site within AsCas12a is located in the interface between its RuvC and Nuc 
domains (Anzalone et al., 2020).  
 
 
Figure 1.8 A schematic representation of Acidaminococcus sp. Cas12a (AsCas12a). 
AsCas12a nucleases recognise DNA target sequences with complementarity to the 
CRISPR RNA (crRNA; light blue) spacer positioned next to a 3ʹ PAM (5′-TTTN). Target 
recognition results in the generation of a staggered DNA double-strand break by a RuvC 





1.8.3 CRISPR uptake and innovation 
In contrast to ZFNs and TALENs, which require the design of proteins that are encoded 
by large repetitive DNA segments (500 to 1500 bp) for each new target site, CRISPR-Cas 
can be easily adapted to target almost any genomic sequence by simply exchanging the 
crRNA sequence. The Cas protein component remains unchanged, alleviating the need 
for complex protein engineering. Therefore, the reagents are simple, cheap, and quick to 
design and generate (Gupta & Musunuru, 2014). Since being repurposed into a genome 
editor in 2012, there has been a flurry of research activity around the technology and an 
ever expanding toolbox of CRISPR-Cas reagents, including base-editors and nickase 
systems, which can mediate editing without the need for introducing DSBs (Anzalone et 
al., 2019; Komor et al., 2016). With these successive innovations, CRISPR-Cas tools 
have become widely adopted for a multitude of basic and applied research applications, 
with some translation now progressing into medicine and industry. 
1.8.4 CRISPR-based gene drives 
CRISPR-Cas facilitates the capability to engineer synthetic gene drives in a standard 
molecular laboratory. SpCas9-based gene drives have been developed in yeast (DiCarlo 
et al., 2013), D. melanogaster (Gantz & Bier, 2015), two species of mosquitoes (Gantz et 
al., 2015; Hammond et al., 2016) and most recently in mice (Grunwald et al., 2019). These 
studies have demonstrated potential mechanisms of how gene drives could be used to 
achieve two potential outcomes: 
1. Population suppression – the spread of a genetic element that causes the number 
of individuals in a population to decrease. 
2.  Population replacement – the spread of a genetic element through a population 
that causes a population’s genotype to change.  
These outcomes could have remarkable impacts and scientists have already proposed a 
wide range of applications for gene drives, including to address public health threats, 
species conservation, agriculture protection and advancing scientific research. Of primary 
interest to this project are strategies that could utilise CRISPR-Cas to develop gene drives 
with the goal of achieving species-specific population suppression in vertebrate pests. 
Additional information on vertebrate population suppression can be found in Appendix 
A.1, which contains a perspective article I authored during my PhD, titled “CRISPR-Based 
Gene Drives for Pest Control”. 
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1.9 Driving population suppression 
Gene drives could enable humane population suppression by distorting the sex-ratio of a 
damaging pest population in a species-specific manner. By distorted the sex ratio of 
breeding population away from the favoured Fisherian ratio of 1:1 male to female, these 
strategies could manipulate the reproductive performance of a population. In most pest 
species, including mice and rats, female procreative capacity is responsible for 
maintaining the overall population size (Champer, Buchman, & Akbari, 2016; Hamilton, 
1967). Therefore, an efficient means of population suppression is to bias the sex ratio of 
the breeding population in favour of males. This could be accomplished by either 
spreading female infertility through a population or by ensuring all or most offspring born 
are male (Galizi et al., 2016; Hammond et al., 2016). A grossly male breeding population 
will result in a population decline, while an all-male breeding population will lead to 
eradication.  
One possibility that has been suggested and is currently under investigation is to engineer 
the t-haplotype (section 1.2.2) to carry the sex-determining Sry gene in genetic females 
so they develop as males but are sterile because they lack essential Y-linked genes for 
sperm development (Backus & Gross, 2016; Koopman et al., 1991; Manser et al., 2019). 
However, this approach is unlikely to gain traction as two laboratory studies on 
independent mouse populations have found that male mice carrying the t-haplotype only 
fertilise approximately 20% of offspring when competing against wild-type males (Manser 
et al., 2017; Sutter & Lindholm, 2015). This can be explained by the relative sperm 
competitiveness of t-haplotype males compared to wild-type males and is likely why the 
frequency of the t-haplotype in natural populations is relatively low, typically varying 
between 5 and 30% (Ardlie, 1998; Manser et al., 2011). 
Instead, within this project I choose to examine the potential of two CRISPR-based sex-
ratio distorting gene drives – (1) homing-based gene drives and (2) X-shredder – both of 
which have the potential to distort the sex-ratio of a breeding population in favour of males. 
To date, these sex-ratio distorting gene drive systems have only been engineered in 
proof-of-concept studies in mosquitoes with the focus on controlling vector-borne 
diseases (Galizi et al., 2016; Hammond et al., 2016). However, homing-based gene drives 
with the alternative aim of population replacement, rather than suppression have been 
developed in other species; including drosophila, yeast and most recently in mice (DiCarlo 




1.9.1  Homing-based gene drives 
CRISPR-based homing gene drives were theorised and named after Austin Burt’s homing 
endonuclease gene drive approach, which drive through an over-replication mechanism. 
A homing gene drive works by copying or ‘homing’ itself into a target site in the genome. 
To build a CRISPR-based homing gene drive, an animal is engineered with a gene drive 
cassette that expresses a Cas endonuclease, such as SpCas9 or AsCas12a, and one or 
more gRNAs. The Cas nuclease and gRNA/s are expressed from one allele to cut at a 
conserved target site on the sister allele on the homologous chromosome (Figure 1.9). 
After CRISPR-mediated cleavage, HDR results in the CRISPR machinery and any 
additional genetic payload (trait of interest) included in the gene drive cassette being 
copied onto the homologous chromosome. This process ensures homozygosity for the 
gene drive cassette. When this process occurs in the zygote or germ cells, the proportion 
of mature gametes in an animal that contains the gene drive cassette is greater than 50%, 
and therefore the cassette could drive itself through the population, spreading the trait of 
interest (Burt, 2003; Burt & Trivers, 2006; Champer et al., 2016; McFarlane et al., 2018). 
 
 
Figure 1.9 CRISPR-based homing gene drive (GD). The GD cassette (purple) 
expresses Cas and one or more guide RNAs that cut the sister allele on the homologous 
wild-type (WT) chromosome. The cell then repairs the cut by homology-direct repair 
(HDR), using the GD chromosome as the repair template. This process copies the GD 
cassette and any genetic payload (trait) onto the WT chromosome and ensures that most 
of mature gametes in the animal carry the GD cassette, passing on to most or all of the 




Grunwald et al. (2019) successfully demonstrated a homing-based gene drive in mice, 
capable of driving a mCherry fluorescent genetic element embedded in the mouse 
tyrosinase (Tyr) gene, through the female germline. Tyr affects mouse coat colour, which 
enabled the frequency of the gene drive to be tracked over generations by monitoring coat 
colour and confirmed by PCR-based genotyping. Their initial design ubiquitously 
expressed the SpCas9 component of the gene drive using a synthetic CAG promoter 
along with a ubiquitously expressed gRNA targeting the Tyr gene. Homologous repair 
was not observed in 180 pups born across 10 families with ubiquitous SpCas9 expression. 
Their successful gene drive design expressed SpCas9 with germline specificity, although 
the mechanism of restricting SpCas9 to the germline was crude. By crossing a Cre-
inducible SpCas9 expressing mouse (CAG–LSL–SpCas9) with a germline VASA-Cre 
expressing mouse they were able to restrict SpCas9 expression to the germline. With this 
design, they achieved up to 72% homing in the female germline, but only NHEJ was 
observed in males harbouring the same genetic construct. The reason for the sex-specific 
differences in homing efficiency requires further investigation but it is likely due to timing 
or pattern of SpCas9 expression, which may be a result of the Cre-inducible system or a 
phenomenon specific to the Tyr locus. Importantly, Grunwald and colleagues (2019) 
demonstrated that CRISPR-based homing gene drive could be applied in mammals. 
For population suppression, a homing gene drive can be targeted to a haplosufficient 
female-fertility gene (HFFG) to disrupt the coding sequence of the gene, rendering 
homozygous female offspring infertile, while males and heterozygous females will retain 
normal fertility. By targeting a homing gene drive to insert within a gene essential for 
female-fertility this disrupts the gene’s coding sequence and ensures that most female 
offspring are infertile; whilst males will retain normal fertility and continue transmitting the 
drive. With every generation, the sex-ratio of the breeding population will become more 
biased towards males, eventually resulting in a population crash (Hammond et al., 2016; 
Prowse et al., 2017). Hammond et al. (2016) developed this system in mosquito and 
achieved transmission rates of 91.4 to 99.6% in caged populations.  
In theory, homing gene drives targeting female reproduction could be adapted to control 
most vertebrate pests, including mice and rats; however, it remains unknown if such high 
transmission rates can also be achieved in vertebrates. Further investigation on the 
impact of gene drive construct size on homing efficiency is also needed. Simoni et al. 
(2014) observed no correlation between gene drive construct size and homing activity 
when testing constructs varying in size by 1.5 to 2 kb in Drosophila. Although as construct 
size in standard gene targeting experiments typically reduces HDR efficiency, it is 
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conceivable that future work will uncover a construct size threshold that lowers the homing 
activity of homing-based gene drives. 
1.9.2  X-Shredder 
An alternative to homing-based gene drive is an X-shredder (XS), which is a synthetic 
meiotic drive. In XY heterogametic species, an XS is a type of sex-ratio distorting gene 
drive that cuts the X-chromosome at multiple sites during spermatogenesis, thus 
shredding the X-chromosome beyond repair (Champer et al., 2016). To engineer a 
CRISPR-based XS, an XS cassette is inserted within a neutral intergenic region of the Y-
chromosome. The cassette encodes a Cas nuclease, which is expressed under the 
control of a spermatogenesis-specific promoter, and one or more gRNAs that target 
conserved repetitive sequences unique to the X-chromosome (Figure 1.10). Given that 
X-chromosomes will be destroyed during spermatogenesis, most sperm that mature and 
reach the oocyte are Y-bearing, resulting in a biased sex ratio in favour of males. By 
placing the XS cassette on the Y-chromosome, all male offspring will inherit the cassette 
and continue transmitting the XS to subsequent generations (McFarlane et al., 2018). 
 
 
Figure 1.10 X-Shredder (XS). During spermatogenesis, Cas and guide RNA(s) are 
expressed from the XS cassette (orange) located on the Y-chromosome (Y) and shred 
the X-chromosome (X) beyond repair. Most sperm that mature and reach the oocyte are 
Y-bearing, resulting in most offspring being XS males.  
 
A CRISPR-based XS has been engineered in mosquitoes, although the system 
expressed the XS cassette from an autosome instead of the Y-chromosome. With this 
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approach, Galizi et al. (2016) achieved male bias among progeny ranging from 86.1 to 
94.8% in laboratory-contained mosquito populations. Although successful in mosquito, 
technical challenges facing the adaption of an XS into vertebrates include identifying 
appropriate spermatogenesis-specific promoters in target species and the transcriptional 
silencing of mammalian sex chromosomes during meiosis. The latter may hinder 
expression of Cas from the Y-chromosome, as well as the accessibility of the 
endonuclease to shred the X-chromosome (McFarlane et al., 2018).  
1.10 Containing the spread 
The two forms of sex-ratio distorting gene drives described above may only require the 
release of a small number of animals to spread through an entire population. The duration 
and extent of spread would be limited by naturally arising resistant alleles that prevent 
CRISPR-mediated cleavage. Resistant alleles could exist in the population before release 
or originate from indels generated when CRISPR-mediated cleavage is repaired by the 
error-prone NHEJ pathway and alters the gRNA recognition sequence (Bull, 2015; 
Champer et al., 2016). The rate of NHEJ-mediated repair will be dependent on the 
species, target site, and the stage of development at which DNA cleavage occurs. Given 
that natural selection tends to favour equal sex ratios, resistant alleles that restore function 
would spread rapidly through the population (Hammond et al., 2017; McFarlane et al., 
2018). 
Compared to a homing gene drive, XS should be less prone to inactivation by resistant 
alleles because it targets multiple sites and, therefore, would require an animal to 
simultaneously acquire multiple resistant alleles to incapacitate the drive (McFarlane et 
al., 2018). Following a similar approach, it has been suggested that the evolutionary 
stability of homing gene drives could be improved by using multiple gRNAs closely spaced 
along the target region (Esvelt et al., 2014). Several in silico and in vivo studies have now 
demonstrated that multiple gRNAs can assist homing gene drives to evade drive 
resistance and successfully spread through pest populations (Champer et al., 2018; 
Champer, Yang, et al., 2019; Champer et al., 2020; Prowse et al., 2017). Even if drive 
resistance were to prevail, it would be possible to release a second gene drive targeting 
a different sequence to continue suppressing the population. 
Conversely, if a gene drive were not limited by naturally arising resistance, it would have 
the potential to spread indefinitely through a species. Therefore, it is essential to have 
strategies in place that could deliberately inactivate a gene drive that escaped 
containment or was causing unforeseen impacts. Fortunately, both homing gene drive 
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and XS systems can be inactivated by the release of animals bearing engineered 
functionally resistant alleles or a reversal gene drive that immunises the animal against 
the original drive (McFarlane et al., 2018). However, these reactive stop buttons are not 
ideal as timely deployment requires that appropriate animals are on hand, in sufficient 
numbers and at the required location. 
More proactive approaches are needed, and scientists are working to develop gene drives 
that are inherently self-limiting – that is, they stay in a population transiently and could 
therefore be localised to targeted populations. Several self-limiting gene drive concepts 
have been proposed and it is hoped these systems will soon be realised (Min et al., 2017a, 
2017b; Noble et al., 2016; Oberhofer, Ivy, & Hay, 2019). Of these, daisy drives have been 
the focus of several in silico population modelling studies and well publicised; daisy drives 
include: ‘daisy-chain’ and daisy-field’ drives. These systems are complex and have yet to 
be engineered in species, however, there is value in describing them here as future 
development would put the power in the hands of communities to deploy a gene drive 
locally, avoiding the need for highly complex geopolitical agreements that will be required 
for self-perpetuating gene drive systems. 
1.10.1  Daisy-chain system 
In daisy-chain drive systems, the CRISPR components are split up and scattered 
throughout the genome so that none of them can be copied on its own. Though physically 
separated, they are functionally arranged in a daisy-chain: element C causes element B 
to drive, and element B causes element A to drive. Element C doesn't drive, so its 
abundance is limited by the number of daisy drive organisms released. That means B will 
initially increase in abundance, then decline and vanish. In turn, A will increase even more 
rapidly, but eventually will run out of B and disappear (Figure 1.11a; Esvelt, 2019; Noble 
et al. 2016). 
In other words, the elements of a daisy-chain system are similar to booster stages of a 
genetic rocket: those at the base of the daisy-chain help lift the payload until they run out 
of fuel and are successively lost (Figure 1.11b). Adding more links to the daisy chain will 
spread the payload to more organisms. Releasing a daisy-chain drive organism with a 
five-element chain (E→D→C→B→A) is hundreds of times more effective than releasing 
one with only element A (Esvelt, 2019; Noble et al., 2016). In theory, daisy-chain systems 
can do anything a standard homing gene-drive system can achieve, although the 
complexity of engineering such a system and having it stably inherited with little fitness 
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cost poses a significant hurdle. Daisy-chain drives were theorised in 2016; at present, a 
daisy chain of two or more homing elements has not been reported. 
 
 
Figure 1.11 Daisy chains drive system. In a daisy chain drive system, the CRISPR 
components are separated and arranged so that each daisy element drives the next in 
the chain. The element at the end, in this case C, is not copied and is lost in half of 
offspring. In these organisms, B is no longer copied and is lost in turn; this process 
continues until the drive system stops. (b) The loss of nondriving elements to natural 
selection is analogous to gravity on a rocket. Adding more elements to the daisy chain 
allows the system to spread further before it runs out of genetic fuel and halts. Image from 
Esvelt and Gemmell (2017). 
 
1.10.2  Daisy-field system 
Another option is to use a form of daisy drive that doesn't require each of the booster 
elements to home via HDR. This significantly reduces the engineering complexity. Instead 
of a daisy-chain of linked elements (C→B→A), a daisy-field system scatters B elements 
(gRNA expression cassettes), throughout neutral loci in the genome (Figure 1.12a). As 
long as at least one of these is present, element A (Cas nuclease) will be copied, 
propagating the trait of interest. Depending of the location of the Cas nuclease, this could 
knock-out a gene of interest by disrupting the coding sequence or propagate a genetic 
cargo that contains a trait of interest. With every generation of mating with wild-type it 
halves the number of daisy B elements (gRNAs) eventually burning out as the 
generational clock winds down (Figure 1.12b; Esvelt, 2019; Min et al. 2017b). 
Compared to a daisy-chain drives, a daisy-field system should be much simpler to 
engineer. For example, the element A (Cas nuclease) could be targeted to the site of 
interested using CRISPR-assisted genome engineering and the B elements (gRNA 
expression cassettes) scattered through the genome using lentiviral integration to 
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generate a daisy field animal. Daisy field drives consisting of one B element have been 
successfully constructed as a ‘split drive’ confinement strategies (section 3.3.4.2; DiCarlo 
et al. 2015), and the engineering technicalities of increasing the number B elements 
should not be inhibitory. 
 
 
Figure 1.12 Daisy-field system. Daisy-field drive systems employ multiple daisy 
elements encoding the same guide RNAs. (a) A simple four-element daisy-field has four 
elements that target the wild-type locus harbouring the payload and CRISPR nuclease. 
Cutting and subsequent homology-directed repair (HDR) copies the payload and 
nuclease. (b) daisy-field drives are tantamount to using multiple parallel boosters, half of 
which run out of fuel and are lost in each generation of mating to wild-type organisms. 
Image from Esvelt (2017). 
 
1.11 Mice as a model organism 
Mice are the ideal species for the development and testing of population suppression 
gene drive technology in vertebrates. In addition to being well known invasive pests, at 
the population, genetic and ecological level we have more information on mice than for 
most other potential targets of genetic pest management (Berry & Scriven, 2005; Pocock, 
Hauffe, & Searle, 2005). Importantly, we also have highly developed tools for manipulating 
the genomes of mice. Scientists can either manipulate the zygote by directly introducing 
gene editing reagents or use mouse embryonic stem cell (ES) cell technology 
(Gurumurthy & Lloyd, 2019). 
Direct zygote manipulation is highly efficient for generating simple knock-out and small 
knock-in alleles, however, the generation of larger more complexed knock-in alleles (>2 
kb) requires HDR with a donor DNA plasmid, which is difficult to produce by direct zygote 
manipulation (Skarnes, 2015). In a study by Gu, Posfai, and Rossant (2018), they 
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reported that only 1 to 6.5% of zygotes co-injected with CRISPR-SpCas9 and plasmid 
repair template carried the desired modification. As such, the ‘gold standard’ for 
generating large-scale knock-in mouse models remains the well-established ES cell 
technology. With this approach, CRISPR-Cas and donor plasmid DNA are transfected 
into ES cells. Donor plasmids typically consist of homology arms (each >500 bp), the 
cassette of interest and selection markers, such as genes encoding antibiotic resistance 
or fluorescent proteins to facilitate identification of successfully transfected cells. 
Following selection, researchers can screen and expand correctly modified clones for 
injection into wild-type blastocysts to generate chimeric offspring for germline 
transmission (Gurumurthy & Lloyd, 2019; Singh, Schimenti, & Bolcun-Filas, 2015). 
Although more laborious and costly than direct zygote injection, the proven ability of ES 
cell technology to handle complex knock-in alleles, such as gene drive elements, is yet to 
be rivalled by direct zygote manipulation (Gurumurthy & Lloyd, 2019; Skarnes, 2015).  
ES cell technology makes the testing of gene drive elements much easier than for other 
species. However, it should be noted that for the vast majority of potential vertebrate 
applications of gene drive, ES cell technology does not exist as embryonic stem cells have 
not been isolated from the species. Therefore, engineering of gene drives in these target 
species will likely require genome engineering via a zygotic route. 
1.12 Public perception 
Genetically engineered animals normally come with few ecological risks. Most engineered 
traits are for human benefit and will not be favoured by natural selection. By contrast, 
gene drives can spread through populations even if they reduce the fitness of each carrier 
animal. This gives gene drives more scope to escape the target population and 
unintentionally affect extraneous ecosystems if adequate control and containment 
measures are not in place (Esvelt et al., 2014; McFarlane et al., 2018). Although technical 
and regulatory hurdles exist for the practical use of gene drive-based control of invasive 
species, perhaps the greatest hurdle to be overcome will be public acceptance of the 
technology.  
The prospects for the development and deployment of gene drive will likely hinge on public 
perception of whether the use of such new technologies is sufficiently warranted to solve 
the problems being addressed. A recent Pew Research Center study by Funk and 
Hefferon (2018) indicates public attitudes toward the use of genetic engineering on 
animals, at least in the US, tend to be supportive if the technology is being applied to a 
major human health issue (e.g. preventing disease transmitted by mosquitoes). The US 
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public was less supportive of other uses involving the environment (e.g. recovering extinct 
species as a means of restoring biodiversity). 
Whether the general public would consider the eradication of invasive species a problem 
that warrants the use of genetic engineering is yet to be determined. A landscape analysis 
by Delborne et al. (2019) on the use of gene drives in mice showed that the research 
community was concerned that gene drives would only receive public support if they could 
effectively eradicate the species, with a general concern that if implementation of gene 
drive were only partially successful, the public support for the strategy and even research 
on gene drive would be greatly diminished. 
This public perception is complicated by the fact that the science involved in invasive 
species eradication is often complex and is not currently well understood by or 
communicated to the general public. In a survey of the public on gene drive in agriculture, 
more than 85% of respondents had never heard of gene drive technology prior to receiving 
the survey (Jones et al., 2019). 
Although there are risks attached to gene drive technology, the potential benefits of gene 
drives are equally as impactful as the risks. Gene drives could revolutionize public health, 
agriculture, and as discussed here, could be applied for pest control, restoring 
ecosystems and securing livelihoods. Public attitudes will likely be determined, not by 
scientific debate regarding the risks of gene drives and mitigation strategies used to 
manage risk, but rather on the outcomes of initial trials and how these results are 
communicated.  
1.13 Project aims 
Although the relative simplicity of the X-shredder design is an attractive prospect, there is 
substantial groundwork needed to adapt this system to mammals, with the most 
significant of these hurdles being the identification of a promoter that restricts Cas-
nuclease expression to spermatogenesis. In light of this hurdle, the primary object of my 
PhD studentship has been to engineer a CRISPR-based homing gene drive targeting 
female reproduction that could be tested in a laboratory-contained population of mice. 
The development of this CRISPR-based homing gene drive system was separated into 
three sections: (1) modelling, safeguarding and strategy design; (2) reagent development 
and validation; and (3) genome engineering in mouse embryonic stem cells and genotype 
confirmation. These sections form natural demarcation for the chapters of my thesis. 
Chapter 3 focuses on identifying an appropriate gene drive strategy through in silico 
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modelling, target gene identification and integration of safeguard strategies. In addition, a 
system for in vitro testing gene drives is described. Chapter 4 describes the substantial 
reagent design, development and validation required for this project. Chapter 5 focuses 
on engineering of the gene drive system in mouse embryonic stem cells and the 
genotyping pipeline for the confirmation of engineered cell lines. 
This body of work describes all points of the gene drive development process up until the 
injection of genome engineered mouse embryonic stem cells into recipient blastocysts to 
generate gene drive transgenic mice. It is hoped that the insights gained from this work 
will contribute to the development of humane, safe, cost-effective and species-specific 






2 Materials and methods 
All chemicals were purchased from Sigma-Aldrich unless otherwise stated. 
2.1 General molecular biology 
2.1.1 Genomic DNA extraction 
Mouse ear clippings or cultured cells (other those cells in 96 well plate format) were 
collected in a 1.5 ml microfuge tube and genomic DNA (gDNA) extracted using the 
DNeasy Blood and Tissue Kit (Qiagen) following the manufacturer’s guidelines.  
To extract gDNA from cells cultured in 96 well plate (WP) format, cells were lysed with 
100 μl lysis buffer (section 2.7.4) per well and incubated at 37 °C for 16 hours. Lithium 
chloride and isopropanol DNA purification was then performed on the lysate. To do this, 
10 μl of 8 M lithium chloride and 100 μl isopropanol were added to each well and placed 
on a rocking platform for 20 minutes. The plate was then centrifuged at 16,000 x g for 20 
minutes and the supernatant discarded. Each well was washed twice with 150 μl per well 
of 70% ethanol and the resulting DNA pellet was resuspended in 40 μl of 0.1% Tris-EDTA 
(TE) buffer per well. 
2.1.2 Polymerase chain reaction (PCR) 
Unless otherwise stated, PCRs were performed using 100 ng of gDNA extracted as 
described in section 2.1.1 as template for each 50 μl of PCR master mix. A list of primer 
pairs used, and their annealing temperatures are in Appendix A.2 and thermocycling 
conditions used for each polymerase listed below can be found the Appendix A.3. 
2.1.2.1 Phusion High-Fidelity Polymerase 
Phusion polymerase by NEB was used for all PCRs for T7 endonuclease I assays (T7EI) 
and Inference of CRISPR Edits (ICE) analyses. 25 μl of 2X NEB Phusion PCR Master 
Mix with HF Buffer, 1 μl of 10 μM forward primer, 1 μl of 10 μM reverse primer, 100 ng of 
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gDNA, 10 μl of Fi-RED (section 2.7.4) were made up to a final volume of 50 μl with 
nuclease-free water.  
2.1.2.2 Q5 High-Fidelity Polymerase 
Q5 polymerase by NEB was used for all PCR amplified DNA fragments for molecular 
cloning. NEB reports an ultra-low error rate and very high-fidelity for this polymerase. 25 
μl of 2X NEB Q5 PCR Master Mix, 1 μl of 10 μM forward primer, 1 μl of 10 μM reverse 
primer, 100ng of gDNA, 10 μl of 5X Fi-RED (section 2.7.4) were made up to a final volume 
of 50 μl with nuclease-free water.  
2.1.2.3 OneTaq Polymerase 
OneTaq polymerase by NEB was used for routine screening for targeted genomic 
integration of DNA constructs in genome engineered cell lines. 25 μl of 2X NEB OneTaq 
PCR Master Mix with GC Buffer, 1 μl of 10 μM forward primer, 1 μl of 10 μM reverse 
primer, 100 ng of gDNA, 10 μl of 5X Fi-RED (section 2.7.4) were made up to a final volume 
of 50 μl with nuclease-free water.  
2.1.3 Agarose gel electrophoresis 
Agarose gels were made by dissolving UltraPure agarose (Life Technologies) in 1X Tris-
acetate-EDTA (TAE) buffer (section 2.7.4). PCR products <1 kb were run in 2% agarose 
gel, while products >1 kb were run in 1% agarose gel. For example, to make a 1% agarose 
gel, 1 g of agarose was added to 100 ml of 1X TAE and the mixture was heated in a 
microwave to completely dissolve the agarose solution. Once the gel mixture had cooled, 
8 μl of 10,000X SYBR Safe DNA stain (Thermo Fisher) was added before pouring the gel. 
The DNA samples were loaded alongside 5 μl of GeneRuler DNA Ladder Mix (Thermo 
Fisher) or GeneRuler 1 kb Ladder (Thermo Fisher) for DNA length and mass 
approximations. These were separated by running gels at a voltage between 1–10 V/cm, 
depending on the requirement, and bands were visualised and imaged on a UV 
Transilluminator Gel Dock. 
2.1.4 Purification of DNA from agarose gels and PCR reactions 
To extract DNA fragments from agarose gels, the desired bands were visualised on a blue 
light box and excised from the gel with a scalpel. DNA from the gel slices or PCR reactions 
were purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare Life Sciences). All centrifugation steps were carried out at 16,000 x g for 1 
minute. Purification was carried out according to the manufacturer’s guidelines. To purify 
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PCRs, up to 50 μl of PCR reaction was mixed thoroughly with 500 μl of Capture Buffer 3 
and then loaded directly into a GFX column. Gel slices were incubated with 500 μl of 
Capture Buffer 3 at 60 °C until the agarose was completely dissolved before loading into 
the GFX column. After loading, GFX columns were centrifuged, washed once with 500 μl 
of Wash 1, and then incubated with 25 μl of Elution Buffer 4 for 1 minute before 
centrifugation to elute the DNA from the column into a new DNase free 1.5 ml microfuge 
tube.  
2.1.5 Nucleic acid quantification 
The concentration of DNA samples was routinely estimated using a Nanodrop 1000 
spectrophotometer with the ND-1000 software (Thermo Fisher). Prior to measuring the 
DNA samples, the Nanodrop was initialised with 1 μl of deionized water and then a blank 
measurement was taken using 1 μl of the suspension solution without DNA. After 
initialising and blanking, 1 μl of the DNA solution was pipetted onto the receiving fibre 
sensor on the lowest pedestal before lowering the upper pedestal arm and taking a 
spectral measurement. The ND-1000 software calculates the concentration of the DNA 
displayed in ng/μl (one OD260 unit = 50 ng/μl of dsDNA). It also displays the 260/280 and 
260/230 absorbance ratios for each sample, which was used to assess the purity of DNA. 
A 260/280 ratio of ~1.8 is considered clean for DNA and an acceptable range for the 
260/230 ratio was between 1.8–2.2. 
2.1.6 DNA sequencing 
All DNA sequencing in this project was by Sanger sequencing through Source BioScience 
based in Nottingham, UK. To prepare samples, 5 μl of each sample at a concentration of 
100 ng/μl for plasmid DNA and 10 ng/μl for PCR samples were sent by post with 5 μl of 
accompanying primer in a separate tube at 3.2 μM. A list of primers used for Sanger 
sequencing can be found in Appendix A.4. The data from each Sanger sequencing 
reaction was returned in both .ab1 and .seq formats. The chromatograms were viewed 
using SnapGene software. 
2.1.7 Droplet digital PCR 
Droplet digital PCR (ddPCR) was used to determine the copy number of the transgenes 
in each engineered ES cell line. ddPCR reactions were prepared at the Roslin Institute 
and taken on ice to the MRC Institute of Genetics and Molecular Medicine (IGMM) in 
Edinburgh. Primers used for ddPCR can be found in Appendix A.1 and probes are in 
Appendix A.5. To prepare samples all components were thawed to room temperature 
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(excluding the restriction enzyme). Tubes were mixed thoroughly by vortexing and 
centrifuged briefly to collect contents at bottom. Each 24 μl PCR reaction contained: 12 
μl of 2X Bio-Rad ddPCR Supermix for Probes, 0.6 μl oGM243 (36 μM), 0.6 μl oGM248 
(36 μM), 0.6 μl oGM249 (36 μM), 0.6 μl oGM253 (36 μM), 0.6 μl oGM255 (10 μM), 0.6 μl 
oGM256 (10 μM), 3 units of AluI restriction enzyme, 48 ng gDNA and made up to 24 μl 
with double-distilled nuclease-free water. Samples were prepared in a 96 WP PCR plate 
(Eppendorf twin.tec) and immediately taken to IGMM on ice for processing. At IGMM, 
each 96 WP PCR plate was allowed to come to room temperate and droplets were 
generated using a Bio-Rad QX200 Auto DG ddPCR system. Once droplets were 
generated the PCR plate was foil sealed using a Bio-Rad PX1 PCR plate sealer at  
180 °C for 5 seconds. The plate was then transferred to begin PCR amplification on Bio-
Rad C1000 Touch Thermo Cycler using the following thermocycling conditions: 
Step Temp. ( C) Time Cycles 
Enzyme activation 95 10 minutes 1 
Denaturation 94 30 seconds 40 
Annealing/extension 60 1 minute  
Enzyme deactivation 98 10 minutes 1 
Hold 4 Infinite 1 
 
Following PCR amplification, the plate was transferred to the QX200 droplet reader and 
the resulting data analysed using Bio-Rad’s QuantaSoft Pro software. 
2.2 Molecular cloning 
2.2.1 Restriction enzyme digestion 
Restriction enzyme digestion was required for many of the molecular cloning strategies 
used in the project. Digests were performed following the enzyme manufacturer’s 
guidelines. A typical restriction enzyme digest included DNA, restriction enzyme(s), buffer 
and distilled water. For example, 1 μg of plasmid DNA, 10 units of each restriction enzyme, 
5 μl of the appropriate buffer and made up to 50 μl with distilled water. This reaction was 
gently mixed by pipetting and incubated at the recommended temperature. DNA 
fragments were resolved by gel electrophoresis (section 2.1.3) and purified using a silica-
based column (section 2.1.4) 
2.2.2 Annealing DNA oligos 
Some cloning strategies required single stranded DNA oligos (ssODN) to be annealed. A 
list of oligos used for annealing can be found in Appendix A.6. To do this ssODN were 
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resuspended in annealing buffer (10mM Tris, pH 7.5–8.0, 50 mM NaCl, 1 mM EDTA) and 
mixed in equimolar concentrations in a 1.5 ml microfuge tube. The tube was place in a 
heating block at 95 °C for 5 minutes before turning off the heat block and allowing it to 
slowly cool to room temperature (~45 minutes). 
2.2.3 Restriction cloning 
Restriction enzyme cloning of plasmids was performed with NEB Quick Ligation Kit 
following the manufacturer’s instructions. All restriction cloning strategies were designed 
and simulated using SnapGene software. Each reaction was set up in a 200 μl microfuge 
tube on ice, typically with a molar ratio of 1:3 vector to insert. An example of the 
components of a reaction are: 10 μl 2X Quick Ligase Reaction Buffer, 50 ng of 3 kb vector 
DNA, 37.5 ng of 1 kb insert DNA and made up to 20 μl with nuclease free water. Finally, 
1 μl of Quick Ligase was added to the 20 μl mix and gently pipetting up and down. 
Reactions were incubated at room temperature for 5 minutes and then chilled on ice. 3 µl 
of the ligation reaction was transformed into 50 µl Top10 competent cells following the 
protocol in section 2.3.1. 
2.2.4 Gibson assembly 
Gibson assembly of plasmids were performed using NEB Gibson Assembly Kit in 
accordance with the manufacturer’s guidelines. All Gibson assembly cloning strategies 
were designed and simulated using SnapGene software. Some Gibson assembly cloning 
reactions used synthesised gene fragments (gBlocks). A list of gBlocks can be found in 
Appendix A.6. All overlapping DNA portions were 20 to 50 bp in length. Typical Gibson 
assembly reactions contained a total of 0.02–0.5 pmols of DNA fragments when 1 or 2 
fragments are being assembled into a vector and 0.2–1.0 pmols of DNA fragments when 
4–6 fragments were being assembled. In a 200 μl microfuge tube on ice, the total DNA 
fragments was made up to 10 μl with deionised water before adding 10 μl of 2X NEB 
Gibson assembly master mix. The reaction was then incubated in a thermocycler at 50°C 
for 60 minutes before chilling on ice. 3 μl of the reaction was then add 50 μl of NEB stable 
cells following the protocol in section 2.3.1. 
2.2.5 Topoisomerase (TOPO) cloning  
On occasion, PCR products with blunt ends were cloned into TOPO vectors for Sanger 
sequencing using Thermo Fisher Zero Blunt PCR Cloning Kit. For this, 0.5 μl of PCR 
product was used in the reaction if the insert was <1 kb or 2 μl if the yield was low or the 
product was >1 kb. The cloning reaction also contained 0.5 μl of salt solution, 0.5 μl of 
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pCRII-Blunt-TOPO vector and distilled water to make it up to a final volume or 3 μl. The 
pCRII-Blunt-TOPO vector was added last and the solution gently mixed using the pipette 
tip. The mix was incubated for 5 minutes at room temperature and the 3 μl was 
transformed into Top10 cells as described in section 2.3.1 followed by selection with 
kanamycin at 50 μg/ml. 
2.3 Bacterial molecular biology 
2.3.1 Transformation protocol 
50 μl aliquots of chemically competent E. coli (Top10 or NEB stable cells – section 2.6) 
were thawed on ice for 5 minutes prior to use. Once thawed, cells were gently mixed with 
3 μl (0.001–10 ng) of plasmid DNA, and incubated on ice for 30 minutes, followed by heat 
shocking the mixture at 42 °C for 45 seconds, then immediately returning to ice for 5 
minutes. 125 μl of SOC medium (section 2.7.1) was then added to each transformation 
before incubating at 37 °C in shaking incubator for 45 minutes. 50 μl of each culture was 
pipetted onto Luria-Bertani (LB) agar plates (section 2.7.1) containing carbenicillin at 50 
μg/ml and spread using a disposable plate spreader. The plates were then incubated 
overnight (12–16 hours) at 37 °C and analysed or stored at 4 °C for a maximum of 1 week 
until analysis was performed. 
2.3.2 Small scale preparation of plasmid DNA 
Qiagen Plasmid Spin Miniprep Kit was used to extract up to 20 μg of plasmid DNA, 
following the manufacturers guidelines. All centrifugation steps were carried out at  
16,000 x g unless stated otherwise. 
Single bacterial colonies were inoculated in 5 ml of LB broth (section 2.7.1) supplemented 
with appropriate antibiotics and incubated at 37 °C with shaking overnight (12–16 hours). 
1.5 ml of the overnight culture was transferred to 1.5 ml microfuge tube and spun at 6000 
x g for 3 minutes to pellet bacteria. After the supernatant was discarded, the bacterial 
pellet was resuspended in 250 μl of Buffer P1 and lysed in 250 μl of Buffer P2 for no 
longer than 5 minutes. The cellular debris and gDNA was precipitated with the additional 
of 350 μl of Buffer N3 and then pelleted by centrifugation for 10 minutes. The supernatant 
was collected and transferred into QIAprep spin column and centrifuged for 30 seconds. 
Flow through was discarded and the column was washed with 750 μl of Buffer PE, with 
the flow-through again being discarded. The centrifugation step was then repeated for 1 
minute to remove residual wash buffer. Each column was then transferred into a new 1.5 
ml microfuge tube. 30–50 μl of EB Buffer was added to each column and incubated at 
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room temperature for 1 minute. Plasmid was eluted with a final centrifugation step for 1 
minute. The plasmid DNA was quantified using Nanodrop 1000 spectrophotometer 
(section 2.1.5) and stored at -20 °C for future use. 
2.3.3 Large scale preparation of plasmid DNA 
Qiagen EndoFree Plasmid Maxi Kit was used to extract up to 500 μg of plasmid DNA for 
large scale, endotoxin free preparations for plasmids following the manufacturers 
guidelines. All incubation steps were carried out at 37 °C with shaking unless otherwise 
stated. 
Single colonies were inoculated into 5 ml of LB broth (section 2.7.1) supplemented with 
appropriate antibiotics and incubated for 6–8 hours. After the initial incubation, the 5 ml 
culture was transferred into a 500 ml conical flask containing 100 ml of LB broth 
supplemented with appropriate antibiotics and incubated overnight (12–16 hours). To 
harvest bacteria, the culture was centrifuged at 6000 x g for 15 minutes at 4 °C. The 
supernatant was discarded, and the cell pellet left to air-dry by inverting the open tube 
until most of the medium had drained. The bacterial pellet was resuspended thoroughly 
in 10 ml of Buffer P1 by vortexing. The cells were lysed with the addition of 10 ml of Buffer 
P2 and gently mixed by inverting the tube 4–6 times followed by an incubation at room 
temperature for no longer than 5 minutes. The lysis step was terminated with the addition 
of 10 ml of chilled Buffer P3 and immediate mixing by inverting the tube 4–6 times. The 
lysate was transferred into the QIAfilter Cartridge and incubated at room temperature for 
10 minutes after which it was passed through the QIAfilter cartridge using the supplied 
plunger. To remove endotoxins, 2.5 ml of Buffer ER was added to the filtered lysate before 
inverting the tube 10 times and incubating on ice for 30 minutes. The lysate was loaded 
into an equilibrated QIAGEN-tip 500 column (column equilibrated by flowing 10 ml of 
Buffer QBT through the column) and allowed to flow through. The column was washed 
three times with 30 ml of Buffer QC before the plasmid DNA was eluted in 15 ml of Buffer 
QN into an endotoxin free 15 ml falcon tube. The DNA was precipitated with the addition 
of 10.5 ml of isopropanol and pelleted at 5000 x g for 1 hour at 4 °C. The supernatant was 
discarded, and the DNA pellet was subsequently washed with 5 ml of endotoxin-free 70% 
ethanol and centrifugation step was repeated at 5000 x g for 1 hour at 4 °C. The pellet 
was air dried for 5–10 minutes at room temperature and resuspended in 200 μl of 
endotoxin free Buffer TE. Plasmids were quantified using the Nanodrop 1000 




2.4 CRISPR reagent development 
All plasmid and protein SpCas9 used in this project was delivered as a variant known as 
SpCas9-HF1. Herein all mention of SpCas9 is in reference to the SpCas9-HF1 
(N497A/R661A/Q695A/Q926A). SpCas9-HF1 has four residue substitutions and shows 
at least 70% of the activity observed with native SpCas9 but exhibits considerably higher 
genome-wide specificity, reducing nearly all genome-wide off-target effects to nearly 
undetectable levels (Cebrian-Serrano & Davies, 2017; Kleinstiver et al., 2016). 
2.4.1 gRNA design 
SpCas9 and AsCas12a guide RNAs (gRNAs) were designed using the CRISPOR online 
tool (version 4.97; http://crispor.tefor.net) by Haeussler et al. (2016) by entering the target 
region of less than 2 kb, selecting the reference genome “Mus musculus – Mouse 
(reference) – UCSC Dec. 2011 (mm10=C57BL/6J) + SNPS” and the PAM as either “20bp-
NGG – SpCas9, SpCas9-HF1, eSpCas9 1.1” for SpCas9 or “TTT(A/C/G)-21bp – Cas12a 
(Cpf1) – 21bp guides recommended by IDT” or “TTT(A/C/G)-23bp – Cas12a (Cpf1) 
recommended, 23bp guides” for AsCas12a. An image of the CRISPOR input screen is 
shown below in Figure 2.1. SpCas9 gRNAs were selected based on MIT specificity score 
(Hsu et al., 2013), predicted efficiency score (Doench et al., 2016), out-of-frame score 
(Bae, Park, & Kim, 2014) and potential off target mismatches in the reference genome. 
Although other predicted parameters are provided by CRISPOR for SpCas9 gRNAs and 
these can be seen in the CRISPOR output window in Figure 2.2, they were not used for 
gRNA selection in this project. CRISPOR provides fewer parameters for AsCas12a 
gRNAs and these were selected based on predicted efficiency (Kim et al., 2018), out-of-
frame score (Bae et al., 2014) and off-target mismatches in the reference genome.  
Once the guide RNA sequences were chosen, SpCas9 gRNA sequences for cloning in 
plasmid pSL70 (section 2.7.3) were screened to ensure the nucleotide at the 5’ terminus 
was a guanine (G), if this nucleotide was not a G, an additional G was added to the 5’ 
terminus. The human U6 RNA polymerase III promoter (hU6) within the pSL70 used for 
CRISPR-SpCas9 plasmid expression throughout this work requires a purine (usually a G) 
nucleotide to initiate gRNA transcription. The pY094 vector (section 2.7.3) for CRISPR-
AsCas12a plasmid expression already has this initiating G for the hU6 to initiate gRNA 
transcription and therefore this modification was not required for AsCas12a gRNAs. gRNA 
DNA oligos (Appendix A.7) were ordered as standard, 25 nM DNA oligos from IDT with 
BbsI overhangs for SpCas9 gRNA oligos and BsmBI overhangs for AsCas12a gRNA 
oligos to clone annealed oligos to be cloned into the corresponding plasmid in the correct 




Figure 2.1 Example of the CRISPOR input screen for SpCas9 guide RNA (gRNA) design in the mouse reference genome. 
 





2.4.2 Preparation and cloning of gRNAs in plasmids 
Lyophilised gRNA DNA oligos (Appendix A.7) from IDT were resuspended to 100 μM in 
nuclease-free distilled water. To prepare gRNA DNA oligos for cloning, corresponding 
oligos were annealed in the following reaction; 1 μl of each oligo (100 μM), 1 μl of NEBuffer 
2 and 7 μl of nuclease-free distilled water were incubated at 37 °C for 30 minutes, 95 °C 
for 5 minutes and then ramped down to 25 °C at a rate of 5 °C per minutes. The annealed 
oligos were then diluted 1:100 by adding 1 μl of annealed  oligo mix to 100 μl of nuclease-
free distilled water.  
To clone the annealed oligos into their respective vectors a ligation reaction for each was 
prepared; 0.5 μl of vector (pSL70 or pY094 at 100 ng/μl), 2ul of diluted annealed gRNA 
DNA oligos, 2 μl of T4 ligase buffer (NEB), 0.2 μl T4 ligase (NEB), 1 μl of BbsI or BsmBI 
(NEB) and made up to 20 μl with nuclease-free distilled water. The ligation reactions 
where incubated in a thermocycler for 37 °C for 5 minutes followed by 21 °C for 5 minutes 
for six cycles. The ligation reaction was then treated with plasmid safe nuclease to digest 
any remaining linearized DNA. For this, the following components were added to 10 μl of 
ligation reaction; 2 μl of 10X plasmid safe buffer (Cambio), 2 μl of ATP (10 mM), 1 μl of 
plasmid safe nuclease (Cambio) and nuclease-free distilled water to give a final volume 
of 20 μl. The plasmid safe reaction was incubated at 37 °C for 30 minutes followed by 70 
°C for 30 minutes. 2 μl of plasmid safe treated plasmid ligation was transformed into 
Top10 competent cells following the protocol in section 2.3.1. Colonies were picked and 
small-scale plasmid preparations performed (section 2.3.2). Cloning of gRNAs in 
respective vectors was confirmed by Sanger sequencing plasmids (section 2.1.6) with 
primer oSL35 (Appendix A.5). 
2.4.3 Preparation of SpCas9 ribonucleoprotein complex 
Within this project, SpCas9 protein was used for some genome engineering application 
to limit random integration of plasmid DNA into the host genome. For this 
recombinant SpCas9 protein, purified from an E. coli strain expressing the nuclease was 
purchased from IDT. The protein contains a nuclear localisation sequence (NLS) and C-
terminal 6-His tag. It was provided in solution at 10 µg/µl. 36 nt crRNAs (Appendix A.8) 
and a proprietary universal 67 nt tracrRNA were also purchased from IDT. 
The crRNA and tracrRNA were duplexed. Working under RNase free conditions, crRNA 
and tracrRNA were resuspended in nuclease free duplex buffer (IDT) to 100 μM. A 
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duplexing reaction was then prepared; 1 μl of crRNA (100 μM), 1 μl of tracrRNA (100 μM) 
and 98 μl of duplex buffer added to 1.5 ml microfuge tube. The reaction was added to a 
heat block at 95 °C for 5 minutes. The heat block was then turned off and allowed to slowly 
cool to room temperature (~45 minutes). Duplexed crRNA:tracrRNA (1 μM) was then 
stored at -80 °C for no more than 1 month before using.  
To form ribonucleoprotein (RNP) complex, SpCas9 was thoroughly mixed by inverting the 
tube several times, and briefly centrifuged before diluting to 1 μM in Opti-MEM (Thermo 
Fisher). For each 100 μl of RNP solution, 8 μl of crRNA:tracrRNA (1 μM), 8 μl of SpCas9 
(1 μM) and 84 μl of Opti-MEM were mixed in a 1.5 ml microfuge tube, vortexed briefly and 
incubated at room temperature for 5 minutes to assemble RNP. RNP was either used 
immediately or stored at -80 °C for up to 6 months. 
2.4.4 Screening gRNAs 
2.4.4.1 T7 endonuclease I (T7EI) assay  
T7EI assay was used to screen gRNA cutting efficiency due to the enzymes ability to 
detect and cleave miss-matched DNA. After extracting of gDNA from CRISPR-Cas 
transfected cells (section 2.1.1), a PCR was performed to amplify across the gRNA target 
site with NEB Phusion High-Fidelity polymerase (section 2.1.2.1). 2 μl from each PCR 
was run on a 1% agarose gel to estimate DNA concentrations. 200 ng of PCR product 
from each PCR reaction was then denatured and reannealed in the thermocycler using 
the cycling conditions listed below: 
Step Temperature Ramp Rate Time 
Denaturation 95 C  5 minutes 
Annealing 95-85 C -2 C per second  
 85-25 C -0.1 C per second  
Hold 4 C  Infinite 
 
After reannealing, 1 µl (10 units) of T7EI was added into the reannealed PCR amplicons, 
mixed and incubated at 37 °C for 15 minutes. Immediately after incubation, the digestion 
was resolved on a 2% agarose gel. The resulting cleaved and full-length PCR products 
were visualised and imaged using a UV transilluminator Gel Dock.  
2.4.4.2 Inference of CRISPR Edits (ICE) analysis 
ICE analysis was performed by extracting gDNA from CRISPR-Cas transfected cells and 
a negative wild type control and PCR amplifying across the gRNA target site using NEB 
Phusion High-Fidelity polymerase (section 2.1.2.1). The PCR product was then purified 
(section 2.1.4) and sent for Sanger sequencing (section 2.1.6). ICE analysis uses the 
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quantitative trace data from the two returned Sanger sequencing reactions to determine 
the differences between the negative wild type control and the CRISPR-Cas edited cells 
(section 4.1.4.2). Synthego’s online tool (https://ice.synthego.com/) was used for ICE 
analysis with default settings. This online tool was developed by Hsiau et al. (2019). The 
outputs include indel % (relative estimate of total cutting efficiency) and knock-out score, 
which were used to select optimal gRNAs for both SpCas9 and AsCas12a. 
2.5 Mammalian cell culture 
All cells were cultured at 37 °C with 5% CO2. Culture media was refreshed as appropriate. 
Media and other mammalian cell culture reagent formulations can be found in section 
2.7.2. All work was performed with Class II biosafety cabinets. All media, phosphate 
buffered saline (PBS) and trypsin were prewarmed to 37 °C before adding to cells. When 
required cells were counted using a haemocytometer. 
2.5.1 Mouse embryonic stem (ES) cells 
E14 mouse embryonic stem (ES) cells were thawed and expanded in ES cell medium on 
0.1% gelatine coated flask and expanded up to T75 culture flask in feeder independent 
conditions. Passaging of ES cells involved aspirating off growth medium and washing 
twice with PBS before adding Trypsin 2X+G (section 2.7.2) and incubating for up to 8 
minutes at 37 °C with 5% CO2. Trypsin was then neutralised with an appropriate amount 
of cell culture medium. 
2.5.1.1 Lipofection of ES cells 
DNA plasmid transfection 
In preparation for plasmid transfection in a 24 WP, a DNA mix of 5 μl of endotoxin free 
plasmid DNA (100 ng/μl) and 45 μl of Opti-MEM (Life Technologies) was prepared in 1.5 
ml microfuge tube. A lipofectamine mix of 2.5 μl of Lipofectamine 2000 (Thermo Fisher) 
and 47.5 μl of Opti-MEM was prepared in a separate 1.5 ml microfuge tube. When two 
plasmids were co-transfected, ratios were equimolar. 
For plasmid transfection in a 6 WP, a DNA mix of 2 μl of plasmid DNA (1 μg/μl) and 198 
μl of Opti-MEM was prepared in 1.5 ml microfuge tube. A lipofectamine mix of 9 μl of 
Lipofectamine 2000 and 191 μl of Opti-MEM was prepared in a separate 1.5 ml microfuge 
tube. When two plasmids were co-transfected, ratios were equimolar. 
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Each mix was then vortexed briefly and incubate at room temperature for 5 minutes. For 
both 24 and 6 WP transfections, the DNA mix was then added to the lipofectamine mix 
and the DNA:lipofectamine mix was incubated at room temperature for a further 20-30 
minutes. Whilst the mix was incubating, the cells were prepared by passaging and 
seeding at 2 x 105 cells per well in 24 WP or 8 x 105 cells per well in a 6 WP. The 
DNA:lipofectamine mix (100 μl for 24 WP or 400 μl for 6 WP) was then dripped onto cells 
in each well and swirled to distribute. Cells were incubated overnight 37 °C in 5% CO2 
before refreshing the medium the morning of the following day. 
SpCas9 ribonucleoprotein transfection 
For SpCas9 ribonucleoprotein (RNP) transfections in a 24 WP, an RNP mix of 50 μl of 
SpCas9 RNP complex (section 2.4.3) was prepared in 1.5 ml microfuge tube. A 
lipofectamine mix of 2.5 μl of Lipofectamine 2000 and 47.5 μl of Opti-MEM was prepared 
in a separate 1.5 microfuge tube. 
Each lipofectamine mix was then vortexed briefly and incubate at room temperature for 5 
minutes. The RNP mix was then added to the lipofectamine mix and the 
RNP:lipofectamine mix was incubated at room temperature for a further up to 20-30 
minutes. Whilst the mix was incubating, the cells were prepared by passaging and 
seeding 2 x 105 cells per well in 24 WP. The 100 μl of RNP:lipofectamine mix was then 
dripped onto cells in each well and swirled to distribute. Cells were incubated overnight 
37 °C in 5% CO2 before refreshing the medium the morning of the following day. 
Co-transfection of SpCas9 ribonucleoprotein and DNA plasmid 
When SpCas9 RNP and DNA plasmid were co-transfected in 24 WP, plasmid was 
transfected into cells following the ‘DNA plasmid transfection’ protocol above followed by 
a separate transfection of SpCas9 RNP following the ‘SpCas9 ribonucleoprotein 
transfection’ protocol above 1 hour after the plasmid transfection. This separate 
transfection protocol was used as when an eGFP expressing plasmid and SpCas9 RNP 
were simultaneously transfected, no eGFP expression was observed, suggesting the 
plasmid was not efficiently transfecting the ES cells. Transfections separated by 1 hour 
overcame this issue.  
Guide RNA transfection 
crRNA:tracrRNA were duplex to form gRNA (section 2.4.3). For gRNA transfections in a 
24 WP, an RNA mix of 2 μl gRNA (12.5 μM) and 48 μl of Opti-MEM was prepared in 1.5 
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ml microfuge tube. A lipofectamine mix of 2.5 μl of Lipofectamine 2000 and 47.5 μl of Opti-
MEM was prepared in a separate 1.5 ml microfuge tube. 
Each mix was then vortexed briefly and incubate at room temperature for 5 minutes. The 
RNA mix was then added to the lipofectamine mix and the RNA:lipofectamine mix was 
incubated at room temperature for a further up to 20-30 minutes. Whilst the mix was 
incubating, the cells were prepared by passaging and seeding 2 x 105 cells per well in 24 
WP. The 100 μl of RNA:lipofectamine mix was then dripped onto cells in each well and 
swirled to distribute. Cells were incubated overnight 37 °C in 5% CO2 before refreshing 
the medium the morning of the following day. 
2.5.1.2 Fluorescence-activated cell sorting 
Some cells in 6 WP format underwent fluorescence-activated cell sorting (FACS), 24 
hours post-transfection, once strong eGFP expression was observed. Cells were 
passaged and resuspended in 400 μl of FACS medium (section 2.7.2) and transferred 
into a 5 ml Falcon Test Tube with Cell Strainer Snap Cap by pipetting through the strainer 
cap before being sorted for eGFP expression. FACS was performed by Mr Bob Fleming 
or Mr Graeme Robertson at the Roslin Institute Bioimaging and Flow cytometry facility. 
Prior to each FACS, a negative and positive control for each fluorescent marker were 
used to gate the cells using a BD FACS Aria III machine. The eGFP positive cells were 
collected in 15 ml falcon tube with 10 ml ES cell medium with pen/strep. After sorting, cells 
were collected by centrifuging at 200 x g and resuspended in 500 μl before returning to a 
0.1% gelatine coated 24 WP with ES cell medium with pen/strep. The plate was incubated 
overnight at 37 °C in 5% CO2  Cells were checked the following day for fluorescence. 
2.5.1.3 Clonal isolation of ES cells 
ES cell clonal isolation in this project was enhanced with the use of puromycin selection. 
After 72 hours of selection in ES cell medium with puromycin (section 2.7.2), single 
isolated ES cells colonies were picked. The term ‘picked’ refers to removing a single 
colony under a phase microscope using 20 µl filter pipette tip set to 10 µl and transferred 
into a round bottom 96 WP holding 30 µl of trypsin in each well. After picking, the 96 WP 
was incubated for 5 minutes at 37°C before neutralising the trypsin by adding 70 µl of ES 
cells medium into each well. Picked colonies in the 96 WP were then resuspended by 
pipetting up and down and transferred to a 0.1% gelatine coated flat bottom 96 WP and 
an additional 100 µl of ES cells culture medium was added to each well. The medium was 
refreshed the following day once cells had attached. 
39 
 
2.5.1.4 Splitting a 96 well plate 1:3 
Once ES cell clones became confluent, the 96 WP was split into three 96 WPs. Medium 
was removed from the original 96 WP and washed twice with PBS. 30 µl of trypsin 2X+G 
was added to each well and incubated for 8 minutes before neutralizing with 150 ul of ES 
cell culture medium. Three 0.1% gelatine coated 96 WPs were then prepared to collect 
the cells with 150 µl of ES cell culture medium. Once the collection plates were prepared, 
60 µl of the 180µl of cell suspension was split into each well of the three prepared 96 
WPs. The medium was refreshed the following day. 
2.5.1.5 Freezing a 96 well plate 
To freeze a 96 WP, the medium was aspirated off and wells washed twice with 150 µl of 
PBS. 30 μl of trypsin 2X+G was then added to each well and incubated for 8 minutes. The 
trypsin 2X+G was then neutralised with 70 µl of cell culture medium. 100 µl of Freeze mix 
(section 2.7.2) was then added to each well. Each well was covered with 50 µl of mineral 
oil suitable for embryo cell culture before and the plate was sealed with parafilm and 
placed into a Styrofoam box layered with wet ice. The box was then stored at -80 °C. 
Once frozen, plates were kept in the -80 °C for short term storage and transferred to the 
-150 °C for long term storage. 
2.5.1.6 Freezing cells in cryovials 
Media was aspirated off cells in the culture flask and cells were washed twice with a 
suitable amount of PBS. Trypsin 2X+G was added and incubated for 8 minutes at 37°C 
before neutralizing with ES cell culture medium. Cells were then resuspended before 
centrifuging for 5 minutes at 200 x g. The supernatant was aspirated off and the cell pellet 
was resuspended in ES cell culture medium (250 µl per cryovial). To each cryovial, 250 
µl of freeze mix and 250µl of the cell suspension was added. Cryovials were placed into 
‘Mr Frosty’ freezing vessel and transferred to -80 °C. Cryovials were stored at -80 °C for 
short term storage or transferred to the -150 °C for long term storage. 
2.5.1.7 Thawing positive clones from 96 well plate 
A 0.1% gelatine coated 24 WP was prepared with 1 ml of prewarmed ES cell culture 
medium with 2i. The 96 WP was thawed inside a waterproof bag in a 37 °C water bath 
(~3 minutes). Once thawed, a 200 µl pipette, set to 180µl was plunged into the well holding 
the clone to be thawed. With the tip of the pipette below the mineral oil, the cells were 
extracted. The entire 180µl was transferred into the prepared 24 WP and cultured in ES 
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cell culture medium with 2i until ready to passage. 2i supplement was used on thawing 
cells to help maintain pluripotency of the ES cells. 
2.5.1.8 Thawing positive clones from a cryovial 
The cryovial was thawed in a 37°C water bath (~1 minutes). Once a small piece of ice 
was visible, 0.5 ml of prewarmed ES cell culture medium was added to complete the thaw. 
The entire contents of the thawed cryovial was added to a 15 ml falcon tube, along with 
an additional 4 ml of ES cell culture medium. The falcon tube was centrifuged at 200 x g 
for 5 minutes. The supernatant was discarded, and cell pellet was resuspended in a 
suitable volume of ES cell culture medium with 2i for the intended purpose. Cells were 
culture in ES cell culture medium with 2i until ready to passage. 
2.5.1.9 Differentiating ES cells to cardiomyocytes 
Firstly, embryoid bodies (EBs) were generated by passaging and directly adding cells into 
bacterial-grade Petri dishes at 10 x 105 cells per 10 mm dish with ES cell medium without 
mouse leukaemia inhibitory factor (LIF) and incubating for 48 hours at 37 °C with 5% CO2. 
After 48 hours, EBs had formed (Figure 2.3a), approximately six EBs were placed into 
each well of a 0.1% gelatine coated 6 WP with 2 ml of ES cell medium without LIF (Figure 
2.3b). Plated EBs were incubated for 12 days at 37 °C with 5% CO2, with medium changed 
every third day. Beating cardiomyocytes were identified under brightfield microscope and 
imaged on day 12. 
 
 
Figure 2.3 Embryoid body (EB) formation and plated EBs. a) Formation of EBs after 
48 hours in suspension in ES cell medium without mouse LIF. b) EBs plated onto gelatine 





2.5.1.10 Karyotyping of ES cells 
To karyotype ES cells, old medium was removed from ES cells in a T75 flask at 60% 
confluency and refreshed with 10 ml of ES cell medium with 0.1 μg/ml KaryoMAX 
colcemid solution in HBSS (Thermo Fisher). The plate was then incubated at 37 °C with 
5% CO2 for 3 hours before removing the medium containing the colcemid, washing twice 
with PBS and harvesting cells by trypsinisation. The cell pellet was resuspended in 7 ml 
of ES cell medium. The resuspended pellet was centrifuged at 200 x g for 5 minutes before 
removing the supernatant and resuspending the pellet in 300 μl ES cell medium. 5 ml of 
0.4% KCl was gently added to the 300 μl cell suspension and incubated in a 37 °C 
circulating water bath for 10 minutes. After 10 minutes, 100 μl of freshly prepared ice-cold 
fixative (3:1 methanol to acetic acid) was added and gently mixed my inverting the tube 4 
times. The cell suspension was then centrifuged at 300 x g for 5 minutes before removing 
the supernatant. 5 ml of ice-cold fixative was added to the cell pellet and resuspend gently. 
The cell suspension was incubated on ice for 20 minutes before centrifuging at 200 x g 
for 5 minutes. The supernatant was removed, and the cell pellet was resuspended in 200 
μl fixative. 10 μl drops of cell suspension was placed onto Super Frost Plus microscopy 
slides (Thermo Fisher) from approximately 30cm above the slide. The slides were then 
allowed to dry overnight before staining with KaryoMAX Giemse Stain (Thermo Fisher). 
Images of metaphase chromosome spreads were taken with a phase contrast microscope 
at 60x and counted using Fiji image software. 
2.5.2 Human embryonic kidney 293T (HEK) cells 
HEK cells were cultured in HEK medium (section 2.7.2) at 37 °C in 5% CO2. Cells were 
thawed and passaged at least once up to a T75 flask before transfecting. Passaging cells 
involved washing once with PBS before adding trypsin (TrypLE Express from Thermo 
Fisher) and incubating for 4 minutes at 37 °C in 5% CO2. Trypsin was then neutralised 
with an appropriate amount of cell culture medium. 
2.5.2.1 Lipofection of HEK cells with plasmid DNA 
For lipofection, HEK cells were seeded into a 24 WP at 5 x 105 cells per well. After 48 
hours, the cells were 80% confluent cells and ready for lipofection. Culture medium was 
refreshed 4 hours prior to lipofection. 1 μg of total plasmid was mixed with 100 μl of Opti-
MEM medium and 4 μl of Lipofectamine 2000 in 1.5 ml microcentrifuge tube. When two 
plasmids were co-transfected, ratios were equimolar. The DNA-lipid complex was formed 
by incubating at room temperature for 5 minutes. 50 µl of DNA-lipid complex was then 
added to one of the wells in a 24 WP with 80% confluent HEK cells and gently swirled. 
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Cells were then incubated for 24 hours before refreshing medium. At 48 hours post 
transfection cells were viewed and imaged under an epifluorescence microscope with a 
FITC filter for eGFP expression or TxRed filter for dsRED expression. 
2.6 Bacteria, cells and mice 
Bacteria 
Cells Source Utility 
Top10 E. coli Dr Spring Tan Routine plasmid amplification 




Cell line Source Utility 
HEK 293T Dr Dennis Headon Testing plasmid functionality 
E14 mouse ES cells (P24) Dr Derya Ozdemir Genome engineering 
 
Mice 
Strain Source Utility 
C57BL/6NCrl 
 
Roslin Institute Ear clipping for gDNA 
2.7 Reagents and buffers 
2.7.1 Bacterial culture 
Antibiotics 
Kanamycin and carbenicillin were made up to a concentration of 50 mg/ml in distilled 
water and stored at -20 °C in 1 ml aliquots. The appropriate volumes of each antibiotic to 
give a final working concentration of 50 μg/ml was added to LB broth or agar prior to 
inoculating with bacteria. The antibiotic used was dependent on the purpose of the 
bacterial cultures. 
Luria-Bertani (LB) Broth  
1% (w/v) Bacto Tryptone, 0.5% (w/v) Bacto Yeast Extract and 125 mM NaCl made up 
with distilled water, this solution was then autoclaved on liquid cycle for 20 minutes at 15 
PSI before use. An appropriate volume of antibiotics to give a final working concentration 
of 50 ug/ml was used as required. 
Luria-Bertani (LB) Agar 
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1% (w/v) Bacto Tryptone, 0.5% (w/v) Bacto Yeast Extract, 125 mM NaCl and 1.5% sugar 
plus 15 g/L of agar made up with distilled water, this solution was then autoclaved under 
the same conditions as LB Broth. An appropriate volume of antibiotics to give a final 
working concentration of 50 ug/ml were pipetted into the melted agar once it reached 
approximately 50 °C. It was thoroughly mixed into the agar by gently swirling the flask 
before immediately pouring into 90 mm single vent petri dishes. 
Super Optimal Broth (SOB) medium 
2% (w/v) Bacto Tryptone, 0.5% (w/v) Bacto Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 5 mM MgSO4 made up in distilled water, the solution was then autoclaved 
under the same conditions as LB Broth. 
Super Optimal Borth with Catabolite repression (SOC) medium 
2% (w/v) Bacto Tryptone, 0.5% (w/v) Bacto Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 5 mM MgSO4, 20 mM glucose was made up in distilled water, the solution 
was autoclaved before the addition of glucose. The glucose was filter sterilized by passing 
a 1 M solution through a 0.2 uM filter. 
2.7.2 Cell culture media and reagents 
All culture media and reagent formulations (excluding Freezing medium) in this section 
were sterilise filtered through a Stericup-GP Sterile Vacuum 0.22 μm Filtration System 
(Merck). 
ES cell media 
Components Amount Company 
KnockOut DMEM (1X) 500 ml Thermo Fisher, US 
Foetal calf serum (FCS) 50 ml Life technologies, US 
Non-essential Amino acids (0.1 mM) 5 ml Sigma-Aldrich, US 
L-glutamine (2mM) 5 ml  
2-mercaptoethanol (0.1 mM) 550 μl Sigma-Aldrich, US 








MEK/GSK3 Inhibitor Supplement 500 μl Millipore, UK 
 
With puromycin selection: 
  





Components Amount Company 
DMEM (1x) + GlutaMAX 50ml Gibco, US 
FCS 5ml Gibco, US 
Penicillin/streptomycin (10,000 U/ml) 0.6ml Gibco, US 
 
Trypsin 2X+G 
Components Amount Company 
EDTA (0.5M) 0.1g Sigma-Aldrich, US 
D-Glucose 0.5g Sigma-Aldrich, US 
Chicken Serum 5ml Life Technologies, US 
Trypsin (2.5%) 20ml Thermo Fisher, US 
PBS 500ml Life technologies 
 
Freezing medium 
Components Percentage (%) Company 
Cell culture media 40 Roslin, UK 
FCS 40 Thermo Fisher, US 
DMSO 20 Sigma-Aldrich, US 
 
FACS medium 
Components Percentage (%) Company 
PBS 10 ml Life technologies, US 




pSL70 was initially acquired from the Addgene repository, where its official name is 
pSpCas9(BB)–2A–eGFP (PX458; Plasmid #48138). It expresses huSpCas9–T2A–eGFP 
and has a cloning backbone for a SpCas9 single gRNA (see Figure 2.4a). The plasmid 
was a gift to the Addgene repository from Prof Feng Zhang. After acquiring the plasmid 
from Addgene, Dr Simon Lillico of The Roslin Institute modified the plasmid by introducing 
5 bp substitutions within the coding sequence of SpCas9 to convert the nuclease to 
SpCas9-HF1, as well as introducing 2 bp substitutions and two 5 bp additions to the gRNA 
scaffold to improve transcription and stability of the gRNAs. Subsequently, the plasmid 





pY094 was acquired from the Addgene repository (Plasmid #84743). The plasmid 
expresses huAsCas12a–T2A–eGFP and has a cloning backbone for an AsCas12a gRNA 
(see Figure 2.4b). It was a gift to the repository from Prof Feng Zhang. 
pMTL23 
pMTL23 is a plasmid backbone with a multiple cloning site (see Figure 2.4c). It was used 
as the backbone for gene drive plasmid constructs and was kindly supplied by Prof 
Marshall Stark from the University of Glasgow. 
Cre-Reporter 
Cre-Reporter was purchased from the Addgene repository (Plasmid #62732). The 
plasmid was a gift to the repository from Dr Niels Geijsen (see Figure 2.4d). Cre-Reporter 
provided the conditional LoxP–dsRED–LoxP element for the development of all Cre-
inducible gene drive construct, OOEP_IVT in section 4.3.5. 
pVASA-Cre 
pVASA-Cre was purchased from the Addgene repository (Plasmid #15885). The plasmid 
was a gift to the repository from Dr Diego Castrillon (Figure 2.4e). This plasmid provides 
the germline specific mouse VASA promoter (cloned from FVB strain) for constructing 
OOEP_VASA plasmid in section 4.3.5.  
pDonor-ROSA26 
pDonor-ROSA26 was purchased from the Addgene repository (Plasmid #62732). The 
plasmids official name in the repository is pDonor-MCS-ROSA26 and was a gift from Prof 
Charles Gersbach. It is a mouse ROSA26 targeting vector with a multiple cloning site 
situated between two homology arms (See Figure 2.4f). It was used for developing 
ROSA26_gRNAs plasmid in section 4.3.5. 
Cre-Puro 
Cre-Puro plasmid was kindly supplied by Dr Stephen Meek from The Roslin Institute. The 
exact map of this plasmid is unknown, but an approximation is shown in Figure 2.4g. It 






2.7.4 Other buffers 
50X Tris-acetate-EDTA (TAE) buffer 
For 1 l of 50X TAE stock solution, 242 g of Tris, 57.1 ml glacial acetic acid, and 100 ml of 
0.5 M EDTA (pH 8.0) solution was made up to final volume of 1 l with deionised water. 
This stock solution was diluted 50:1 with deionised water to make a 1X working solution 
(40mM Tris, 20mM acetic acid, and 1 mM EDTA). 
5X PCR compatible loading buffer (5X Fi-RED) 
10% (v/v) Ficoll-400 and a trace of cresol red dye was made up in nuclease free water in 
sterile conditions, the solution was filtered through 0.22 uM filter before use. 
Cell lysis buffer for 96 well plate DNA extraction 
For every 1 ml of 0.1% SDS, 20 μl of Proteinase K (20 mg/μl) and 4 μl of RNase A (10 
mg/μl) was add. Lysis buffer was prepared fresh prior to use. 
2.8 Computational tools 
Bioinformatic tools 
Tool Organisation Utility 
CRISPOR (v4.97) Tefor Infrastructure gRNA design 
Ensembl EMBL-EBI Genome browser 
ICE CRISPR tool Synthego gRNA screening 
PrimerBLAST NCBI PCR primer design 
Primer3Plus Whitehead Institute PCR primer design 
SnapGene GSL Biotech LLC DNA visualisation and cloning 
QuantaSoft Pro Bio-Rad ddPCR data analysis 
 
Other software  
Software Organisation Utility 
BioRender BioRender Image development 
Fiji Fiji contributors Image analysis 
GraphPad GraphPad Statistics and graphs 
Office Microsoft Text, statistics and images  
ZEN 2 Carl Zeiss AG Microscopy image analysis 








3 Gene drive population modelling, 
strategy formulation and 
experimental design 
3.1 Introduction 
Gene drives propagate through sexually reproducing organisms, which limits their study 
to in vivo systems (Burt & Trivers, 2006). In vivo genome engineering studies in mammals 
are typically costly and labour intensive. Furthermore, gene drive research can pose a 
greater risk the environment than conventional genome engineering projects. For these 
reasons, it is important that substantial background work is done before considering 
development and testing of a gene drive system in a laboratory-contained animal 
population. Thoughtful strategy design and experimental planning helps safeguard wild 
populations and ecosystems from unintentional release, as well ensuring value will be 
gained from undertaking animal research. 
Important background work before embarking on the development of a population 
suppressing homing gene drive, include: (1) selecting candidate gene drive designs and 
identifying their mechanisms of inheritance; (2) in silico modelling these approaches in 
the targeted population; (3) identifying and applying safeguards and contingency 
strategies; (4) designing DNA constructs and gaining knowledge from in vitro systems; 
and (5) design of animal experiments, including risk assessment and regulatory approval.  
3.1.1 Homing-based gene drive designs 
There are three key parameters to consider when designing a CRISPR-based homing 
gene drive targeting female reproduction. These are the promoter used to express the 
Cas nuclease, the number of gRNAs, and the biology of the target gene. Although other 
parameters are also important, including the type of Cas nuclease used and the efficiency, 
specificity and characteristics of the gRNA recognition sequences, these factors are 
covered Chapter 4. 
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3.1.1.1 Promoter selection 
The timing of expression of the Cas nuclease is an important parameter for the successful 
propagation of a gene drive as it determines were homing will take place (Grunwald et al., 
2019; Li et al., 2020; Prowse et al., 2017). This can be adjusted by using promoters that 
drive expression at different stages for development. It is desirable to restrict expression 
and, therefore, homing to either germ cells or the zygote as the DNA repair machinery in 
somatic cells, outside these niches, typically favour NHEJ over HDR, which could reduce 
homing and slow propagation of the drive through the population (Gantz et al., 2015; 
Wang et al., 2013; Zheng et al., 2018).  
As described earlier in section 1.9.1, Grunwald et al. (2019) were only able to achieve 
homing in female mice when SpCas9 expression was restricted to the germ line. They did 
not observe any HDR homing events when SpCas9 was expressed from a ubiquitous 
promoter but indels induced by NHEJ were present on the homologous chromosome. 
With ubiquitously expressed SpCas9, Grunwald and colleagues were hoping to achieve 
homing within the zygote. The first possibility for the lack of homing events with ubiquitous 
SpCas9 expression is that the homologous chromosomes are not aligned in the early 
zygote for inter-homologue HDR to repair DSBs. The second possibility is expression of 
SpCas9 is delayed in the early zygote leading to mosaic animals that went undetected in 
the study. The final possibility is that the outcomes were unique to the target site and 
constructs they used. In all cases, further investigation is needed to better understand if 
zygotic homing can occur in mammals with ubiquitous Cas expression. 
In addition to not observing homing with ubiquitous expression, Grunwald and colleagues 
only confirmed homing events in the female germline and no homing events in males. 
There are two potential explanations here. First, despite equivalent genotypes in the male 
and female, Cre, SpCas9 and/or gRNA may not be well-expressed in the male germline. 
Second, spermatogonia continually undergo mitosis and produce new primary 
spermatocytes throughout the life of male mammals. By contrast, oogonia directly enlarge 
without further mitosis to form all of the primary oocytes during development in the 
embryo. The difference in the observed efficiency of inter-homologue HDR between 
females and males at this locus may therefore reflect a requirement for the precise timing 
of CRISPR–Cas activity to coincide with meiosis, although further data on this is also 
required. 
Importantly, Grunwald et al. (2019) did demonstrate the significance of timing and pattern 
of expression of the Cas nuclease in a CRISPR-based homing gene drive. 
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3.1.1.2 gRNA array 
Resistant alleles that prevent CRISPR-Cas recognising its gRNA target site could exist in 
the population before release or originate from indels generated when CRISPR-mediated 
cleavage is repaired by the error-prone NHEJ or MMEJ pathways (Champer et al., 2016; 
McFarlane et al., 2018). In laboratory studies, the former should be identified in the target 
population prior testing, the latter represents an important risk to preventing super-
mendelian inheritance. A high occurrence of indel mutations in the target species would 
impair the spread of a suppression gene drive. 
To overcome the impact of resistant alleles, it may be beneficial to utilise multiple gRNAs 
in a homing gene drive. The emergence of resistance within a few generations is currently 
one of the main causes of failure in experimental evolution gene drive studies (Hammond 
et al., 2017; KaramiNejadRanjbar et al., 2018). Using several gRNAs that target multiple 
sites decreases the rate of emergence of resistance alleles (Champer et al., 2020; Prowse 
et al., 2017). This strategy is similar to multi-drug therapy, whereby targeting multiple sites 
makes the evolution of resistance simultaneously at all sites less likely (Perron et al., 
2012). Several experimental studies found that targeting multiple sites decreases the 
appearance of alleles resistant to cleavage (Champer et al., 2018; Champer, Yang, et al., 
2019; Champer et al., 2020; Prowse et al., 2017). 
Although multiplexing gRNAs is proposed as a critical component of any successful gene 
drive, having excessive numbers can lead to Cas activity saturation and reduced repair 
fidelity when homology ends for HDR around the DSB fail to line up perfectly. Using 
computational and experimental studies from Drosphilia, S. Champer et al. 2020 
suggested that the total number of gRNAs should be kept relatively low to achieve 
maximum effectiveness of multiple-gRNA drives: at least two, but well under a dozen, with 
the exact number depending on the type of drive and other performance characteristics. 
3.1.1.3 Target genes 
As described in section 1.9, the development of a homing-based sex-ratio distorting gene 
drive for population suppression is most efficient when targeting an essential female-
fertility gene, as female reproductive performance typically controls population size. 
Important questions to ask when selecting candidate target genes are: 
Does disruption of the fertility gene have any unintended phenotypic impacts or 
fitness costs on either sex?  
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Where does the gene play a biologically role in female reproduction? (i.e. 
germline or soma) 
Is the gene haplosufficient or haploinsufficient? 
Are there confirmed knock-out models and what has been reported? 
These are critical questions to be resolved before developing a gene drive and if good 
data is not available in the literature, scientific investigation may be required before 
proceeding. As demonstrated in section 3.3 of this chapter, the biology of the target gene 
has a significant impact on the effectiveness of a gene drive to propagate.  
3.1.2 In silico population modelling  
Just as pharmacokinetic modelling is an essential component of developing and testing a 
new drug, population modelling has an important role to play when developing gene drives 
for pest management (Sinkins & Gould, 2006; Wedell, Price, & Lindholm, 2019). In silico 
modelling provides valuable insight into the ability of a gene drive to spread and suppress. 
It is feasible for the human mind to elucidate how a gene drive will be inherited over 
several generations but at a population scale over multiple generations this becomes 
incomprehensible. Therefore, modelling is a valuable tool for evaluating the feasibility of 
gene drive strategies, and for advancing fundamental knowledge on the potential of gene 
drive technology (Beaghton et al., 2019; Wedell et al., 2019). 
Gene drive models are only as good as the data they are based upon. Often these 
modelling approaches can assess key thresholds, such as how many individuals must be 
released for the gene drive strategy to succeed if propagating at or above a threshold. 
Using models, it may be impossible to absolutely know whether these simulated events 
will occur until the release actually takes place and the system is closely monitored. 
However, models are useful in gauging the probabilities of success and possible 
outcomes. For this reason, it is prudent for research on gene drive technology to include 
simulations that help to refine strategy design and identify risks (Beaghton et al., 2019; 
National Academies of Sciences, 2016). 
3.1.3 Safeguarding gene drive research 
The unintentional release or escape of gene drive animals, in this case mice, represents 
a risk to the environment. Best practice guidelines have been proposed by various groups 
of experts (Akbari et al., 2015; Lunshof & Birnbaum, 2017; National Academies of 
Sciences, 2016) and it is recommended that gene drive animals should be managed using 
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an appropriate combination of confinement strategies to mitigate these risks. Akbari et al. 
(2015), which was authored by a collection of 27 leading gene drive researchers from 
around the globe, suggest that at least two of the below confinement strategies should be 
implemented for gene drive research. 
Ecological confinement: by conducting gene drive research in countries where 
the target species is not present or would have difficulty establishing in the wild. 
Physical containment: by using physical barriers (e.g. secured rodent facility or 
nets). 
Reproductive confinement: by using lab strains that cannot reproduce with wild 
individuals (e.g. Drosophila strain with chromosomal rearrangements; Akbari et 
al. 2015). 
Molecular confinement: by molecularly restricting the gene drive to experimental 
population (eg. gene drive targeting an artificial sequence or by using split gene 
drives with the Cas gene and gRNA/s on different chromosomes; DiCarlo et al. 
2015; J. Champer et al. 2019); 
Although there are guidelines for the transportation of genetically altered animals, there 
are currently no specific guidelines for the transport of gene drive animals, and some 
researchers have suggested that they should not be transported or distributed to other 
laboratories (Akbari et al., 2015). This project plans to adhere to this recommendation. 
3.1.4 Construct design and in vitro gene drive systems 
A critical aspect of gene drive development is the design of the targeting DNA construct 
(Prowse et al., 2017). As gene drive constructs are typically large, including a promoter, 
Cas nuclease and gRNA array, plasmid DNA target constructs are usually required. 
Strategies for developing these constructs are highlighted in section 4.1.6. As gene drives 
propagate through sexually-reproduction, the animal work needed to study gene drives in 
vertebrates is both costly and time consuming. It would be beneficial to gain as much 
information as possible about a putative gene drive strategy in vitro, prior to commencing 
animal work. It may be possible to test the functionality and quantify homing efficiency of 
prospective gene drives using inducible gene drive systems – systems that when switched 
on are designed to change a cell from a heterozygous to homozygous state through HDR 
inter-homology repair. At the very least, the data gained from such an in vitro system could 
ensure constructs are functional prior to testing in animal studies. A key challenge of 
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developing such a system is finding an approach that can reliably induce expression, with 
no leaky gene drive expression prior to induction. 
3.1.5 Experimental design for animal research 
Where there is no alternative to the use of animals in research, as is the case for gene 
drive studies, it is important that experiments are well designed and correctly analysed in 
order to minimise the number of animals and suffering, while maximising the chance of 
generating scientifically valid results. Experiments that use too few animals may fail to 
pick up important effects, while those who use them in excess may waste animals or 
subject the animals to unnecessary suffering (Kilkenny et al., 2009). 
In the UK, the laws on research using animals are set out in the Animals (Scientific 
Procedures) Act 1986, or ‘ASPA’. The Home Office enforces the laws, including 
regulations on housing, environment, welfare, care, and health. Permission to work with 
animals is granted by the Home Office by licence only under very specific conditions. The 
Home Office has an inspection system to ensure compliance with laws and regulations 
(Wells, 2011). 
Before consideration by the Home Office, each project is evaluated by one or several 
expert committees within their host institute. One key criterion for animal research work 
to go ahead is that the research cannot be carried out using non-animal methods, which 
is the case for gene drive. Once the experimental design has been internally approved, it 
is then passed on for assessment by the Home Office. This can be a lengthy process and 
the project cannot commence before Home Office approval is granted. 
Throughout the design and assessment process there is an emphasis on the importance 
of the Three Rs (3Rs). These are guiding principles for the ethical use of animals in 
research. They were first described by Russell and Burch (1959). The 3Rs are: 
Replacement: methods which avoid or replace the use of animals in research 
Reduction: use of methods that enable researchers to obtain comparable levels 
of information from fewer animals, or to obtain more information from the same 
number of animals. 
Refinement: use of methods that alleviate or minimise potential pain, suffering 
or distress, and enhance animal welfare for the animals used. 
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The 3Rs have a broader scope than simply encouraging alternatives to animal testing but 
aim to improve animal welfare and scientific quality where the use of animals cannot be 
avoided.  
3.1.6 Aims  
The aim of the work described in this chapter was to identify candidate gene drive designs, 
establish their mechanisms of inheritance and in silico model the potential impact of these 
approaches on a wild mouse population. Once a strategy was selected for further 
development, safeguards to prevent escape were included in the design and rudimentary 
DNA targeting constructs are proposed. Based on this planned gene drive system, animal 
experiments were then designed, risk assessments undertaken and regulatory approval 
for the work was obtained. As the final animal experiments are still ongoing and do not 
form part of this thesis, an overview of their design has been included within the results 
of this chapter. The findings in this chapter provide essential background information and 
justifies the work undertaken in proceeding two Chapters, 4 and 5.  
3.2 Additional materials and Methods 
Gene drive simulations in a wild mouse population were run in an individual based model 
that was adapted from a previously published model by Dr Gregor Gorjanc and Nicky 
Faber of the Roslin Institute. These simulations were based on code Prowse et al. (2017), 
which is freely available in R code from the Dryad Digital Repository: 
http://dx.doi.org/10.5061/dryad.t78gv. Gene drive strategies, mechanisms of inheritance 
and model parameters were developed by Gus McFarlane. Dr Gregor Gorjanc and Nicky 
Faber adjusted the Prowse et al. (2017) code to include the following parameters: 
simultaneous gRNA expression; CRISPR-Cas cutting efficiency of 95% (based on non-
vertebrate data from Hammond et al. 2016); NHEJ repair frequencies of 0, 2 and 10%. 
The demographic parameters within the modelled wild mouse population were: inter-
breeding interval of 0.1 years (Caughley et al., 1998); litter size of 6 (Caughley et al., 
1998); survival rate at carrying capacity of 0.25; maximum survival rate of 0.54 (Prowse 
et al., 2017) and maximum annual population growth rate of 7.76 (Caughley et al., 1998). 
Simulations were performed on populations of 50,000 mice of equal sex-ratio (1:1 male 
to female) and run for 10 to 20 years. This population is intended to represent an isolated 
island population of invasive mice. Initial inoculation of all populations was with 100 male 
gene drive mice. Following the initial inoculation some simulations included six-monthly 
supplementation of male gene drive mice at rates ranging from 0 to 50% of the remaining 









Figure 3.5 In silico simulation of Strategy A in a population of 50,000 wild mice. Population size over time after the introduction 
of 100 Strategy A gene drive male mice. Lines represent the average population size over 100 model iterations, opaque ribbons 





Strategy B and C were also modelled in the same isolated population of 50,000 wild mice. 
Although the molecular mechanism of gene drive propagation is different between 
Strategy B and C, their fundamental inheritance pattern (propagation through male 
germline) and underlying ‘genetically daughterless’ suppression approach is the same. 
Therefore, simulations of Strategies B and C are represented in the same plots (Figure 
3.6). Although, in practice, as homing either occurs in the germline (Strategy B) or in the 
zygote (Strategy C) the rates of NHEJ will likely lead to differences in efficiency between 
these strategies. 
Population simulations for Strategies B and C consisted of an initial release of 100 gene 
drive male mice harbouring 3 gRNAs followed by 6-monthly supplementation of gene 
drive males at rates ranging from 0 to 50% of the remaining population size. 3 gRNAs 
were selected as the fixed gRNA number in simulations of both these strategies. It was 
reasoned that 3 gRNAs would help combat the development of drive resistant alleles 
whilst being a gRNA array that remained feasible to engineer in subsequent DNA 
constructs developed for the in vivo portion of this project. 
Within the simulations in Figure 3.6, following the initial release of 100 gene drive males 
and no further supplementation of animals (purple line), there is negligible short term and 
no long-term impact on mouse population size with either Strategies B and C. These 
strategies required substantial numbers of animals and 0% NHEJ to have significant long-
term population suppression or lead to eradication of the mouse population. Under ideal 
conditions of 0% NHEJ it required 6-monthly population supplementation of at least 10% 
of the remaining population with gene drive male mice to achieve eradication within the 
20-year time frame simulated here.  
Although strategies B and C do not have the efficiency to act as stand-alone pest 
management strategies. These approaches could find use as complementary pest 
management tools after deploying more traditional pest control methods or to prevent that 
advancement of invasive fronts. In the scope of this project, strategies B and C both offer 
a safe approach to study gene drives in the laboratory due to their low invasive potential. 
The remainder of this project focused on the development of Strategy B and C for testing 






Figure 3.6 In silico population simulation of Strategy B and C with 3 gRNAs in a population of 50,000 wild mice. Population 
size over time after the initial introduction of 100 Strategy B or C gene drive male mice. Lines represent the average population size 
over 100 model iterations, opaque ribbons represent the 95% confidence interval. The model was run with 3 different rates of NHEJ 
(0, 2 and 10%) and 6-monthly supplementation ranging from 0 to 50% of the remaining population with either Strategy B or C gene 







3.3.4 Safeguarding against spread 
As our population simulations indicate that Strategies B and C do not operate as ‘true’ 
self-propagating gene drives, they pose less risk to the environment than Strategy A. 
However, in line with recommendations made by Akbari et al. (2015) additional safeguard 
strategies were included to further reduce the risk of an escaped animal spreading a gene 
drive element through a wild population. At the outset of this project no data was available 
on the efficiency of CRISPR-based gene drives in vertebrates. To ensure the gene drive 
systems developed in this project could not spread in wild mouse population, an additional 
two-tiers of confinement were included; these were barrier and molecular confinement. 
3.3.4.1 Barrier confinement 
Gene drive mice developed in this project will be housed at the Roslin Institute in a 
containment level (CL) 2 rodent facility to provide physical containment and inhibit mating 
with wild animals. The CL 2 facility for housing of animals has doubled doors, which are 
locked with restricted key access and have animal barriers at all exit points. The animal 
holding rooms within the facility have sealed pipework and removable rodent barriers that 
are in place during animal handling. The rodents are housed within an individually 
ventilated cage system. Only experienced handlers are allowed to open the cage and only 
one cage is opened at any one time. In addition, stock management procedures are in 
place to ensure all mice are identified and records kept for the Institute, University and 
Home Office. 
Although barrier containment measures are extensive, this form of containment is known 
to be vulnerable to human error (Manuel, 2008), therefore, a molecular confinement 
strategy will also be used. 
3.3.4.2 Molecular confinement 
The molecular confinement strategy to be employed in this study is known as a split gene 
drive (SGD). A SGD system works by ‘splitting up’ the Cas-nuclease and gRNA array onto 
separate chromosomes (Del Amo et al., 2019). A Cas nuclease-only element expressed 
from either NLRP5 or OOEP loci could spread readily in engineered mice that already 
express the corresponding gRNAs from an alternate chromosome but cannot bias 
inheritance without the gRNA (Figure 3.8). Therefore, if a SGD mouse escaped the CL 2 
facility, and in the unlikely event it survived and mated with a wild mouse, the population 
frequency of the gRNA array will be determined by normal Mendelian dynamics and 





Figure 3.8 A split gene drive (SGD) separates the gRNA/s and Cas onto separate 
chromosomes. Within the cell, the gRNA/s and Cas are expressed, complex and cleave 
the target site, being the OOEP or NLRP5 gene (yellow) on the homologous wild-type 
(WT) chromosome. Once the cut is made, homology-direct repair (HDR) copies the Cas 
into the cut site. Cas will only spread (drive) in the presence of the gRNA/s. As wild-type 
mice cannot provide the requisite gRNA/s, the SGD could not spread at a rate greater 
than Mendelian within a wild population. 
 
The obvious candidate locus for expressing the gRNA array in a model mouse population 
is the ROSA26. The ROSA26 locus encodes long non-coding RNAs that are ubiquitously 
expressed (Figure 3.9). The locus is considered a safe harbour and is commonly used for 
constitutive transgene expression in knock-in mouse models (Casola, 2010; Chen et al., 
2017). Importantly, for a SGD configuration, the ROSA26 is located on chromosome 6, 
while NLRP5 and OOEP are on chromosome 7 and 9, respectively (Figure 3.10). Over 
130 knock-in lines have been created by integrating constructs into the ROSA26 locus. In 
line with the reports within the scientific literature, we anticipate no phenotypic effects as 
a result of construct integration and disruption of the ROSA26 target site (Casola, 2010; 
Friedrich & Soriano, 1991; Yang et al., 2016). 
 
 
Figure 3.9 ROSA26 from the mouse reference genome (GRCm38.p6). The mouse 
ROSA26 encodes a long non-coding RNA consisting of 3 exons making up the 551 nt 
(transcript ENSMUST00000167415.7). Intron 1 is commonly used a safe harbour for 





drive alleles to a reference gene within the population of GFP positive cells. This could be 
done by assessing the transgene copy number against a reference gene by ddPCR in 
pooled GFP positive cells. To develop this system, the construct in Figure 3.12a was 
developed and tested in section 4.3.5. 
3.3.7 Experimental design of animal experiments 
Following the in silico identification of a suitable strategy, experimental design of the 
prospective animal studies was undertaken so the lengthy process towards obtaining 
University and regulatory approval through the UK Home Office for these experiments 
could commence. This would allow for both efficient time management of the project and 
prevent waste of resources if approval of animal studies was not granted. 
Animal experiments will result in the generation of three lines of transgenic mice: (1) 
ROSA26_gRNAs mice, (2) CAG_Cas mice, and (3) VASA_Cas mice. SGD mice will be 
generated by separately crossing ROSA26_gRNAs mice with CAG-Cas mice and 
VASA_Cas. Doubly heterozygous male mice harbouring a SGD will be bred with wild-type 
females to produce up to 8 litters of pups. The transmission frequency of both SGDs will 
be quantified by genotyping all offspring born from a SGD male or female (if females are 
fertile) at the OOEP or NLRP5 locus and ROSA26 locus. Genotyping will be performed 
by a combination of PCR, Sanger sequencing and ddPCR. ddPCR will be used to 
determine the copy number of the OOEP or NLRP5 transgene in mice genotyped as 
homozygous for the transgene by PCR and Sanger sequencing. The use of ddPCR is to 
ensure animals are not falsely genotyped as homozygous but have a large CRISPR 
induced deletion on the homologous chromosome. If the system ‘drives’ it should be 
transmitted at a frequency much higher than 50%. The rate of transmission between the 
two-SGD systems, which differ by the promoter used to express Cas, will be compared.  
We will also assess the phenotypic impact of the SGD in both mouse lines, confirming if 
inheritance confers female infertility and assessing if any unanticipated phenotypes are 
present. Once SGD female pups reach sexual maturity (6 weeks), a small cohort will be 
mated to establish their fertility status. We expect SGD females to be infertile. We will test 
this by mating females up to four times (with vaginal plugs) with wild-type stud males 
rented from the Roslin Institute Transgenic Core that have a record of successful matings. 






Figure 3.12 Workflow for in vitro testing gene drive functionality and homing 
efficiency in ES cells. a) Cre-inducible gene drive construct and Cas RNP would be 
transfected into ES cells to integrate the construct within the targeted female-fertility gene 
(NLRP5 or OOEP). b) Fluorescence-activated cell sorting (FACS) would isolate RFP-
positive clones and clones would be screened to identify heterozygotes with a WT female-
fertility gene. c) Hetrozygous cells would be treated with Cre-mRNA to activate the gene 
drive. Cells with an active gene drive element would be collected using FACS. d) The 
functionality and homing efficiency of the gene drive could then be quantified by using 
droplet digital PCR (ddPCR) to determine transgene copy number in the pooled 





3.4.1 Strategy A is highly invasive 
Three homing-based gene drive strategies were computationally modelled in wild mouse 
populations and considered for development. Of the three approaches, Strategy A was 
the most efficient at population control, achieving eradication in some scenarios with only 
100 gene-drive carriers being introduced into a population of 50,000 wild mice. As can be 
seen in Figure 3.5, within the simulations, an increasing rate of NHEJ requires an 
increasing number of gRNAs to help combat development of resistant alleles. 
The results for Strategy A are consistent with both Eckhoff et al. (2016) and Prowse et al. 
(2017), who modelled gene drives in mosquito mouse and respectively, and found that if 
functional resistant alleles that restored fertility were formed then it is likely that a gene 
drive will not succeed in eradicating the population. They reasoned that multiplexing 
gRNAs could help overcome this problem. As long as at least one site remains wild-type 
and, thus, cleavable, HDR can still mediate homing. The Prowse et al. (2017) model, 
which these simulations are based on, does not consider MMEJ-based repair outcomes 
but does take into account the likelihood of deletions of intervening sequences between 
any two of the multiplexed gRNAs. Deletion of intervening sequence between two gRNA 
recognition sites is assumed to result in loss of function of the female-fertility gene, 
regardless of the intervening sequence distance. In practice, deletion may not always lead 
to gene disruption. 
Although this model provides insight into the potential of multiplexing gRNAs within 
homing gene drive designs, it is important to note that there may be additional factors to 
consider that are not included within this simulation. These include the potential for 
reduction in HDR efficiency with increasing number of gRNAs due to the imperfect 
homology from an increasing spacer region containing the gRNA target sites. Another 
factor that should also be considered is the potential of Cas nuclease activity saturation 
due to multiple expressed gRNAs. 
A key technical hurdle with Strategy A is identifying a female-fertility gene that is not 
required in the germ cells for fertility but is required in the soma for female mice to be 
fertile. The progesterone receptor gene (PR) was suggested as an “attractive candidate” 
by Prowse et al. (2017), however, they did not mention that female mice lacking a 
functional PR gene have reproductive abnormalities, inflammation and severely limited 
mammary gland development (Chappell et al., 1997; Lydon et al., 1995). These 
phenotypes pose a significant welfare concern for the infertile gene drive females. To the 
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best of my knowledge no other suitable gene in mammals has been identified and this 
would require a separate in-depth scientific investigation to identify candidate genes. 
Strategy A was eliminated as a candidate strategy for development due to its potentially 
highly invasive nature illustrated in the simulations and the challenges of finding a suitable 
target gene, which requires a separate investigation. At the outset of this project, CRISPR-
based gene drive technology had not been tested in vertebrates and there remained 
numerous unknowns regarding the application of the technology in mice. In light of these 
concerns, a conservative and safeguarded strategy was considered the best path 
forwards. 
3.4.2 Strategy B and C have low invasive potential 
Fortunately, compared to Strategy A, Strategies B and C demonstrated low invasiveness 
within the simulations and only consistently lead to eradication of the targeted population 
at substantial rates of animal supplementation and in the absence of NHEJ (Figure 3.6). 
Unlike Strategy A, Strategies B and C do not spread through the population in somatically 
heterozygous individuals and therefore results in a threshold dependent spread and a 
requirement for constant ongoing supplementation to achieve significant suppression. 
As a pest control approach, Strategies B and C may only be practical on small island 
populations or as a complementary tool to other traditional pest control approaches. 
Because of the pest status of mice and rats, a number of conventional approaches are 
available and can reduce densities by over 90% (Brown, 2006; Brown et al., 2007). If mice 
containing constructs consistent with strategies B or C were introduced following the use 
of conventional control, they could likely eradicate the population using a relatively smaller 
number of individuals to saturate the remaining population. Future modelling work should 
investigate this scenario. 
In the scope of this project, the limited invasive potential of Strategies B and C pose a 
low-risk, proof-of-concept gene drive strategy to test in laboratory-contained mice. 
Furthermore, there are suitable target genes within the scientific literature for these 
approaches. Two promising candidate genes that were identified in this project are OOEP 
and NLRP5. However, one principle downfall of these strategies is that the homing 
capacity in the female germline will not be able to be qualified, as heterozygote females 




3.4.3 Limitations of the model 
Although these simulations helped guide the strategy selection, it should be highlighted 
that this model is simplistic, taking into account only a small number of parameters. 
Although much is known about wild mouse populations, there is still a need for more 
empirical data for increased accuracy of models. Some on the parameters, such as the 
95% cutting efficiency at the target site has been taken from insect studies and it remains 
unknown if vertebrate systems can achieve similar efficiency (Hammond et al., 2016). 
Another important shortcoming of this model is that density and spatial parameters are 
excluded, along with the potential for behaviour resistance to gene drive animals and 
structured mating systems in the wild. These components are only now being 
implemented into the latest invertebrate gene drive models and should be considered in 
future vertebrate models (Champer, Kim, et al., 2019; North, Burt, & Godfray, 2019; Rode 
et al., 2019). Despite the limitation of the simulations presented here, they have been 
valuable in gaining insight and guiding decisions on strategy development. 
3.4.4 Expression and design 
The population simulations of Strategies B and C illustrate these approaches have the 
same ability to suppress a population when the rate of NHEJ is equal. However, in practice 
the rate of NHEJ is unlikely to be equal for both these systems. This study will test two 
different promoters to express the Cas nuclease, one using a synthetic CAG promoter to 
constitutively express the Cas nuclease, which aims to drive homing within the zygote or 
within the early developing embryo. The other system will use a germline specific mouse 
VASA (as known as DDX4) promoter to drive expression and homing in the germ cells. 
As Grunwald et al. (2019) report, it is likely that the timing of Cas expression will influence 
HDR efficiency and the resulting genome editing outcomes (Figure 3.13). 
3.4.5 Safeguard strategies 
Although our modelling indicates that both Strategies B and C require considerable 
numbers and ongoing release of gene drive animals to have an impact on population size, 
two additional safeguard strategies were incorporated in the experimental design: barrier 
confinement and molecular confinement. Barrier confinement involves housing animals in 
a CL 2 facility, while the molecular confinement strategy is a SGD, which works by 
separating the gRNA and Cas onto separate chromosomes so one allele will drive in the 
presence of the other but not the other way around. A SGD drive poses no greater risk to 
the environment than a traditional genetically engineered mouse, and the transgenes 
employed in this study are not predicted to confer a selective benefit. ROSA26 is the 
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obvious choice for gRNA expression in a laboratory mouse project, with history of 
successful gene targeting events in mice (Casola, 2010). 
3.4.6 In vitro gene drive strategy 
In addition to design and modelling, I also layout the design of a strategy for in vitro testing 
homing gene drives. The approach would allow constructs to be functionally tested and 
HDR interhomolog repair to be quantified. One advantage of this in vitro system is that it 
could be used to assess how factors, such as RAD-51, Mek1 or Spo11, can impact HDR-
mediated interhomolog repair. If successful, factors that increase interhomolog repair 
could be co-expressed in future gene drive designs. However, it is important to note that 
genome editing efficiencies and outcomes are cell type dependent (Komor, Badran, & Liu, 
2017). The in vitro system to be developed in this project is intended for testing in ES 





Figure 3.13 Possible genome editing outcomes from germline Cas expression (Strategy B) and constitutive Cas expression 
(Strategy C). Red band represents gene drive cassette. Turquoise shading represents a region of Cas expression. Black bands 
indicate an insertion or deletion of base pairs (indel). For Strategy B, it is expected that upon fertilisation Cas is not expressed within 
zygote, embryo or soma. Cas is expressed in the germline of mature males and females, which leads to cleavage of the maternal 
wild-type chromosome. The DSB is repaired by either (a) HDR, copying the gene drive cassette into the cut site leading to fertile male 
and infertile female offspring or (b) non-homologous end joining (NHEJ), leading to fertile male and infertile or fertile female offspring. 
For Strategy C, upon fertilisation cleavage of the maternal wild-type chromosome will either be repaired by (c) HDR, leading to fertile 
male and infertile female offspring; (d) NHEJ, leading to fertile male and infertile or fertile female offspring; (e) delayed Cas expression 





3.4.7 Experimental design and regulatory approval 
As may be expected, gene drive research receives greater oversight and scrutiny than 
conventional production of transgenic research animals. Gene drives have the potential 
to impact the shared environment. This project, being the first example of a vertebrate 
gene drive in the UK, was highly scrutinised. Ultimately, much of my time on this project 
was spent writing a total of nine risks assessments for genetically modified cell lines and 
animals, attending biosafety committee meetings, training courses, presenting to various 
safety committees within the University and finally writing a Project License (PPL) for the 
UK Home Office. After the lengthy journey navigating the regulatory landscape, a PPL for 
this project was granted by the Home Office until the 14th of January 2020. The cover 
page of the PPL and a non-technical summary can be found in Appendix A.9. The 
administrative burden required for progression of this gene drive project was a significant 
hurdle and as an emerging researcher I would consider this when weighing up future gene 
drive research opportunities.  
3.4.8 Conclusions 
Modelling can provide insight into the potential of gene drive technology at the population 
level. It is a valuable tool for gene drive research and helped guide the decision-making 
process in this project. A weak performing gene drive was purposefully selected, and 
multiple safeguards were incorporated into the design. It is hoped that the data generated 
from this project will allow for improved accuracy of subsequent gene drive models and 
permit the safe testing of gene drives with greater potential for real-world application. 
Following the experimental design of animal studies and significant university and 
regulatory scrutiny, the animal work received the ‘green light’ as safe and valuable 





4 Reagent development and validation 
4.1 Introduction 
After selecting two split gene drive (SGD) strategies to develop in Chapter 3, the reagents 
needed to engineer these approaches in ES cells were designed, developed and tested. 
This included designing and screening gRNAs, Cas nuclease selection and determining 
the best female-fertility gene of two candidates based on cutting efficiency, as well as 
designing, cloning and validating targeting constructs. The majority of these reagents 
were validated in ES cells. Background on mouse ES cell culture can be found in section 
5.1. 
4.1.1 Cell transfection methods 
To test genome engineering reagents in vitro, scientists must introduce DNA, RNA or 
protein into cells. In eukaryotic cells this is called transfection and can be divided into 
transient and stable approaches. In transient transfection, the foreign material is 
expressed for a limited amount of time, and any transfected DNA does not integrate into 
the genome, which is typically the case when screening gRNA efficiency or validating 
plasmid functionality. Stable transfection results in the integration of foreign DNA into the 
cell’s genome, which is the case when engineering a gene drive in ES cells (Behringer et 
al., 2014; Kim & Eberwine, 2010). Many factors affect the efficiency of transfection, 
including the quality of the cells being cultured, optimal medium and growth conditions, 
and cell characteristic, as well as the quality and quantity of the transfected material 
(Behringer et al., 2014). 
The most widely used non-viral methods for the delivery of genome editing reagents into 
ES cells are electroporation and lipofection (Behringer et al., 2014). Electroporation 
involves applying an electrical field to cells in order to increase the permeability of the cell 
membrane, allowing the genome editing reagents to enter into the cell (Capecchi, 2005; 
Kotnik et al., 2019). Lipofection achieves the same results but using synthetic cationic 
lipids that interact with nucleic acids or proteins to form lipid complexes, which fuse with 
the cell membrane to be delivered into the cell (Ma et al., 2004). As there was a robust 
77 
 
ES cell lipofection protocol established at The Roslin Institute with proven ability to deliver 
successful germline transmission, lipofection was the transfection method used 
throughout this project. 
4.1.2 SpCas9 vs AsCas12a 
This project set out to test two Cas nucleases – SpCas9 and AsCas12a – for use in the 
proposed SGD strategies (section 3.3.5). A biological and structural description of both 
SpCas9 and AsCas12a can be found in section 1.8.1 and 1.8.2, respectively. As gene 
drive nucleases, both SpCas9 and AsCas12a have potential advantageous. SpCas9 is 
currently the best-characterised Cas nuclease for genome editing (Christie et al., 2020). 
It has a record of success in genome engineering projects in diverse species, include 
mice, and is currently considered the most robust Cas nuclease for genome engineering 
applications (Lee, Yoon, & Kim, 2020). Furthermore, SpCas9 has been successfully 
applied to engineer gene drives in yeast, D. melanogaster, mosquito and mice  (DiCarlo 
et al., 2013; Gantz & Bier, 2015; Gantz et al., 2015; Grunwald et al., 2019). 
An AsCas12a gene drive has not yet been reported. As a gene drive nuclease, AsCas12a 
may have the benefit of limiting the development of drive resistant alleles generated by 
the error-prone NHEJ repair pathway. Unlike SpCas9, AsCas12a cleaves relatively far 
away from the PAM (nucleotides 19 and 23; see Figure 1.8). AsCas12a-mediated NHEJ 
events are likely to retain the PAM sequence. Therefore, if HDR does not initially occur 
after AsCas12a-mediated cleavage, the continued presence of the PAM may give 
AsCas12a the ability to cleave again and possibly mediate HDR (Naduthodi et al., 2019). 
This ‘second chance’ mechanism could improve the homing frequency of a gene drive 
and limit the development of gene drive resistant alleles. Furthermore, AsCas12a (3950 
bp) is smaller than SpCas9 (4250 bp) and has the ability process its own gRNAs from a 
single transcript, which is beneficial when multiplexing gRNAs (Zetsche et al., 2017).  
For these reasons, both AsCas12a and SpCas9 with corresponding gRNAs were 
screened in this project. 
4.1.3 In silico gRNA design 
Two major challenges hinder the development and application of the CRISPR-Cas 
systems: potential off-target effects (specificity) and on-target efficiency of the gRNAs 
(Liu, Zhang, & Zhang, 2019). Careful gRNA design can help resolve these issues and 
powerful computational approaches facilitate in silico design of specific gRNAs with 
efficiency predictions. There are a number of gRNA design tools now available, including 
CHOPCHOP, E-CRISP, CCTop, EuPaGDT and CRISPOR. 
78 
 
Within this project, the CRISPOR online tool was used as it provides an ensemble of tools 
in one package. At present, CRISPOR (version 4.97) contains 521 genomes and 32 
gRNA types, including both SpCas9 and AsCas12a guides. In a recent review by Liu, 
Zhang, et al. (2019) were they evaluated 15 gRNA design tools; they state “CRISPOR 
may be the best tool for designing gRNAs”. CRISPOR takes genome coordinates and 
sequences of less than 2 kb as inputs and provides comprehensive information as 
outputs, which include specificity, efficiency and out-of-frame scores, and likely 
mismatches in the selected genome are listed for each gRNA. A detailed step-by-step 
methodology and screen shots of the CRISPOR interface can be found in section 2.4.1. 
4.1.4 gRNA screening 
Although in silico tools provide valuable insight, in vitro screening in the cell type of interest 
is needed to rank gRNAs. When in vitro screening gRNAs, it is beneficial to screen 
multiple gRNAs to increase the prospect of identifying guides with suitable characteristics 
(Kabadi & Gersbach, 2014). Unlike gRNAs for most genome engineering projects, guides 
for gene drives are required to cut the target site in every generation. In addition to having 
highly optimised gRNAs, sequence location is also critical for gene drive gRNAs to bias 
MMEJ events in favour of out-of-frame mutations rather than cutting at sites where micro-
homology around the cut site is likely to lead to a small in-frame mutation that can create 
a functional but resistant allele. Within this project the SpCas9 and AsCas12a gRNAs that 
were designed using CRISPOR were in vitro screened via two methods: (1) T7 
endonuclease I assay (T7EI) and (2) Sanger sequencing followed by Inference of 
CRISPR Edits (ICE) analysis.  
Both these approaches are based on PCR amplification of relatively small regions 
spanning the gRNA target site. SpCas9 complexed with a single gRNA has been shown 
to induce large deletions, at least kilobases in size and complex lesions, such as 
translocations, large insertion and non-contiguous lesions at significant frequencies 
(Kosicki, Tomberg, & Bradley, 2018). Therefore, screening gRNAs with T7EI and ICE 
assays will not provide insight into the frequency of these possible outcomes. 
4.1.4.1 T7 endonuclease I (T7EI) assay 
In the T7EI assay, Cas nuclease and gRNA targeting the region of interest are transfected 
into cells, which results in cutting and repair, predominantly by NHEJ or MMEJ at the 
targeted site. gDNA from the pooled population is purified and the targeted region is PCR 
amplified. Following PCR amplification, the PCR product is denatured and re-annealed 
through a series of heating and cooling steps. The re-complexed PCR product should 
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result in heteroduplexed DNA owning to the variation of indels in the pooled population 
generated from the repair of CRISPR-mediated cleavage by NHEJ or MMEJ pathways. 
The assay takes advantage of T7 endonuclease I, which preferentially cleaves 
mismatched DNA, down to a 1 bp resolution. T7EI recognises and cleaves DNA 
heteroduplexes that contain mismatches, generating smaller-sized DNA fragments that 
can be resolved by agarose gel electrophoresis. This method can be used to identify the 
presence of CRISPR-generated mutations based on indel formation. The frequency of 
indels is used to make an inference of gRNA cutting efficiency (Kim et al., 2009; Kim, Kim, 
Kim, et al., 2014). Researchers can use densitometry to calculate the ratio of the smaller 
nuclease-specific band to the uncut band in the agarose gel, this helps compare gRNA 
efficiencies (Sentmanat et al., 2018); however, T7EI is not a quantitative method and does 
not provide information on the different types of indels generated. The method is 
commonly used to short-list gRNAs before screening by quantitative methods, such as 
ICE analysis. 
4.1.4.2 Inference of CRISPR edits (ICE) analysis 
In an ICE analysis, like the T7EI assay, the targeted region containing CRISPR-mediated 
indels is PCR amplified from a pooled population of cells that have been transfected with 
the Cas nuclease and gRNA, however, the PCR product is Sanger sequenced along with 
a wild-type control sample. The Sanger sequencing trace data is used to determine the 
relative abundance and levels of indels due to CRISPR-mediated cleavage. ICE software 
aligns the unedited wild-type control sequence to the edited targeted sample sequence to 
determine the differences between samples. The ICE software then calculates gRNA 
cutting efficiency based on indel frequency and provides detailed information on the 
different types and distributions of indels generated as a knock-out score, this is helpful 
in determining the likelihood of in-frame indels that could create functional resistant gene 
drive alleles (Hsiau et al., 2019; Sentmanat et al., 2018).  
4.1.5 Construct design 
As in any CRISPR-based genome engineering project, once the Cas nuclease and 
gRNAs have been selected, the targeting constructs can be designed. Due to the large 
size of gene drive constructs, plasmid DNA vectors are typically used for delivering 
constructs into cells for homologous recombination. Important genetic elements for 
plasmid generation include a plasmid backbone with a bacterial origin of replication and 
an antibiotic-resistance gene to allow for the propagation of the plasmid within bacteria, 
while selecting against any bacteria not carrying the plasmid (Howe, 2007). Genetic 
elements used in the gene drive systems designed in this project, including promoters, 
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fluorescent proteins, bicistronic elements, inducible systems, selectable markers and 
homology arms. These elements are discussed further below. 
4.1.5.1 Promoters 
Although the role of promoters is generally understood, the important function they play 
in specifying Cas nuclease expression in gene drives justifies a short explanation. 
Promoters were originally defined as a site on the DNA were the RNA polymerase 
recognises a specific signal that allows it to bind tightly as a prerequisite for transcriptional 
initiation. Today the definition is broader and also includes cis-regulatory elements 
responsible for controlling transcriptional machinery and determining the level and 
specificity of transcription (Behringer et al., 2014). Promoters can be endogenous or 
exogenous, where they are built into the foreign vector and introduced into the cell, as is 
the case of the promoters driving expression within the constructs used in this project. For 
reliable expression in ES cells, the PGK-1 promoter is commonly used (Wang et al., 
2008). Were the goal is high transgene expression, the CMV early enhancer-chicken B-
actin promoter (CAG) is widely used (Alexopoulou, Couchman, & Whiteford, 2008). VASA 
has been described as a germline-specific promoter and is used for germline expression 
of Cre recombinase in the widely used VASA-Cre mouse line (Gallardo et al., 2007). For 
expressing small RNAs, such as gRNAs, expression is routinely driven by an RNA 
polymerase III promoter, most often by the human U6 promoter in mammalian systems 
(Good et al., 1997). 
4.1.5.2 Fluorescent proteins 
Fluorescent proteins can be used as reporter molecules and have had a major impact on 
our understanding of biology. The expression of these proteins has been shown to be 
compatible with in vitro and in vivo applications. Visualisation requires an excitation light 
and a compatible filter. Each fluorescent protein has its own excitation spectrum with one 
or two peak maxima. In response to the excitation light, each protein emits a different-
wavelength light. By ‘tagging’ genes with a fluorescent protein by terminal fusion or using 
a bicstronic element (section 4.1.5.3), it is possible to monitor protein expression and 
trafficking (Behringer et al., 2014).  
The parental proteins of the two major classes of fluorescent proteins are the green 
fluorescent protein (GFP), isolated from the jellyfish Aequorea victoria, and the red 
fluorescent protein dsRED, isolated from mushroom coral (Discosoma sp.). Many mutants 
of these parental proteins with spectral and intensity variations in light emissions have 
now been isolated (Behringer et al., 2014; Rizzo, Davidson, & Piston, 2009). This project 
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used the original dsRED and the enhanced GFP (eGFP), which contains two-point 
mutations (F64L and S65T) relative to the original GFP. These point mutations increase 
fluorescence and photostability of GFP, allowing for better use in mammalian cells at 37 
°C (Arpino, Rizkallah, & Jones, 2012; Yang, Cheng, & Kain, 1996). 
4.1.5.3 Bicistronic elements 
Co-expression of multiple genes is needed for many experiments. There are a multitude 
of techniques to achieve this, including the use of multiple or bidirectional promoters, or 
the creation of bicistronic or multicistronic elements. Unlike promoters which will create 
unique mRNA transcripts for each gene, multicistronic vectors simultaneously express 
two or more separate proteins from the same mRNA (Fan et al., 2014). The two strategies 
most widely incorporated into plasmids for research purposes are IRES and 2A peptide 
sequences (Shaimardanova et al., 2019).  
IRES sequences allow for the internal initiation of translation in a cap-independent manner 
(Hellen & Sarnow, 2001). This type of translation initiation was first discovered on 
picornavirus RNAs (Jang et al., 1989). The IRES sequence, which comprises ~500 bp, 
allows the construction of artificial bicistronic genes containing two or more coding 
regions. IRES elements are very useful and commonly found in bicistronic vectors, 
however, they do have some disadvantages. These elements are quite large (~500 bp) 
and it may not be feasible to express more than two genes at a time using IRES elements 
(Fan et al., 2014). Scientists have also reported lower expression of the downstream 
cistron due to factors such as the experimental cell type and the specific genes cloned 
into the vector (Mizuguchi et al., 2000). 
Some viruses have evolved another strategy to induce the expression of multiple proteins 
from a single transcript. In this approach, the coding regions of these proteins are linked 
by a distinct sequence that encodes for an 18 to 22 amino acid peptide (2A). During 
translation, the 2A sequence leads to a cleavage event before its carboxyl terminus 
proline, releasing the protein produced that far and initiating the translation of the 
downstream protein at the proline. This re-initiation creates a second protein (Behringer 
et al., 2014). There are four main 2A peptides used in multicistronic constructs – P2A, 
T2A, E2A and F2A. 2A cleavage is universal in eukaryotic cells, and, although some 
scientists report close to 100% cleavage with some of these 2A peptides, no consensus 
has been reached on which peptide works best (Fan et al., 2014; Liu et al., 2017). Within 




4.1.5.4 Inducible systems 
In many genome engineering projects, inducible expression of genetic elements is 
required, as was the case for the in vitro gene drive system outlined in section 3.3.6. 
Several inducible gene expression systems have been developed, these include small 
molecule activations systems, such as tetracycline-inducible gene expression and site-
specific recombinase systems, such as Cre-LoxP or Flp-FRT (Behringer et al., 2014). 
These additions to the molecular toolbox have made it possible to ‘switch on’ gene 
expression when desired. Within this project, the Cre-LoxP system was used. 
The Cre-LoxP system, derived from P1 bacteriophage comprises of a Cre recombinase 
that recognizes a 34 bp consensus sequence consisting of two 13 bp palindromic 
sequences (Cre recognition sites) and an 8 bp non-palindromic core that is responsible 
for the directional nature of the recognition site (Figure 4.1a). The 34 bp LoxP recognition 
site is small enough to be considered a ‘neutral’ sequence when integrated into the mouse 
genome and occurs at very low frequency (Kwan, 2002). Semprini et al. (2007) report that 
the overall frequency of primary cryptic LoxP sites in the mouse genome is 1.2 per 
megabase. Within Figure 4.1b, it can be seen that two LoxP sites in the same direction 
will result in excision of the intervening DNA by Cre-induced recombination, leaving one 
intact LoxP site. This approach can be used to excise a stop codon to initiate expression 
of a downstream gene of interest. In contrast, where two LoxP sites are in the opposing 
directions (Figure 4.1c), the Cre recombinase will invert the intervening piece of DNA to 
align or detach a promoter from a gene of interest. 
 
 
Figure 4.1 Cre-LoxP system. Structure and sequence of the LoxP recombinase 
recognition sites. Each site consists of two 13 bp inverted repeats flanking an asymmetric 
8 bp core region that defines the directionality of the recognition site. (b) Diagram of a 
deletion by Cre-LoxP mediated recombination. (c) Diagram of an inversion by Cre-LoxP 




4.1.5.5 Selectable markers 
Genome engineering in ES cells allows for the use of selectable markers. Selectable 
markers can either be used to identify those cells where integration has occurred (positive 
selection) or in which the result of genome alteration was loss of a selectable marker 
(negative selection). This project used positive selection for genome engineering events. 
There are three positive selection antibiotics commonly used in ES cell-based 
applications. These are neomycin, hygromycin and puromycin (Behringer et al., 2014). Of 
these antibiotics, puromycin selection is the fastest, with sensitive cells dying within 2 
days when used at 1 μg/ml concentration (Tate & Skarnes, 2011; Te Riele, Maandag, & 
Berns, 1992). Puromycin is an amino nucleoside antibiotic produced by Streptomyces 
albongier. It specifically inhibits peptide transfer on ribosomes. In this way, puro impedes 
the growth of various insects and animals, including ES cells. The expression the PAC 
gene (puromycin-N-acetyl-transferase) confers puromycin resistance (Behringer et al., 
2014). Within this project the PAC gene was included in all constructs for puromycin 
selection of genome engineering events. 
4.1.5.6 Homology arms 
Homology arms on targeting vectors are placed flanking the construct and positive 
selection markers and have the same nucleotide sequence as the two segments of the 
gene of interest with equivalent orientation. Relative to the orientation of the gene of 
interest, there are two distinguished arms – the 5’ arm and the 3’ arm. The sequence 
between these two segments should integrate by HDR (Behringer et al., 2014). Although 
early genetic engineering experiments typically utilised arms with at least 6 to 8 kb of total 
homology (Thomas & Capecchi, 1987), the double strand break induced by 
programmable nuclease stimulates repair at the target site, thereby reducing the size 
requirement of homology arms . The Zhang lab typically uses arms of 800 bp when the 
insert is >100 bp (Cong, 2013; Yang et al., 2013). In line with the recommendation of the 
Zhang lab, who pioneered CRISPR-SpCas9 gene editing in mammalian cells, this project 
utilised 800bp homology arms. 
4.1.6 Molecular cloning techniques 
After designing constructs, molecular cloning strategies are used to generate the targeting 
vectors. There are a broad range of cloning strategies available, including type II 
restriction enzyme cloning, Gibson assembly, gateway cloning with site-specific 
recombinases, topoisomerase cloning, Golden gate cloning with type IIs restriction 
endonucleases and ligation independent cloning (Casini et al., 2015; Fan et al., 2014). 
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This project used both restriction enzyme cloning and Gibson assembly to develop 
targeting vectors in the form of DNA plasmids. Constructs were generating using these 
cloning strategies and were transformed into bacteria for amplification, before purifying 
and validation of the resulting plasmid. Some background on these processes is provided 
below. 
4.1.6.1 Restriction enzyme cloning 
This cloning approach uses restriction endonucleases to create double strand DNA 
breaks at specific recognition sequences generating either blunt ends, where both strands 
of the target DNA are cut at the same spot creating blunt ends, or sticky ends, where the 
endonuclease cut both strands of the target DNA at different spots creating overhangs. 
To be able to clone a DNA insert into a cloning or expression vector using restriction 
enzyme cloning, both the insert and vector have to be treated with restriction enzymes 
that create compatible ends. If orientation of the cloning operation is important, at least 
one of the restriction enzymes used should be a sticky end cutter to ensure that the insert 
is incorporated in the correct orientation (Fan et al., 2014; Lessard, 2013). 
In practice, restriction enzyme cloning typically consists of restriction digests for your 
insert and plasmid vector, followed by isolation and purification of the appropriate 
linearized DNA fragments before ligating the insert and the vector together. Ligation is 
accomplished by covalently connecting the sugar backbone of the two DNA fragments. 
This reaction is commonly performed by the T4 DNA ligase. The DNA ligase catalyses 
the formation of covalent phosphodiester linkages, which permanently joins the 
nucleotides together. After ligation, the insert is physically integrated into the vector and 
the complete plasmid can be transformed into bacterial cells for amplification (Allison, 
2007; Lessard, 2013). 
4.1.6.2 Gibson assembly 
In 2009, Dr Daniel Gibson and colleagues developed a method for the easy assembly of 
multiple linear DNA fragments, now called Gibson assembly (Gibson et al., 2009). 
Regardless of fragment length or end compatibility, multiple overlapping DNA fragments 
(15 to 50 bp overlap) can be joined in a single isothermal reaction (Fan et al., 2014). The 
Gibson assembly process can be used to assembly up to six fragments in one step, 
resulting in scar-free assembly that does not require the presence of specific restriction 
sites. The reaction exploits three different enzymes: (1) T5 exonuclease, which chews 
back the 5’ ends of the fragment, generating long overhangs which allows the single 
stranded regions with homology to anneal; (2) a DNA polymerase, to fill in the gaps; (3) 
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Taq DNA ligase, covalently joins the annealed complementary DNA fragments, removing 
any nicks and creating a contiguous DNA fragment. This mix of enzymes has been 
optimised to work at the same temperature, so the entire reaction takes an hour or less 
to complete at 50 °C. The sample can then be immediately transformed into bacterial cells 
for amplification (Fan et al., 2014; Gibson, 2011). 
4.1.6.3 Transformation and amplification 
After cloning a plasmid, it is typically transformed into bacteria to be amplified. Bacterial 
transformation is a process of horizontal gene transfer by which some bacteria take up 
foreign genetic material from the environment. Bacteria that have the ability to take up 
free extracellular DNA are termed competent cells (Howe, 2007). The majority of 
commercial competent cells are lab strains of E. coli are derived from two individual 
isolates, the K-12 strain and the B strain. K-12 has led to the common lab strains MG1655 
and its derivatives DH5alpha and DH10b (also known as TOP10) among others, while the 
B strain gave rise to BL21 and its derivatives (Fan et al., 2014; Samuelson, 2011). 
In the laboratory, bacterial cells can be made competent and DNA subsequently 
introduced by a procedure called the heat shock method. Heat shock transformation uses 
a calcium rich environment provided by calcium chloride to counteract the electrostatic 
repulsion between the plasmid DNA and bacterial cellular membrane (Dagert & Ehrlich, 
1979; Koontz, 2013). A sudden increase in temperature creates pores in the plasma 
membrane of the bacteria and allows for plasmid DNA to enter the bacterial cell. Once 
inside a bacterium, the plasmid encoded origin of replication facilitates multiplication of 
the plasmid, which is further amplified during consecutive rounds of cell division (Howe, 
2007).  
The transformed plasmid usually contains an antibiotic resistance gene. For example, a 
plasmid carrying the gene beta lactamase (Amp R) leads to ampicillin-resistance, allowing 
only transformed bacteria with the plasmid to readily grow in medium containing ampicillin. 
Because bacteria are easy to grow in a lab, divide relatively quickly, and exhibit 
exponential growth rates, plasmids can be replicated easily and efficiently in a laboratory 
setting using this approach (Howe, 2007). 
4.1.6.4 Validation and purification of plasmid 
After cloning and amplifying a plasmid, it is critical that the cloning events are verified. 
This is important to catch any errors in cloning, sample handling or sequence assembly 
steps. Initially this can be done by restriction enzyme (RE) analysis, which involves 
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digesting the plasmid with one or more restriction enzymes and resolving digested 
products on an agarose gel. Putative positive plasmids with expected band patterns 
should then be verified by Sanger sequencing (Fan et al., 2014; Lessard, 2013). 
Sequencing of the entire plasmid can be performed but it is more cost effective to 
sequence the “insert” (the gene or genetic element cloned into the plasmid), and any other 
important features that differentiate this plasmid from its predecessor. Important features 
may include cloning junctions (where most sequence assembly errors occur), in-frame 
protein fusions and PCR amplified fragments. 
Following Sanger sequence verification of a plasmid, it is critical that any plasmid to be 
introduced into ES cells is high-quality DNA, free of endotoxins, proteins, RNA and 
contaminating chemicals such as oxidised phenol. The DNA should be purified either with 
a QIAGEN EndoFree Maxi Kit or similar purification kit, or by CsCl centrifugation 
(Behringer et al., 2014). Once a purified plasmid preparation is obtained, functional 
validation of plasmids should be performed where possible, such as expression of 
fluorescent reporter proteins. 
4.1.7 Aims 
The aim of this chapter was to generate and validate the reagents for engineering two 
SGD strategies in mouse ES cells. This includes designing and screening SpCas9 and 
AsCas12a gRNAs, primer design and optimisation, and the design, cloning and validation 
of plasmid constructs. Furthermore, a construct for a Cre-inducible gene drive system was 






4.3.1  In silico gRNA design 
Using the CRISPOR tool four SpCas9 and four AsCas12a gRNAs were designed 
targeting both NLRP5 and OOEP. The NLRP5 gRNAs were targeted to exon 7, the largest 
exon of the 15 exon gene (Figure 4.3). For OOEP, four SpCas9 gRNAs were designed 
targeting exon 1 and four AsCas12a gRNAs were designed to target sites in both exons 
1 and 2. OOEP AsCas12a gRNAs were spread across exon 1 and 2 due to the limited 
number of AsCas12a PAM sites (5’-TTTV) within exon 1. A further two SpCas9 and two 
AsCas12a gRNAs were designed targeting the ROSA26 safe-harbour locus, located 
within intron 1 of the gene. This safe-harbour site corresponded to the genomic region 
between homology arms of pDonor-ROSA26 plasmid. To multiplex gRNAs within the 
SGD design, gRNAs were restricted to a short genomic region for OOEP and NLRP5 to 
allow for efficient HDR with multiplexed gRNAs. OOEP SpCas9 and AsCas12a gRNAs 
were restricted to a 70 and 395 bp region, respectively, while NLRP5 SpCas9 and 
AsCas12a gRNAs were within a 143 and 196 bp windows. 
CRISPR gRNAs were selected from the CRISPOR online tool based on predictive gRNA 
outputs the software provides. Examples of the CRISPOR input and output screens can 
be found in Figures 2.1 and 2.2, respectively. gRNAs selected for this project were 
required to have an MIT specificity score scores greater than 50, with no identical gRNA 
target sites in the mouse reference genome. gRNAs were also required to have an out-
of-frame score greater than 50. In addition to specificity and out of frame score, predicted 
efficiency was also taken into account but with less reverence. The sequences of the 
gRNAs and the CRISPOR data outputs can be seen in Appendix A.10. The location of 










4.3.3.1 T7 endonuclease I (T7EI) assays 
T7EI assays were performed, and gel electrophoresis were visually assessed based on 
the fraction of nuclease-specific cleavage products. The substrate for each T7EI assay 
was a PCR product spanning the gRNA target region (see section 4.1.4.1 for further 
details on T7EI assay). As gRNAs within a gene drive system are required to cut within 
every generation, it is desirable to have highly efficient gRNAs.  
For those gRNAs targeting one of the essential female-fertility genes, either OOEP or 
NLRP5, SpCas9 gRNAs cutting at exon 1 of OOEP were the most efficient by T7EI assay 
(Figure 4.8 and 4.9). NRLP5 SpCas9 gRNA 4 in Figure 4.9, also cut well, however, this 
project aimed to multiplex gRNAs within the SGD construct and no other NLRP5 SpCas9 
gRNAs demonstrated cutting at acceptable efficiency at the NLRP5 locus. There was 
evidence of AsCas12a gRNAs cutting at both the OOEP and NLRP5 locus but in all cases 
the AsCas12a gRNAs had less nuclease-specific cleavage product than the SpCas9 
counterparts. From the T7EI assay, OOEP SpCas9 gRNAs were short listed as potential 
candidates and an ICE analyses were performed to gain further information and help 
select the best performing three gRNAs at the OOEP locus for the SGD gRNA array. 
All of the ROSA26 gRNAs cut with acceptable efficiency. In order to generate a split drive 
system and knock-in an array of OOEP SpCas9 gRNAs into the ROSA26 locus, whilst 
preserving the integrity of OOEP target site, ROSA26 AsCas12a gRNAs were selected 




Figure 4.8 T7 endonuclease I (T7EI) assays of SpCas9 (top) and AsCas12a (bottom) 
gRNAs at the OOEP locus. D = T7EI digested PCR product. UD = Undigested PCR 





Figure 4.9 T7 endonuclease I (T7EI) assays of SpCas9 (top) and AsCas12a (bottom) 
at the NLRP5 locus. D = T7EI digested PCR product. UD = Undigested PCR product. 




Figure 4.10 T7 endonuclease I (T7EI) assays of SpCas9 (top) and AsCas12a 
(bottom) at the ROSA26 locus. D = T7EI digested PCR product. UD = Undigested PCR 
product. Red arrows indicate the expected size of nuclease-specific second band. 
 
4.3.3.2 Inference of CRISPR edits (ICE) analyses 
To perform the ICE analyses, Sanger sequencing of the targeted region was performed 
on the PCR products of gDNA extracted from the pooled population of CRISPR-Cas 
transfected cells. As a quality control, the sequence data was checked to verify 
overlapping of the trace data occurred proximal to the expected cut site, indicating indel 
mutations at the site within the pooled population (Figures 4.11 and 4.12). A wild-type 






Figure 4.11 Sanger sequence chromatograms from the OOEP target region. Regions 
were PCR amplified from pooled genomic DNA using primer pair ppOOEP. PCR products 
were sequenced with oGM75. A clear overlapping of multiple traces can be seen proximal 




Figure 4.12 Sanger sequence chromatograms from the ROSA26 target region. 
Regions were PCR amplified from pooled genomic DNA with primer pair ppROSA26. PCR 
products were sequenced with oGM95. A clear overlapping of multiple traces can be seen 






no inferences on the comparative efficiency of plasmid vs RNP delivered CRISPR-
SpCas9 can be made here. RNP versions of OOEP SpCas9 gRNA 1 and 4 when 
transfected separately and co-transfected can mediate cleavage. 
 
 
Figure 4.16 T7 endonuclease I (T7EI) assays of OOEP SpCas9 gRNAs 1 and 4 in 
ribonucleoprotein (RNP) form. D = T7EI digested PCR product. UD = Undigested PCR 
product. Red arrows indicate the expected size of nuclease-specific second band. 
 
4.3.5 Construct development 
After identifying target genes and gRNAs, plasmid SGD constructs were developed using 
the molecular cloning protocols described in section 2.2. Four plasmids were constructed 
in the following order: (1) OOEP_IVT; (2) OOEP_CAG; (3) OOEP_VASA and (4) 
ROSA26_gRNAs. Detailed workflows for construction of each plasmid vector can be seen 
in expandable construction histories stored on the Edinburgh data share at 
https://doi.org/10.7488/ds/2744. A list of primers, gene fragments (gBlocks) and DNA 
oligos used for cloning these vectors can be found in Appendices A.2 and A.6. A 
description of the elements contained in all plasmid vectors generated can be found in 
Table 4.1. A map and description of each vector, along with the validation data is provided 
on the following pages. 
OOEP_IVT was developed to in vitro test interhomolog repair efficiency of gene drives 
(section 3.3.6). The construct (Figure 4.17a) has a Cre inducible SpCas9–T2A–eGFP. In 
the absence of Cre, SpCas9–T2A–eGFP is inhibited by a floxed dsRED–STOP element 
upstream. dsREP is expressed by the CAG promoter. With the addition of Cre, the floxed 
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dsRED–STOP is excised, and the CAG promoter expresses the SpCas9–T2A–eGFP. 
OOEP_IVT was developed by Gibson assembly of six DNA fragments in a single reaction. 
A subsequent Gibson assembly reaction was used to add a bGHpA regulatory element 
at the AgeI restriction site.  
OOEP_IVT was validated by RE analysis with EcoRI+AhdI, XbaI+BspEI and ApaLI 
(Figure 4.17b). The plasmid was then sequenced (excluding backbone) and three SNPs 
identified. Two SNPs in the 3’ end of the CAG promoter (Figure 4.17c). This region is very 
GC rich and the identified SNPs could be a result of sequencing error or replication error. 
In vitro testing confirmed the CAG promoter was functional (Figure 4.18). 
The OOEP_IVT construct was developed and validated; however, it was not used for its 




Figure 4.17 Development of OOEP_IVT plasmid. (a) Map of the 10,074 bp plasmid. 
See https://doi.org/10.7488/ds/2744 for detailed construct development. (b) Restriction 
enzyme (RE) analysis of OOEP_IVT. Left gel is plasmid digest. Right is in silico simulation 
of anticipated digest outcome. (c) OOEP_IVT Sanger sequencing traces are presented 
as red arrows. Primers used for sequencing are shown in purple. The entire insert was 
sequenced, and three SNPs were identified. 
 
The functionality of the floxed dsRED–stop cassette was tested in HEK cells (following 
the culturing and transfection protocol in section 2.5.2). This was performed by 
transfection of OOEP_IVT or OOEP_IVT + Cre-Puro, which is a Cre recombinase 
expressing plasmid (seen section 2.7.3 for Cre-Puro plasmid map). As can be seen in 
Figure 4.18, there is a clear transition from dsRED to eGFP expression in the presence 
of Cre. This confirmed that the floxed allele was working as expected, although some 




Figure 4.18 Functional testing of OOEP_IVT in HEK cells. Column 1: cells under 
phase. Column 2: cells under Texas Red (TxRed) filter show dsRed expression. Column 
3: cells under fluorescein isothiocyanate (FITC) filter show eGFP expression. Column 4: 
merged images. OOEP_IVT predominantly express dsRED, although some leakage of 
eGFP was evident. When OOEP_IVT is co-transfected with a Cre-recombinase 
expressing Cre-Puro plasmid the floxed dsRED–STOP cassette is excised and cells 
transition to eGFP expression. Cells imaged at 24 hours post transfection. Scale bar = 
500 μm. 
 
OOEP_CAG was developed by manipulating OOEP_IVT through four separate cloning 
steps. This plasmid has 800 bp OOEP homology arms flanking a CAG promoter for 
constitutive expression of SpCas9–T2A–eGFP (Figure 4.19a). OOEP_IVT also contains 
a floxed PGK–PAC immediately upstream of the CAG promoter. To construct 
OOEP_CAG, firstly, the KpnI and FseI sites were used to exchange the CAG–LoxP–
dsRED–LoxP-–SpCas9 element in OOEP_IVT for the CAG–SpCas9 element from pSL70 
(plasmid map in section 2.7.3). 800 bp 3’ and 5’ homology arms were PCR amplified from 
wild-type E14 ES cell gDNA and inserted by sequential Gibson assembly reactions into 
BamHI and NheI restriction sites, respectively. The alignment of the homology arms 
relative to the OOEP SpCas9 gRNAs can be seen in Figure 4.20. Finally, a floxed PGK–
PAC cassette was added by Gibson assembly into the KpnI site. OOEP_CAG was 
validated by RE analysis with SacI, MspA1I and AatII (Figure 4.19b). Cloning junctions 
and PCR amplified DNA fragments were Sanger sequenced, and no SNPs were identified 
(Figure 4.19c). The plasmid was then transfected into ES cells and eGFP expression was 
verified (Figure 4.22a).  
 106 
 
Figure 4.19 Development of OOEP_CAG plasmid. (a) Map of the 11,761 bp plasmid. 
See https://doi.org/10.7488/ds/2744 for detailed construct development. (b) Restriction 
enzyme (RE) analysis of OOEP_CAG.  Left gel is plasmid digest. Right is in silico 
simulation of anticipated digest outcome. (c) OOEP_CAG Sanger sequencing traces are 
presented as red arrows. Primers used for sequencing are shown in purple. Sequencing 
across all new inserts and junctions was performed and no SNPs were identified. 
 
 
Figure 4.20 Alignment of the homology arms and gRNAs within OOEP_CAG and 
OOEP_VASA plasmids. The alignment is relative to the three selected OOEP SpCas9 
gRNA recognition sites for use in the split gene drive strategies. The blue outlined region 
represents the section of DNA that will be replaced with the split gene drive cassette. 
 
OOEP_VASA was assembled by manipulation of OOEP_CAG (see Figure 4.21a for 
plasmid map). Firstly, oGM237 and oGM238 were annealed and cloned into XbaI and 
NcoI restriction sites to replace the CAG promoter and introduce AscI and PacI restriction 
sites. The VASA promoter from pVASA-Cre was then added into the AscI and PacI 
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restriction sites (see section 2.7.3 for pVASA-Cre plasmid map). OOEP_VASA was 
validated by RE analysis with MfeI, NspI and ApaI+XbaI (Figure 4.21b). Cloning junctions 
in OOEP_VASA were sequenced, and one SNP was identified. This was not unexpected 
as the VASA promoter sequence provided by AddGene for the pVASA-Cre plasmid is 
based upon a prediction and not actual sequence data generated from the plasmid. 




Figure 4.21 Development of OOEP_VASA plasmid. (a) Map of the 16,360 bp plasmid. 
See https://doi.org/10.7488/ds/2744 for detailed construct development. (b) Restriction 
enzyme (RE) analysis of OOEP_VASA.  Left gel is plasmid digest. Right is in silico 
simulation of anticipated digest outcome. (c) OOEP_VASA Sanger sequencing traces are 
presented as red arrows. Primers used for sequencing are shown in purple. Sequencing 




U6-OOEP SpCas9 gRNA 3 was PCR amplified from pSL70 with gRNA 3 using primers 
oGM121 and oGM122 and added via Gibson assembly into the PmeI site. U6-OOEP 
SpCas9 gRNA 4 was then PCR amplified from pSL70 with gRNA4 using primers oGM127 
and oGM128 and added via Gibson assembly into the BamHI site. The 3’ homology arm 
was then adjusted to ensure the ROSA26 AsCas12a gRNA 1 would not cut this arm. 
Homology arm adjustment was achieved by annealing oGM147 and oGM148 and cloning 
into the SbfI and SalI restriction sites. The adjusted homology relative to gRNA recognition 
sequences can be seen in Figure 4.25. Finally, a floxed PGK–PAC was added by Gibson 
assembly into the NheI site. ROSA26_gRNAs was validated by RE analysis with 
XbaI+DraIII, NdeI and BsiWI+NheI (Figure 4.24b), before Sanger sequencing the entire 




Figure 4.24 Development of ROSA26_gRNAs plasmid. (a) Map of the 7,581 bp 
plasmid. See https://doi.org/10.7488/ds/2744 for detailed construct development. (b) 
Restriction enzyme (RE) analysis of ROSA26_gRNAs.  Left gel is plasmid digest. Right is 
in silico simulation of anticipated digest outcome. (c)  ROSA26_gRNAs Sanger 
sequencing traces are presented as red arrows. Primers used for sequencing are shown 




Figure 4.25 Alignment of the gRNA and adjusted homology arms within 
ROSA26_gRNAs plasmid. The alignment is relative to the selected ROSA26 AsCas12a 
gRNA 1 recognition site for integrating the gRNA array for the split gene drive systems. 
 
4.4 Discussion 
This chapter developed and validated the reagents to engineer the two SGD strategies 
identified in Chapter 3. 
4.4.1 Designing gRNAs 
A significant portion of this project was dedicated to gRNA selection. gRNAs for both 
SpCas9 and AsCas12a were designed against OOEP, NLRP5 and ROSA26 in the mouse 
reference genome (GRCm38/mm10) using CRISPOR in silico tool. 
When designing SpCas9 gRNAs using CRISPOR the software provides a MIT specificity 
score, predicted efficiency score, out-of-frame score and off-target mismatches in the 
mouse reference genome. For the MIT specificity score (Hsu et al., 2013), scores ranges 
from 0–100 with the higher the score, the lower the probability that off-target cleavage will 
occur genome. All SpCas9 gRNAs were above the recommended score of 50, with the 
lowest scoring gRNA being NLRP5 SpCas9 gRNA 3, at 55. The threshold of 50 or above 
for specificity score is based on the data from whole-genome off-target assays published 
by Haeussler et al. (2016). There is currently no similar specificity score available for 
AsCas12a but CRISPOR does provide a list of likely off-targets in the genome for both 
SpCas9 and AsCas12a. 
CRISPOR also identifies possible off-targets for both SpCas9 and AsCas12a gRNAs in 
the mouse genome and ranks these by number of mismatches. This CRISPOR output is 
a summary of a whole-genome search for sequences similar to the crRNA sequence. 
Mismatched off-targets are considered if they are flanked by an NGG, NAG or NGA motif. 
When selecting gRNAs in this study, we consider mismatches of 0, 1 or 2 nucleotides in 
the recognition sequence. Or in other words, the number of locations in the genome with 
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no mismatches in the crRNA sequence, number of locations in the genome with 1 
mismatch, and the number of locations with 2 mismatches. The threshold applied in this 
study required that guides have no identical recognition sequences (other than the 
intended target site) and a maximum of 1 location in the genome with 1 nt mismatch, 
providing the potential mismatch was within 12 nt “seed” region closest to the PAM. It has 
been demonstrated using in vitro cleavage assays that off-targets with a mismatch in the 
seed region are very inefficiently (Cho et al., 2014). 
CRISPOR also provides a predicted efficiency for each SpCas9 and AsCas12a gRNAs. 
SpCas9 gRNA efficiency is based on thr Doench et al. (2016) algorithm, which was 
developed from a database of 881 gRNAs in MOLM13/NB4/TF1 cells. While the 
AsCas12a efficiency score is based upon work by Kim et al. (2018), which analysed the 
indel frequencies for 15,000 target sequences delivered by lentivirus to HEK293T cells. 
Considering the large size of the training population this prediction efficiency is likely to 
be more accurate than that of the efficiency predicted with the SpCas9 algorithm. These 
scores give a prediction of how well a given target may be cut by the designed gRNA 
complexed with Cas. Scores range from 0–100 with 100 being the best. The most efficient 
AsCas12a gRNA had a predicted efficiency of just 24, while the least efficient OOEP 
gRNA had a score of 25.  
The final predictive parameter for gRNA selection in CRISPOR is the out-of-frame score, 
which is a prediction of the DNA sequence after DSB repair. This also ranges from 0–100 
and predicts the percentage of clones that will carry out-of-frame deletions, based on the 
micro-homology in the sequence flanking the expected cut site.  The higher the out-of-
frame score, the higher the probability that MMEJ-mediated deletions will have a length 
that is not a multiple of three. This score is based on an algorithm by Bae et al. (2014), 
which was developed for SpCas9. The AsCas12a out-of-frame predictions are also based 
on the Bae et al. 2014 algorithm and it remains unknown if this is useful as SpCas9 makes 
a blunt end cut, and therefore the out-of-frame scores may not be accurate for the 
staggered cut of AsCas12a. There is need for increased data to develop better tools for 
designing AsCas12a gRNAs. 
The out-of-frame scores CRISPOR provides are valuable when aiming to generate a gene 
knock-out with a single gRNA but when multiplexing gRNAs, as is the case in this project, 
this is likely to have little predictive power on the final outcome. While assessing as much 
in silico information is valuable before in vitro testing, the quality of the data from these 
algorithms remains questionable. There are obvious benefits in checking specificity score 
or mismatch scores of candidate gRNAs against reference genomes; however, certainly 
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within this study the efficiency scores and out-of-frame scores from CRISPOR where not 
in accordance with the results of the T7EI assay and the ICE analyses. 
4.4.2 Screening gRNAs 
To in vitro screen the CRISPOR designed gRNAs at their respective target sites, primers 
were designed using Primer3Plus and PrimerBLAST to PCR amplify the targeted regions. 
Collectively, Primer3Plus and PrimerBLAST offer a powerful tool for designing robust 
primers. Primer3Plus provides an intuitive interface for Primer3, which takes into account 
oligonucleotide melting temperature, size, GC content, and primer-dimer possibilities, 
PCR product size and positional constraints within the template sequence when selecting 
primers (Untergasser et al., 2007). While PrimerBLAST, performs a specificity check 
against the reference genome when a target template and both primers are provided (Ye 
et al., 2012). Used together, good primers can be identified, as was the case in this 
project. It can be seen in Figure 4.7, that there is no evidence non-specific priming for 
OOEP, NLRP5 or ROSA26 in the gradient PCRs between 55 to 67 °C, although the 
amount of amplicon does vary with differing annealing temperatures. An integrated 
software package that combines Primer3Plus with PrimerBLAST or a similar tool for 
checking primer specificity against reference genomes would make a powerful and 
streamlined primer design tool. 
Having designed the gRNAs and primers, guides were screened via two methods; T7EI 
assay and ICE analysis. The T7EI assay, offers a relatively cheap method for quickly 
screening gRNAs. It is not quantitative, although a rough estimate of cutting efficiency can 
be calculated based on the intensity of the cut band to uncut band. This was not performed 
in this project as the value of this calculation is questionable and of little use if an ICE 
analysis is later undertaken to quantify indel efficiency. Another issue with assessing 
cutting efficiency by T7EI is that it is dependent on the diversity of indels within the 
targeted population of cells. A high diversity of indels will lead to more heteroduplex 
formation upon denaturing and reannealing and therefore a more intense second band 
than would be predicted for low indel diversity, where more homoduplex formation would 
result in a less intense second band. This dependence on indel diversity could mean that 
T7EI may miss an efficient cutting gRNA that has flanking microhomologies that promotes 
MMEJ-mediated repair to the same indel in the majority of targeted cells. T7EI finds its 
value in quickly shortlisting putative gRNAs for further downstream analysis. 
As an alternative to T7EI, in vitro Cas-RNP digestion of PCR amplified target regions has 
recently become popular as a tool for screening gRNAs (Mehravar, Shirazi, Mehrazar, et 
 113 
al., 2019). While providing a very clear result, this approach fails to account for the impact 
of chromatin and nuclease accessibility to cut the target DNA in the cell type of interest. 
In vitro Cas-RNP digestion of PCR amplified target regions can be used to quickly exclude 
gRNAs that offer little or no Cas-mediated targeted DNA cleavage. This may be useful if 
the cell type used for in vitro gRNA screening has little biological relevance to the final 
targeted cell type. For example, screening gRNAs in an immortalised cancer cell line may 
not correlate with cutting efficiency of the same gRNAs in zygotes. 
Of those gRNAs targeting essential female-fertility genes in this project, OOEP SpCas9 
gRNAs were more efficient than all others when assessed by T7EI assay. All four OOEP 
SpCas9 gRNAs generated indels with good efficiency, displaying a strong nuclease-
specific cleavage product. There was also evidence of indels generated by OOEP 
AsCas12a gRNA 1 and 2, although the signal was not as strong as that of SpCas9 gRNAs 
targeting the same gene. Unfortunately, OOEP AsCas12a gRNAs 3 and 4 needed more 
PCR product to get an accurate T7EI read out but as OOEP SpCas9 gRNAs clearly 
outperformed both OOEP AsCas12a gRNA 1 and 2, the poor quality T7EI assays of 
OOEP AsCas12a gRNAs 3 and 4 were not repeated. 
NLRP5 proved less amendable to CRISPR-cleavage. Of the NLRP5 SpCas9 gRNAs, 
gRNA 4 was the only efficient cutter. As this project was seeking to multiplex gRNAs, a 
single NLRP5 gRNA was not sufficient. All AsCas12a gRNAs at NLRP5 locus had mild 
evidence of indel formation but this was minor when compared that that of OOEP SpCas9 
gRNAs. Based on T7EI assay results it was decided that the OOEP SpCas9 gRNAs would 
move on for further validation by ICE analysis.  
The T7EI assay was used to select between SpCas9 and AsCas12a gRNAs in this 
project, however, direct cutting efficiency comparisons between these nucleases may not 
be valid with this assay. SpCas9 cleavage generates blunt ends, which in the absence of 
a DNA repair template is frequently repaired by the error-prone NHEJ pathway; while 
AsCas12a generates sticky-end overhangs, which may be less prone to the formation of 
indels as the break could be repaired by the higher fidelity single strand annealing (SSA) 
pathway. If this were the case, T7EI assays would underestimate the inferred cutting 
efficiency of AsCas12a gRNAs when compared to SpCas9 gRNAs. The same 
underestimation would also be seen in ICE analysis. Further investigation is needed but 
if the 5 bp overhangs from AsCas12a cleavage is sufficient to initiate Rad51-independent 
SSA, this could be compensated for when screening AsCas12a gRNAs by indel-based 
approaches to more accurately assess the cutting efficiency of AsCas12a gRNas. 
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In parallel to screening the gRNAs targeting OOEP and NLRP5, SpCas9 and AsCas12a 
gRNAs were screened against the ROSA26 locus, intended as the safe harbour for 
expressing the gRNA array for the SGD strategies. Both AsCas12a and SpCas9 gRNAs 
cut ROSA26 with good efficiency. It is worth noting that CRISPOR offers two gRNA 
lengths for AsCas12a, 21 nt or 23 nt. IDT recommends 21 nt based on their inhouse 
testing of AsCas12a. Within this study, OOEP and NLRP5 AsCas12a gRNAs were 
designed to be 21 nt, while the two ROSA26 AsCas12a gRNAs were designed at 23 nt. 
Although no conclusions can be made here due to the potential for loci-dependent 
differences and the insufficient sample size, the 23nt gRNAs all cut with good efficiency, 
while no 21 nt AsCas12a gRNA targeting OOEP or NLRP5 cut with an acceptable level 
of efficiency.  
From the T7EI assays performed at ROSA26, AsCas12a gRNAs were selected for further 
screening. The selection of AsCas12a gRNAs was based on the need to preserve the 
OOEP locus when knocking-in an array of OOEP targeting SpCas9 gRNAs into the 
ROSA26 locus.  
ICE analyses were performed on the four OOEP SpCas9 gRNAs and the two ROSA26 
AsCas12a gRNAs. These assays gave further insight into the cutting efficiency. All four 
OOEP SpCas9 gRNAs had indel efficiencies greater than 60% and knock-out scores 
greater than 50. Based on the location of the gRNAs and to avoid overlap of the 
recognition sequences within the genome, OOEP SpCas9 gRNAs 1, 3 and 4 were 
selected for the SGD design. These gRNA recognition sites were also present in the Bl6 
mouse genome and, therefore, the SGD would be compatible with this strain for laboratory 
contained breeding. Of the two AsCas12a ROSA26 gRNAs assessed by ICE analysis, 
gRNA 1 was the most efficient cutter and would used for integrating the OOEP SpCas9 
gRNA array into this safe harbour locus. 
At the completion of gRNA screening, it was determined that the SGD would target the 
OOEP essential female-fertility gene, using SpCas9 with gRNAs 1, 3 and 4. ROSA26 
would be engineered with the ROSA26 AsCas12a gRNA 1. 
T7EI and ICE analyses were able to effectively screen gRNAs in this project, however, 
the gold standard for screening gRNAs involves targeted next-generation sequencing 
(NGS) to perform deep sequencing of the targeted region. Targeted NGS is an extremely 
sensitive method of detecting editing outcomes, and the high-throughput sequence-based 
data provides a comprehensive view of the indels generated. This level of detailed data 
analysis does not come cheap. At present, NGS is costly and time consuming to analyse 
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(Güell, Yang, & Church, 2014; Zischewski, Fischer, & Bortesi, 2017). In the future, it is 
likely that the cost will be reduced and simplified analysis pipelines with graphical 
interfaces will be developed, making it a more accessible method for genome engineers. 
Furthermore, an abundance of NGS data of CRISPR edits would have the added benefit 
of providing more deep sequencing data to improve the accuracy of gRNA design tools, 
such as CRISPOR. 
4.4.3 Benefits of Cas ribonucleoprotein  
gRNAs in this project were screened by lipofection of plasmids expressing both the Cas 
nuclease and corresponding gRNA into ES cells. Following transfection, integration of the 
dsDNA molecules into the host genome is always a possibility, and this increases in the 
presence of DSBs. This issue was recently highlighted when the US Food and Drug 
Administration found additional plasmid sequence proximal to the target site in genome 
edited hornless bulls (Norris et al., 2020). It is therefore desirable to limit the amount of 
dsDNA entering cells when undertaking genome engineering projects. When utilising 
CRISPR-Cas a common method of reducing the amount of additional dsDNA delivered 
into a cell is to use Cas nuclease in the form of mRNA or protein along with the gRNA, 
instead of expressing from a plasmid. With mRNA, Cas expression decreases as RNA is 
degraded within the cell. With Cas protein, a complex between the nuclease and gRNA 
is formed, called ribonucleoprotein (RNP) which can then be introduced into the cell. RNP 
has instant activity, with the protein degrading relatively shortly after transfection. Reports 
in human cells indicate SpCas9 RNP is substantially degraded within 24 hours following 
transfection (Dodsworth et al., 2020). 
Within this project, it was decided that SpCas9 RNP would be used for CRISPR-assisted 
knock-in of both constructs targeting the OOEP locus, limiting the amount of dsDNA 
entering engineered cells to just the targeting construct (OOEP_CAG or OOEP_VASA), 
reducing the likelihood of undesirable random plasmid integration. For genome 
engineering the OOEP locus, the two peripheral gRNAs (OOEP SpCas9 gRNA 1 and 4) 
were screened by T7EI assay to confirm CRISPR-mediated cleavage could be achieved 
using these gRNAs in RNP format. OOEP SpCas9 gRNAs 1 and 4 had sufficient cutting 
activity as RNP. Due to cost, AsCas12a was not available in RNP format for this project 






Whilst screening gRNAs and determining the exact target region, OOEP_IVT was cloned 
and functionally tested in HEK cells. This plasmid was developed to in vitro test 
interhomolog repair efficiency of gene drive systems. The construct in OOEP_IVT utilises 
a ‘traffic light’ Cre-inducible system. It was cloned by stitching together six fragments in a 
single Gibson Assembly reaction, followed by an additional Gibson Assembly reaction to 
add a polyadenylation signal. Gibson Assembly is undoubtedly a powerful tool for plasmid 
cloning and this is clearly demonstrated here by its ability for yield a 9789 bp plasmid from 
six separate fragments in a single reaction. Gibson assembly, in conjunction with the 
reduced cost and improvements in speed of commercial DNA synthesis now makes it 
possible to generate almost any conceivable plasmid design in a standard molecular 
biology laboratory.  
The OOEP_IVT construct was transfected into HEK cells and it proved capable switching 
from dsRED to SpCas9–T2A–eGFP expression in the presence of Cre recombinase. 
However, there was evidence of leaky transient expression of Cas9–T2A–eGFP in the 
absence of Cre. The functionality of the plasmid was not tested in ES cells. One potential 
solution to prevent leaking of SpCas9–eGFP in the absence of Cre is to introduce a 
polyadenylation sequence, such as bGHpA or SV40 immediately downstream of the 
dsRED within the floxed cassette. Although this system shows promise, it was decided to 
not develop this OOEP_IVT construct further and concentrate solely on the development 
of the in vivo based SGD strategies. There are three main reasons for this decision: (1) 
the potential data gained may not be biologically comparable to a gene drive expressed 
in germ cells or zygotes; (2) it is likely to be difficult and time consuming to isolate a 
heterozygous cell line with an intact wild-type allele on the homologous chromosome; (3) 
leaky expression of the SpCas9–T2A–eGFP is likely to compromise the results, and 
would therefore need to be rectified before continuing. Although this in vitro system was 
not further developed in this project, it has promise as a tool for quantifying interhomolog 
repair efficiency, and if developed further could find application for evaluating HDR 
enhancing and NHEJ inhibiting molecules. 
At the completion of gRNA screening, cloning of OOEP_CAG commenced by modifying 
OOEP_IVT through a series of four Gibson assembly cloning reactions, which included 
adding 800 bp homology arms to the construct. Next, OOEP_VASA was generated by 
modifying OOEP_CAG, through two restriction enzyme cloning steps.  
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To develop the array of three OOEP gRNAs for integration into ROSA26, the 
ROSA26_gRNAs plasmid was cloned using the pDonor-Rosa26 plasmid from Prof 
Charles Gersbach as the base plasmid. A complicated five step cloning series, involving 
both Gibson assembly and restriction enzyme cloning was performed. This included 
removing 63 bp of the 3’ homology arm to accommodate the ROSA26 AsCas12a gRNA 
1. This adjustment meant that the homology arms were not immediately flanking the 
expected cut site but instead the 5’ homology arm started 15 bp downstream and the 3’ 
arm was 48 bp  from upstream the cut site. This spacing between the cut and initiation of 
homology arms is likely to reduce HDR efficiency but given that the ROSA26_gRNAs 
construct has a puromycin selection cassette this reduced efficiency should be tolerable. 
When designing the ROSA26_gRNAs construct to express three SpCas9 gRNAs, 
consideration was given to using a polycistronic gRNA-tRNA array. This approach uses a 
single RNA polymerase III promoter to transcribe all gRNAs in one single transcript, with 
the tRNA sequences being removed by the endogenous tRNA-processing system to 
generate separate gRNAs (Dong et al., 2017). Using this approach, Dong et al. (2017) 
were able to express 2 to 6 gRNAs for precise genome editing of one to three histone 
deacetylase (HDAC) genes in human cells. This approach would limit the likelihood of 
recombination of the repetitive hU6 promoter sequences. For gene drive designs for real 
world application, such a system should be considered for improved evolutionary stability. 
Although the concept of the polycistronic gRNA-tRNA shows promise, to best of my 
knowledge there is currently no data on its effectiveness in vivo, and as robust and reliable 
expression of each guide was desired, it was decided that the ROSA26_gRNAs construct 
would use a separate hU6 polymerase III promoter for each of the three OOEP gRNAs. 
All plasmids were validated by RE analysis and Sanger sequencing. For ROSA26_gRNAs 
and the parental OOEP_IVT plasmid, the entire construct was Sanger sequenced. When 
sequencing OOEP_CAG and OOEP_VASA, which were based on OOEP_IVT, only the 
cloning junctions or PCR amplified fragments were sequenced. Plasmids were also 
functionally tested when a fluorescent protein was expressed in the construct. All plasmids 
expressed fluorescent proteins upon transfection. OOEP_VASA used the mouse VASA 
promoter to drive expression of SpCas9–T2A–eGFP, which should primarily restrict  
expression to germ line, however, low levels of expression are reported in mouse ES cells 
(Gordeeva, Lifantseva, & Khaidukov, 2011). On transient transfection of the OOEP_VASA 
plasmid in mouse ES cells, expression of eGFP was observed. The clear observation of 
eGFP expression in Figure 4.22 may be explained by a high copy number of the 
transiently transfected plasmid. 
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Plasmids are the bread and butter of molecular biology labs, but their development and 
validation can be laborious and costly (Casini et al., 2015). A number of commercial vector 
building companies now offer cost effective and efficient plasmid development and 
validation services. These companies usually employ a library of common genetic 
elements in conjunction with DNA synthesis technology, so users can design constructs 
through online tools and get immediate quotes and expected delivery times. These vector 
building companies are now applying high-throughput NGS technologies for rapid plasmid 
validation. The high costs of sample preparation for NGS sequencing have prevented 
most laboratories from using these methods for routine plasmid validation at small-scale, 
however, it becomes viable when done at scale by commercial plasmid construction 
services. NGS can sequence the entire plasmids providing scientists with even more 
information to aid in the reproducibility of scientific research.  
4.4.5 Conclusions 
This chapter designed, developed and validated the reagents needed to genome engineer 
two SGD strategies in mouse ES cells. During the process, SpCas9 was selected as the 
nuclease to target the OOEP female-fertility gene in the two SDGs to be developed. Three 
OOEP SpCas9 gRNAs were identified for expression from the ROSA26 locus by 
integrating a gRNA array into this locus using a AsCas12a-assisted genome engineering 
approach. With validated reagents at the ready, it was now possible to engineer these 








5 Genome engineering split gene 
drives in mouse embryonic stem 
cells 
5.1 Introduction 
There are a number of approaches used to generate genetically modified mice, including 
ES cell technology (Robertson et al., 1986), ex vivo direct injection of zygotes (Thomas & 
Capecchi, 1987), electroporation of genome editing reagents into zygotes (Chen et al., 
2016) and, most recently, in situ electroporation of genome editing reagents into zygotes 
within the oviduct of female mice (Ohtsuka et al., 2018). Within this project, ES cell 
technology has been selected as the desired route. ES cell technology remains the ‘gold 
standard’ for generating mouse models with complex or large genetic alterations, such as 
the constructs of a CRISPR-based gene drive (Chen et al., 2016). With this approach 
genome engineered ES cells harbouring the split gene drive (SGD) constructs will be 
injected into blastocysts to generate chimeras. Some background on the culturing and 
maintenance of ES cells is provide below, along with a description of gene targeting 
approaches in ES cells, and genotyping and screening techniques for assessing genome 
engineered ES cell. 
5.1.1 ES cell technology 
The isolation of ES cells has revolutionised biomedical research, becoming an important 
tool for the study of early development (Gross & Kioussi, 2014). In the mouse, these cells 
provide the basis for ES cell technology for the generation of genetically altered mice. ES 
cells are characterised by self-renewal, pluripotency, and the ability to contribute to the 
tissues of chimeras generated by injection of ES cells into the early embryo (Romito & 
Cobellis, 2016). Injected ES cells can contribute to the germ cells of the resulting chimeras 
and germline competent chimeras can be bred to produce mice with the ES cell-derived 
genotype (Bradley et al., 1984). Mouse ES cells were first isolated from the pre-
implantation epiblast of embryos in 1981 (Evans & Kaufman, 1981; Martin, 1981), and 
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their ability to contribute to chimeras, colonise the germline and produce healthy offspring 
was demonstrated in 1984 (Bradley et al., 1984). This finding provoked a major effort to 
introduce targeted genetic modifications into mice by implementing homologous 
recombination in ES cells. It was not until the 1990s that the technology became relatively 
routine (Capecchi, 2005).  
A major reason for the time gap between demonstrating germline contribution and 
generating genetically modified mice with ES cells is that cell cultures were frequently 
found to be aneuploid, particularly following clonal selection. This problem gradually 
reduced as appreciation spread of the relatively fastidious demands of ES cell culture 
compared with other cell types (Mulas et al., 2019; Robertson et al., 1986). In particular, 
ES cells must be passaged frequently to avoid overgrowth, which confers advantage to 
genetically abnormal cells (Mulas et al., 2019). Since these early breakthroughs, ES cells 
can now be readily genetically modified, genotyped and clonally expanded, and advances 
such as CRISPR-Cas have made it possible to engineer complex genetic systems, such 
floxed genes or possibly gene drives, in ES cells (Andersson-Rolf et al., 2017; Mulas et 
al., 2019). 
The 129 strain of mice is considered the most efficient for derivation of ES cells. Until 
recently, the 129 strain ES cell lines were the most commonly used and remain an 
important resource (Behringer et al., 2014; Gardner & Brook, 2002). E14 ES cells, that 
are used in this project, are derived from the white-bellied, pink eyed dilute, light chinchilla 
substrain 129P2/Ola, homozygous for chinchilla (Tyrc-ch) and pink eyed dilution (Oca2p). 
E14 ES cells were first derived in 1985 by Dr Martin Hooper in Edinburgh, UK (Hooper et 
al., 1987; Wakayama et al., 1999). The C57BL/6 mouse, comprising of two main 
substrains, C57BL/6N and C57BL/6J, is now the most widely used strain in biomedical 
research, as it is an excellent model for studying metabolism, behaviour, immunology, 
and oncology (Rogers, 2018). Although C57BL/6-derived ES cells, such as the JM8 ES 
cell types, are now widely used, they are generally considered less stable and inefficient 
when compared to 129-derived ES cells (Behringer et al., 2014; Bouabe & Okkenhaug, 
2013).  
5.1.2 Optimal ES cell culture 
Regardless of the strain of ES cells, to maintain their developmental potential, optimal 
culture conditions are required. The power of ES cell technology depends upon the 
genetic and phenotypic fidelity of ES cells during propagation. If ES cells are cultured 
inappropriately, they progressively acquire genetic lesions such as aneuploidy that will 
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compromise their developmental and germline potential. Variants that have undergone 
chromosomal rearrangements or mutations could be selected for in suboptimal culture 
conditions, outgrowing the euploid pluripotent cells. Suboptimal conditions include limited 
supply of some nutrients or growth factors or prolonged culture at densities which favour 
differentiation (Behringer et al., 2014; Mulas et al., 2019). 
Although subjective, an initial choice of correctly genotyped clones with a high probability 
of contributing to the germline can be partially based on colony morphology and growth 
rate. The cells should grow in dense, three-dimensional colonies, having distinct edges 
with a minimal number of flattened colonies and fibroblast like out growths. Clones with 
unusually high or low growth rates should be avoided. Once genetically engineered clones 
have been identified it is important to reduce the time they spend in culture by freezing 
down clones as early as possible during the screening process and recovering these low 
passage number clones for generating chimeras (Czechanski et al., 2014). 
5.1.3 Media formulation  
High-quality medium and supplements are crucial for successful culturing of ES cells. 
Traditionally, ES cells are cultured in Dulbecco’s modified Eagle’s medium (DMEM). 
However, KnockOut D-MEM, which is based on DMEM but with reduced osmolarity to 
approximate that of mouse embryonic tissues, has become popular. This medium is 
optimised for the growth of undifferentiated ES cells and was used when culturing ES cells 
in this project. This basal medium contains vitamins, amino acids, salts, glucose, and a 
pH indicator (Behringer et al., 2014; Mulas et al., 2019). They contain no proteins and 
require supplementation (see section 2.7.2 for ES cell medium formulation). Important 
components that are supplemented are serum or serum replacement and differentiation 
inhibitors, such as leukaemia inhibitory factor (LIF) and MEK/GSK3 inhibitors (2i). 
The variability in ES cell culture is due primarily to serum. Foetal calf serum (FCS) comes 
from the blood drawn from a bovine foetus. Serum is typically produced in large batches 
from many animals. However, samples may differ depending on the age, diet and 
antibiotic usage in pregnant animals, the country of origin, the breed and other factors 
creating lot-to-lot variations (Behringer et al., 2014; van der Valk et al., 2018). Some 
vendors test FCS lots for compatibility with ES cell culture, but this comes at significant 
cost. FCS is increasingly substituted with serum-free supplements for the culture of ES 
cells. The use of serum replacement provides a more defined culture medium and 
eliminates some of the variability found between serum batches (Behringer et al., 2014). 
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The original culture conditions for ES cells comprised co-culture with a feeder layer of 
mitotically arrested mouse embryonic fibroblasts and medium containing FCS (Robertson 
et al., 1986). This was effective, but this complex system was simplified with the discovery 
that a major contribution of feeders was to provide the cytokine LIF (Smith et al., 1988; 
Williams et al., 1988). LIF is a secreted polypeptide cytokine that inhibits the spontaneous 
differentiation of ES cells. Addition of LIF increases the robustness of ES cell cultures on 
feeders and this remains a widely used system. LIF can also support ES cell culture 
without the requirement of feeders, which is the case for E14 ES cells when conditions 
are tightly controlled (Nichols, Evans, & Smith, 1990; Ying et al., 2003). The role of LIF in 
the maintenance of pluripotency and self-renewal, by activation of the STAT3 pathway, 
was shown by Niwa et al. (1998). 
In addition to LIF, the small molecule inhibitors of the MEK and GSK3 pathways (2i) have 
been applied to the propagation and derivation of ES cells. ES cells appear 
morphologically and molecularly relatively homogeneous when maintained in defined 
medium in which the MEK signalling pathway is blocked and GSK3 is partially inhibited 
(Mulas et al., 2019; Wray et al., 2011). Under this dual inhibition of these pathways, ES 
cells exhibit transcriptome similarity to the pre-implantation epiblast (Boroviak et al., 
2014). Importantly, male ES cells maintained in 2i can retain a euploid karyotype and 
germline chimaera competency over multiple passages (Mulas et al., 2019). 
5.1.4 Targeting strategies 
There are a number of factors to considered when designing a genome engineering 
strategy. Of these factors, consideration should be given to the transfection method, 
format of genome editing reagents and clonal isolation method employed. For ES cells, 
the transfection method is likely to be either lipofection or electroporation and the decision 
is often based on the availability of equipment and established protocols in the host 
laboratory. The commercial availability of SpCas9 RNP and the benefits it offers over 
mRNA and plasmid formats has seen a rapid increase in its application, despite it is more 
expensive than plasmid-based CRISPR-Cas formats (Kim, Kim, Cho, et al., 2014; Liang 
et al., 2015; Schumann et al., 2015). The accompanying HDR repair template is usually 
delivered as a plasmid or linearized dsDNA or ssDNA. For large constructs, such as 
CRISPR-based gene drives, plasmid HDR templates are generally used for their stability 
and reduced random genomic integration compared to linearized dsDNA. ssDNA 
templates are best for smaller knock-in alterations due difficulties associated with 
synthesising ssDNA templates longer than 200 bp (Cong, 2013; Song & Stieger, 2017). 
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Following transfection of reagents, modified cells need to be isolated and in ES cells this 
is usually accomplished by antibiotic selection and picking of resistant colonies. 
As integration of the targeting construct occurs in only a fraction of the ES cells 
transfected, the inclusion of an antibiotic-resistance cassette in the targeting construct 
greatly improves screening efficiency. This cassette keeps the cells alive after integration 
when the culture is treated with the corresponding antibiotic (Behringer et al., 2014). In 
this project, a PAC cassette was included in all constructs to confer resistance to 
puromycin. During puromycin treatment, all or most sensitive cells should die, and when 
plated at an appropriate density the resistant cells harbouring the construct within their 
genome grow into individual colonies to be isolated by picking (see section 2.5.1.3 for 
description of picking). The clonal populations are expanded, typically in 96 WP format, 
replica-plated, frozen and gDNA extracted from a replicate for genotyping (Behringer et 
al., 2014). Through the entirety of the genome engineering pipeline, it is desirable to keep 
cells in culture for as short a period of time as possible to limit the likelihood of 
differentiation or chromosomal abnormalities arising (Gaztelumendi & Nogués, 2014; 
Mulas et al., 2019). 
5.1.5 Genotyping ES cells 
One benefit of ES cell technology is that genotyping can be performed prior to generating 
the animals. A genotyping strategy should be established before initiating an experiment. 
Traditionally, ES cells are genotyped by Southern blot, and this remains the benchmark 
technique (Carofino & Justice, 2015; Zhou et al., 2018). There are a number of other 
methods for genotyping genetically altered ES cells, including PCR, quantitative PCR 
(qPCR), Sanger sequencing and droplet digital PCR (ddPCR). A description of these 
techniques is described below. Emerging NGS-based screening techniques are 
discussed in section 5.4.5. 
5.1.5.1 Southern blot 
The method of Southern blotting was first published in 1975 by Edwin Southern, whom 
the technique is named after (Southern, 1975). A Southern blot is a method used for 
detection of a specific DNA sequence in DNA samples. Southern blotting combines 
transfer of electrophoresis-separated DNA fragments to a filter membrane and 
subsequent fragment detection by probe hybridisation (Chowdhury & Dubey, 2014). 
Southern blots performed with restriction enzyme-digested gDNA can be used to 
determine the size and copy number of a genetic element in the genome of ES cell lines 
(Wang et al., 2015). Although a powerful technique, Southern blotting is labour intensive, 
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costly, requires large quantities of gDNA, and in most cases involves the use of hazardous 
radioactive probes (Hoebeeck, Speleman, & Vandesompele, 2007). 
5.1.5.2 PCR 
PCR was invented in 1983 by Kary Mullis. Since it’s invention it has become a 
fundamental technique in molecular biology. Using PCR, targeted DNA sequences can 
be exponentially amplified for further analysis (Bartlett & Stirling, 2003). The majority of 
PCR methods rely on thermal cycling, where reactants, including template DNA, primers 
and DNA polymerase are exposed to repeated cycles of heating and cooling to permit 
DNA melting and enzyme-driven DNA replication (Green et al., 2012). For screening HDR 
genome editing events using PCR, primers are typically designed flanking the homology 
arms. These primer pairs span from inside the construct to outside the homology arms on 
both the 5’ and 3’ ends. Only ES cell lines with site-specific integration will amplify a PCR 
product, which can be resolved by gel electrophoresis or Sanger sequenced (Behringer 
et al., 2014). It is important to note that PCR can amplify very small amounts of DNA and 
this level of sensitivity creates its own drawbacks, primarily the amplification 
contaminating DNA can lead to false positives (Borst, Box, & Fluit, 2004). Furthermore, 
conventional PCR screening approaches cannot detect concurrent random integration or 
quantify copy number of the genetic construct in the genome and, therefore, accurate 
characterisation of a clonal ES cell population requires additional techniques, such as 
Southern blotting, qPCR or ddPCR (Collier et al., 2017; Mancini et al., 2011; Wang et al., 
2015).  
5.1.5.3 Quantitative PCR 
Quantitative PCR (qPCR) is a modification of standard PCR to quantify the amount of 
target DNA by introducing fluorescent or intercalating dyes to detect PCR product as it 
accumulates in real time during PCR thermocycling reaction (Green et al., 2012). qPCR 
can be used as a relative quantification of transgene copy number. For such an analysis, 
the primers and assay require optimisation to generate robust and reproducible results. 
To measure DNA copy number, the amplicon should be located within the unique 
transgene sequence and performed on cells that have undergone at least one passage 
prior to screening to ensure residue HDR template is sufficient degraded or diluted 
through cell division. This assay also uses a control gene that is known to have two copies 
in the genome (Li et al., 2019; Ma & Chung, 2014).  
A master mix is prepared, which includes gDNA template, primers, probes or dyes and 
polymerase. The assay is performed on a qPCR instrument and data is collected in real 
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time. There are two approaches to the assay: fluorescent probes and intercalating dyes. 
In either approach, fluorescence should double with every cycle of PCR, and the amount 
of starting template can be determined from the number of cycles required to achieve a 
specified threshold level of fluorescence. Relative quantification of the transgene to the 
control gene can be used to determine copy number of the transgene in the clone of 
interest (Green et al., 2012; Ma & Chung, 2014).  
Transgene copy number analysis by qPCR can be easily scaled to analysis large numbers 
of samples but this approach suffers from a number of setbacks. It can be affected by 
DNA quality, results may fall between integers (e.g. transgene copy number of 1.4) 
making interpretation difficult and, unlike droplet digital PCR (section 5.1.5.5) triplicates 
are usually required for each run (Taylor, Laperriere, & Germain, 2017). 
5.1.5.4 Sanger sequencing 
PCR products amplified from the gDNA of a targeted ES cell line can be Sanger 
sequenced to confirm that underlying DNA sequence of the integration is correct. The 
method was developed by Frederick Sanger and colleagues in the 1970s that is based 
on selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase 
during in vitro DNA replication (Sanger, Nicklen, & Coulson, 1977). Modern Sanger 
sequencing typically uses fluorescently labelled dideoxynucleotides that are detected by 
a laser after capillary electrophoresis to generate a chromatogram with peaks 
corresponding to incorporation of the four different fluorescent dyes coupled to 
dideoxynucleotides: ddA, ddT, ddC and ddG (Smith et al., 1986). 
Although one could use individual Sanger sequencing reactions to cover an entire 
transgene, this testing approach can be costly and labour intensive and rarely performed 
on large constructs, such as the gene drive constructs used in this project. Sanger 
sequencing is of value in assessing the DNA sequence on the homologous chromosome 
in the ES cells that are heterozygous. Only one allele in ES cells is usually modified by 
HDR and Sanger sequencing can determine whether CRISPR-induced indels by NHEJ 
are present on the homologous chromosomes (Jarazo, Qing, & Schwamborn, 2019).  
5.1.5.5 Droplet Digital PCR  
Droplet Digital PCR (ddPCR) is a recent technology that has been commercially available 
since 2011. ddPCR technology uses DNA polymerase in a standard PCR reaction to 
amplify a target DNA fragment from a sample using validated primers and fluorescently 
labelled probes that are positioned between the two PCR primers (Taylor et al., 2017). 
Because the probe is sequence specific, it will only detect the presence of a single 
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amplicon within the reaction. ddPCR reactions are partitioned into thousands of individual 
reaction droplets prior to amplification. In this project, a Bio-Rad ddPCR system was used, 
in which a 20 μl PCR reaction is divided into 20,000 nanolitre-sized droplets through a 
water-oil emulsion technique (Quan, Sauzade, & Brouzes, 2018). 
After partitioning the PCR in 20,000 droplets, the emulsion undergoes multiple 
amplification cycles to reach the end point of the reaction, then each droplet is checked 
for fluorescence in a cytometer with a binary readout of “0” or “1”. The fraction of 
fluorescing versus non-fluorescing droplets is recorded, allowing calculation of the 
template DNA quantity in the starting sample Poisson Algorithm. Poisson correction 
compensates the presence of more than one copy of target gene in any droplet. Unlike 
analogue quantitative PCR (qPCR), quantification with ddPCR does not require a 
standard curve and PCR reactions have a greater tolerance for inhibitor substances and 
inefficient amplification compared to qPCR (Quan et al., 2018).  
In ES cell genome engineering projects, ddPCR can be used to efficiently determine the 
copy number of the transgene in clonal populations. This can be done by using two sets 
of primers and probes, one targeting a reference gene that is known to have two copies 
in the genome and the other targeting a region within the construct of interest. Examples 
of commonly used reference genes in mice are GAPDH, PGK1, GUSB and TFRC (Boda 
et al., 2009). In this project, the Bio-Rad recommended TFRC gene was used, which 
encodes a cell surface receptor necessary for cellular iron uptake by the process of 
receptor-mediated endocytosis (Locke et al., 2015). Within the construct, the PAC gene 
was targeted, as this element was present in all three constructs. The ratio of positive 
PCR reactions (droplets) of the reference gene (TFRC) to those positive for gene of 
interest (PAC) is the basis for determine the copy number of the transgene. However, 
ddPCR does not provide information of the size of the integration, which can be obtained 
when performing Southern blotting. 
5.1.6 Karyotyping 
The normal mouse mitotic karyotype consists of 40 chromosomes (Behringer et al., 2014). 
ES cell lines should be karyotyped as subsets of aneuploid cells can be selected with 
continuous passages (Gaztelumendi & Nogués, 2014). Variation in frequency of germline 
transmission has been observed since the first applications of ES cell technology and this 
can be largely attributed to the chromosomal abnormalities that provide a growth 
advantage and presumably interfere with the ability to form functional germ cells in 
chimeras (Codner et al., 2016; Suzuki et al., 1997). Chromosomal abnormalities, in 
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particular, the trisomy of chromosome 8, occur rather frequently in ES cells during gene 
targeting (Kim et al., 2013). Trisomy of chromosome 8 confers as a selective growth 
advantage and leads to depletion and eventual loss of normal ES cells during consecutive 
passages. ES cells with trisomy 8 rarely contribute to the germline (Liu et al., 1997).  
Suboptimal culture conditions and enzymatic dissociation of cells with trypsin may 
account for the chromosomal abnormalities accumulated during continuous culture 
(Gaztelumendi & Nogués, 2014; Rebuzzini et al., 2008). It is possible that future 
development of more optimal ES cell culture conditions may facilitate the maintenance of 
a normal karyotype, even after prolonged culture. Until then, it is essential to perform 
karyotype analysis of ES cells lines used for the generation of chimeras. ES cell clones 
with at least 50% of the chromosome spreads containing 40 chromosomes should be 
selected for chimera production (Codner et al., 2016; Cotton et al., 2015). 
5.1.7 Functional analysis of ES cells in vitro 
Another advantage of ES cell mediated transgenesis is that it allows for some introduced 
genetic elements to be tested in vitro before proceeding to generate animals. Examples 
include testing floxed alleles by transfection of Cre recombinase and checking for gene 
expression from the integrated constructs (Flemr & Bühler, 2015; Huang et al., 2008). 
This lets researchers  gain valuable insight into the functionality of the introduced genetic 
elements, limiting the generation and unwanted waste of animals with non-functional 
genetic systems. 
ES cells can develop into many cell types if they are placed into an appropriate 
differentiating environment. This can occur in vitro by modifying culture conditions to 
induce differentiation (Zakrzewski et al., 2019). The desire to differentiate cells towards a 
certain lineage has led to an increasing number of specialised culture conditions that can 
bias the differentiation of ES cells into many cell types, including pancreatic cells, 
haematopoietic cells, endothelial cells, and cardiomyocytes (Valamehr et al., 2011).  
Most ES cell differentiation protocols start through an intermediate stage called the 
embryoid body (EB). EBs are round structures composed of ES cells that have undergone 
some of the initial stages of differentiation. EBs can be manipulated to generate more 
specific cell types (Kibschull, 2017). Differentiating ES cells into cardiomyocytes was 
performed in this project as a method for screening for basic developmental potential, in 




This chapter aimed to genome engineer three ES cell lines: OOEP_CAG, OOEP_VASA 
and ROSA26_gRNAs using a CRISPR-assisted genome engineering approach. 
Engineered cell lines would be clonally isolated and genotyped by PCR, Sanger 
sequencing and ddPCR, as well as confirmation by karyotyping, functional testing of 
genetic constructions and in vitro differentiation. Validated ES cell lines could be used for 
blastocyst injection to generate two lines of SGD mice: OOEP_CAGxROSA26_gRNAs 
and OOEP_VASAxROSA26_gRNAs. 
5.2 Additional methods 
5.2.1 ES cell genome engineering pipeline 
 
Figure 5.1 Workflow for genome engineering ES cells. Cells are seeded into a 24 well 




Mouse E14 ES cells thawed and 
expanded up to T75 flask
Day 2
P25
Seed cells into 24 WP and lipofection 
of plasmid constructs and Cas RNP
Day 3
P26
Spread each well onto a 10 cm 




Pick healthy isolated colonies into 
96 WP - one colony per well
Day 16
P28
Split each clonal population three-
ways into 3 x 96 WP
Day 19
P29
Process 2 x 96 WP for freezing and 
extract gDNA from the remaining 




Figure 5.3 Schematics representation of the transfection combinations used for 
genome engineer three ES cell lines: OOEP_CAG, OOEP_VASA and 
ROSA26_gRNAs. Detailed plasmid (p) maps for pOOEP_CAG, pOOEP_VASA and 
pROSA26_gRNAs can be found in section 4.3.5. A plasmid map of pY094 is shown in 
section 2.7.3.  
 
5.3.2 Primer design and PCR screening 
In order to screen ES cells for CRISPR-mediated genomic integration at the target site, 
PCR primers flanking the homology arms of each construct were designed to confirm 
construct integration at the target site. To confirm the copy number of each construct in 
the clonally isolated populations, ddPCR was used to quantify PAC against a mouse 
reference gene, TFRC. Primers and probes for homology arm flanking PCRs and ddPCR 
screening can be seen in Figure 5.4. All primer and probe sequences can be found in 
Appendices A.2 and A.5, respectively. 
   
 
Figure 5.4 Primers and probes for screening clonal cell populations. a) oGM253 and oGM249 amplify 126 bp of the TFRC 
reference gene used in droplet digital PCR (ddPCR) with the oGM255 hexachlorofluorescein (HEX) probe. b) and c) oGM185 and 
oGM186 flank the 5’ homology arm of OOEP_CAG and OOEP_VASA edited cells to amplify a 1981 bp product. oGM189 and oGM190 
flank the 3’ homology arm of OOEP_CAG and OOEP_VASA edited cells to amplify a 1888 bp product. oGM243 and oGM248 amplify 
150 bp of the PAC gene used for ddPCR with the oGM256 fluorescein (FAM) probe. d) oGM163 and oGM164 flank the 5’ homology 
arm of ROSA26_gRNAs edited cells to amplify a 1597 bp product. oGM236 and oGM168 flank the 3’ homology arm of 
ROSA26_gRNAs edited cells to amplify a 1650 bp product. oGM243 and oGM248 primers, along with the oGM256 FAM probe were 
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expected product sizes of 150 bp for the PAC amplicon and 126 bp for the TFRC 
amplicon, indicating that these primers are suitable for ddPCR experiments. 
 
 
Figure 5.6 Gel electrophoresis of PCR products to check specificity of ddPCR 
primers. PAC amplicon was expected to be 150 bp with primers oGM243 and oGM248, 
and TFRC amplicon was expected to be 126 bp with primers oGM249 and oGM253. 
ddPCR supermix used in the reaction and run for 40 cycles. 
 
5.3.3 ddPCR results 
Tested ddPCR primer pairs were used to determine the copy number of the transgenes 
in each putatively PCR-positive ES clone using ddPCR protocol outlined in section 2.1.7. 
The data generated from the protocol was analysed using BioRad Quantasoft Pro to 
determine the copy number of the PAC gene in each of targeted ES clones. A summary 
of the data can be seen in Figure 5.7 and quality control graphs of each ddPCR 
experiment is available in Appendix A.12. Being diploid cells, the number of copies of the 
reference gene TFRC was set at two. By comparing the number of copies of the PAC 
gene to TFRC in each cell line, the copy number of the targeting construct in each clonal 
population was quantified. OOEP_CAG and OOEP_VASA had 12 and 20 clones with a 
single copy of PAC, respectively. ROSA26_gRNAs had only 2 clones with a single copy 
of PAC. Selection of clones was based on the presence of tight Poisson 95% confidence 
limits and a minimum of 950 fluorescent PCR droplets read, in most cases several 
thousand fluorescent droplets were read (see ddPCR quality control Appendix A.12). 
These clones were considered to be putative heterozygous for their respective constructs. 
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Figure 5.7 Summary of ddPCR transgene copy number results. Copy number of PAC 
gene in clonal ES cell populations against TRFC reference. OOEP_CAG, OOEP_VASA 
and ROSA26_gRNAs had 12, 20 and 2 clones with one copy of the PAC gene, 
respectively. The PAC gene was used to quantify construct copy number in each cell line. 
Error bars reflect Poisson 95% confidence limits. 
 
5.3.4 Reconfirming PCRs 
In parallel to ddPCR screening, gDNA from the same thawed cells was used to reconfirm 
5’ and 3’ integration of the targeting construct by PCR. Based on the results from these 
reconfirmed PCRs and the ddPCR analysis, 4 heterozygous clones of both OOEP_CAG 
and OOEP_VASA and the 2 heterozygous clones from ROSA26_gRNAs were selected 
for further screening. Clones labelled in red with a cross (✢) in Figures 5.8, 5.9 and 5.10 
were selected for further screening. 
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Figure 5.8 Reconfirmation of homology arm integration in thawed OOEP_CAG 
target cells. 5’ flanking PCRs used oGM185 and oGM186 to amplify an expected product 
of 1981 bp. 3’ flanking PCRs used oGM189 and oGM190 to amplify an expected product 




   
 
Figure 5.9 Reconfirmation of homology arm integration in thawed OOEP_VASA targeted cells. 5’ flanking PCRs used oGM185 
and oGM186 to amplify an expected product of 1981 bp. 3’ flanking PCRs used oGM189 and oGM190 to amplify an expected product 
of 1888 bp. Red labels with ✢ denote those clones that were selected for further screening.  
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Figure 5.10 Reconfirmation of homology arm integration in thawed 
ROSA26_gRNAs targeted cells. 5’ flanking PCRs used oGM163 and oGM164 to amplify 
an expected product of 1597 bp. 3’ flanking PCRs used oGM189 and oGM190 to amplify 
an expected product of 1650 bp. Red labels with ✢ denote those clones that were 
selected for further screening.  
 
5.3.5 Wild-type allele sequencing 
PCR and Sanger sequencing of the homologous chromosome (termed ‘wild-type’ here) 
was performed on each of the selected heterozygous clones from section 5.3.4. OOEP 
was amplified with primer pair ppOOEP and ROSA26 was amplified with ppROSA26 
before sending for Sanger sequencing. Of the four OOEP_CAG clones, B3 and E2 wild-
type chromosomes had 45 and 36 bp deletions, respectively. E1 had a 11 bp insertion 
and 1 bp deletion, and H9 had no indel present (Figure 5.11). OOEP_VASA clones had 
deletions at the target site of all four of the wild-type chromosomes sequenced, ranging 
from 8 to 42 bp in size (Figure 5.12). ROSA26_gRNAs clone H10 had a 10 bp deletion in 
the wild-type chromosome, while G10 had multiple overlapping traces following the 
expected cut site, suggesting G10 was a polyclone (Figure 5.13). ROSA26_gRNAs G10 
was subsequently subcloned to isolate clonal populations. 
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Figure 5.11 Sanger sequencing of the OOEP target region on the homologous wild-
type (WT) chromosome in heterozygous OOEP_CAG targeted cells.  
 
 
Figure 5.12 Sanger sequencing of the OOEP target region on the homologous wild-
type (WT) chromosome in heterozygous OOEP_VASA targeted cells.  
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Figure 5.13 Sanger sequencing of the ROSA26 target region on the homologous 
wild-type (WT) chromosome in heterozygous ROSA26_gRNAs targeted cells. The 
ROSA26_gRNAs G10 clone shows multiple overlapping traces proximal to the cut site, 
indicating a polyclone. 
 
5.3.6 Subcloning and reconfirmation of G10 polyclonal line 
ROSA26_gRNAs G10 was subcloned by spreading ES cells at low density into a 6 WP 
and picking healthy, isolated colonies into a 96 WP following the protocol in section 
2.5.1.3. Isolated clones where then expanded up to a 6 WP format and aliquots frozen. 
gDNA was extracted from remaining cells for each clone and PCRs run to reconfirm 5’ 
and 3’ integration (Figure 5.14). All G10 clones were confirmed for 5’ and 3’ integration. 
A2, A5 and B1 cell lines for ROSA26_gRNAs G10 were then selected for Sanger 
sequencing of the wild-type chromosome. 
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Figure 5.14 PCR analysis of the subcloned ROSA26_gRNAs G10 subclones. All 
clones were confirmed by 5’ and 3’ homology arm flanking PCRs. Expected band size of 
5’ homology flanking PCR (top) is 1597 bp. Expected band size of 5’ homology flanking 
PCR (middle) is 1650 bp. Expected band size of wild-type (WT) allele is 562 bp. Red 
labels with ✢ denote those clones that were selected for further screening.  
 
The Sanger sequencing results from the three selected clones identified two allelic 
variants in the ROSA26_gRNAs G10 polyclone. The wild-type chromosome in 
ROSA26_gRNAs G10(B1) clone contained no CRISPR-mediated indel, while both 
G10(A2) and G10(A5) had a 10 bp deletion at the expected AsCas12a cleavage site. As 
the ddPCR identified that the G10 polyclone to be heterozygous, due to the sensitivity of 
the ddPCR, these subclones are also expected to be heterozygous for the construct. 
ROSA26_gRNAs G10(A2) and (B1) were selected for further screening. 
ROSA26_gRNAs G10(A2) and (B1) were selected as they represent two distinct clones 
of the G10 polyclone, while ROSA26_gRNAs G10(A2) and G10(A5) are likely to be 
derived from the same parental cell. 
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Figure 5.15 Sanger sequencing of the ROSA26 target region on the homologous 
chromosome in heterozygous ROSA26_gRNAs G10 subclones. G10(A2) and 
G10(B1) clones were selected for further analysis. 
 
5.3.7 Karyotyping 
Selected ES clones from PCR, ddPCR and Sanger sequencing screening were 
karyotyped following the protocol in section 2.5.1.10. From published reports by Cotton et 
al. (2015) and Codner et al. (2016), a threshold of 50% euploidy metaphase spreads (40 
chromosomes) was required from to qualify an ES clone for further screening. Codner et 
al. (2016) report that germline transmission efficiency of the ES cell derived genotypes 
drops from over 80% to just over 20% when there is less than 50% euploid metaphase 
chromosome spreads. Although their findings are based off counting 30 chromosome 
spreads per clone, within this study only 25 spreads were counted per clone. A summary 
of the karyotyping can be seen in Figure 5.16 and representative karyotype images can 
be seen in Figure 5.17. Of all the 11 clones karyotyped, only clones OOEP_CAG B3 and 
OOEP_CAG H9 were removed from further screening. OOEP_CAG B3 was below 50% 
threshold, while OOEP_CAG H9 had only 55% euploidy counts and was precautionarily 
removed. All OOEP_VASA and ROSA26_gRNAs clones had acceptable karyotypes, 
above the 50% threshold. 
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5.3.8 Morphology of selected ES clones 
Selected ES cells with selected genotypes and karyotypes were thawed from passage 33 
frozen aliquots following the protocol in section 2.5.1.8. Recovered cells were then imaged 
under a phase contrast microscope two days after thawing to compare morphology of 
clones (Figure 5.17). Some colonies in OOEP_VASA F8 had signs of differentiation, with 
cells spreading flat and forming cobblestone-like structures, while some colonies in 
ROSA26_gRNAs H10 were flatter than desired with rough surfaces and the ability 
discriminate individual cells within those flat colonies. All other thawed clones had 
acceptable morphology that are typically rounded or oval in shape with smooth domed 
tops and a phase contrast bright edge. 
 
 
Figure 5.17 Morphology of selected ES clones plated on gelatine at low density. 
Images taken under phase contrast two days after thawing at passage 34. Scale bar is 
200 μm. 
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5.3.9 Cardiomyocyte differentiation 
Following the protocol in section 2.5.1.9, each of the selected clones were differentiated 
into EBs then plated onto gelatine (Figure 2.3) until contracting cardiomyocytes were 
formed. All clones successfully differentiated into beating cardiomyocytes and this was 
used a simplistic method of assessing each clone’s developmental capacity. Images of 
regions of contracting cardiomyocytes for each differentiated ES clone can be seen in 
Figure 5.18. 
 
Figure 5.18 Images of regions of beating cardiomyocytes, differentiated from 
selected clonal ES cell lines. Images taken at day 12 after plating embryoid bodies onto 
gelatine. Scale bar is 200 μm. 
 
5.3.10 Floxed removal of PAC cassette 
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Functional testing of the constructs was then performed on clones with acceptable 
genotype, karyotype and differentiation capacity. This included testing the functionality of 
the LoxP sites surrounding the PAC cassette in each clone. To screen the functionality of 
the LoxP sites, Cre mRNA was transfected into each clone. PCR primers were designed 
that span the floxed cassette of each construct (Figure 5.19). In those clones with no Cre 
mRNA, the floxed cassette remains intact and yields a PCR amplicon of 2008 bp,  
1910 bp and 1843 bp for OOEP_CAG, OOEP_VASA and ROSA26_gRNAs, respectively 
(Figure 5.20). In those cells treated with Cre mRNA, a high proportion of cells are 
transfected and the floxed cassette is excised, leading to a smaller PCR amplicon of 500 
bp, 402 bp and 335 bp for OOEP_CAG, OOEP_VASA and ROSA26_gRNAs, 
respectively, demonstrating functionality of LoxP sites (Figure 5.21). All of the 9 clones 
screened had functional LoxP sites flanking the PAC cassette. 
 
 
Figure 5.19 Primer design for testing the functionality of the LoxP sites flanking the 
PAC cassette in each cell line. a) ROSA26_gRNAs cells use oGM172 and oGM95 
primers to amplify a 1843 bp product with an intact PAC cassette or 335 bp when the 
LoxP sites are recombined by Cre recombinase. b) OOEP_CAG cells use oGM75 and 
oSL35 primers to amplify a 2008 bp product or 500 bp when the LoxP sites are 
recombined. c) OOEP_VASA cells use oGM75 and gGM257 primers to amplify a 1910 
bp product or 402 bp when the LoxP sites are recombined. 
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Figure 5.20 Flanking PCRs of the floxed PAC cassette in selected clones in the 
absence of Cre recombinase. 
 
 
Figure 5.21 Flanking PCRs of the floxed PAC cassette in selected clones in the 
presence of Cre mRNA. 
 
5.3.11 Functional validation of SpCas9 and gRNA expression 
As no eGFP expression was observed in any of the OOEP_CAG or OOEP_VASA 
engineered ES clones using an epifluorescence microscope with a FITC filter (images not 
shown), it was necessary to undertake further screening to determine if SpCas9–T2A–
eGFP was expressed in these clones. Three options were considered: (1) fluorescence 
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flow cytometry could be used to get better detection resolution of eGFP expression; (2) 
use an eGFP antibody to increase the fluorescence intensity; (3) functional testing could 
be undertaken by transfecting a validated gRNA (in the absence of exogenous SpCas9) 
into OOEP_CAG and OOEP_VASA clones. The latter option was selected. 
In Section 4.3.3.1, NLRP5 SpCas9 gRNA 4 was identified as a highly efficient guide by 
T7EI assay. To test if SpCas9 was expressed in the two selected OOEP_CAG clones and 
four selected OOEP_VASA clones, NLRP5 SpCas9 gRNA 4 was ordered as an crRNA 
(Appendix A.8) and duplexed with IDT tracrRNA to form a gRNA. The NLRP5 gRNA 4 
was then transfected into OOEP_CAG and OOEP_VASA cells and a T7EI assay was 
performed to determine if CRISPR induced indels were present at NLRP5. Figure 5.22 
shows that transfected NLRP5 SpCas9 gRNA 4 complexed with endogenously expressed 
SpCas9 and resulted in CRISPR-mediated indels in the NLRP5 target site in all 
OOEP_CAG and OOEP_VASA clones. OOEP_VASA C6 and F8, had the weakest 
evidence of cleavage at the NLRP5 locus. Importantly, this assay confirmed SpCas9 was 
expressed in all of the selected OOEP_CAG and OOEP_VASA clones. 
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Figure 5.22 Functional analysis of SpCas9 expression using T7 endonuclease I 
assay on selected cell lines transfected with NLRP5 gRNA 4 (gRNA). All cell lines 
transfected with the gRNA, displayed the expected second nuclease-specific band 
following gel electrophoresis. PCRs were performed using primer pair ppNLRP5. Red 
arrows indicate the expected size of nuclease-specific second band. 
 
In a similar way, gRNA expression in ROSA26_gRNAs clones was confirmed by 
transfecting a SpCas9 only expressing plasmid into each of the three selected 
ROSA26_gRNAs clones. Expression of the OOEP gRNAs should result in SpCas9-
mediated indels at OOEP. The OOEP target site was screened using a T7EI assay. 
ROSA26_gRNAs was genome engineered using an AsCas12a-assisted approach and 
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5.4 Discussion  
5.4.1  ES cell technology 
ES cell technology remains the gold standard for the production of genome engineered 
mice that harbour large or complex constructs; however, the approach is labour intensive, 
time-consuming and costly (Champer, Kim, et al., 2019; Skarnes, 2015). The pipeline of 
transfection, isolation, screening and freezing, expanding and validating, prior to injection 
for the generation of chimeric offspring deters many scientists. I was asked on several 
occasion during this project “why don’t you try zygote injection; it will save so much time?” 
Excluding construct design, generation and gRNA screening, at least six months is 
typically required to produce and breed ES cell-derived chimeras by blastocyst injection, 
with no assurance that the ES cell genotype will gain germline transmission (Skarnes, 
2015). 
A further hindrance to ES cell technology is that not all ES cell types are robust, especially 
those derived from mice other than the 129 strain (Behringer et al., 2014). Often multiple 
independent targeted clones must be injected before successful production of chimeric 
pups. Genome instability of cultured ES cells is one reason for failure of germline 
transmission, overtly manifested by the loss or gain of whole chromosomes in culture. 
This highlights the requirement for karyotyping each clone prior to injection, which was 
performed in this project. Despite these difficulties, more than 25,000 genetically modified 
mouse strains that have so far been produced using ES cell technology (Skarnes, 2015). 
Although direct zygotic injection is faster and cost-effective, there are benefits to ES cell 
technology. In vitro transfection protocols have the ability to engineer thousands of cells 
simultaneously, and the application of selectable markers such as the PAC cassette used 
in this project allows enrichment for, and subsequent characterisation of, the desired 
genotype, prior to commencing animal work. There have been efforts to develop well 
defined pipelines for generating genome engineered ES cells. The field would benefit from 
a stringent methodology for ES cell culture and recently Mulas et al. (2019) in Cambridge, 
UK detailed a standardised 2i medium composition and cell handling procedures for 
robust propagation and genetic manipulation of ES cells. This is a much needed 
contribution to the field of mouse genome engineering. 
Although there are efforts to improve ES cell technology, researchers have undoubtedly 
embraced the relatively simplistic strategy of direct addition of CRISPR-Cas reagents to 
zygotes for generating rudimentary alteration. Simple indels induced by NHEJ or the 
integration of ssODN template by HDR for knock-ins of <100bp are now routinely carried 
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out in genome engineering facilities using direct injection or electroporation of zygotes. 
However, more complex alleles, such as gene drive constructs, that usually require HDR 
with a donor plasmid are more difficult to produce by zygote injection, although not 
impossible (Burgio, 2018; Skarnes, 2015). Typically, only a few percent of embryos co-
injected with a CRISPR-Cas and a donor plasmid carry the desired targeted modification 
(Gu et al., 2018). Because the founder animals are often mosaic, transmission of the 
genetic alteration to the next generation is also not guaranteed (Mehravar, Shirazi, Nazari, 
et al., 2019). Thus, further improvement of CRISPR-assisted targeting in zygotes is 
required to rival the broad range of highly complex genetic modifications possible with ES 
cell technology. 
5.4.2  Non-model species 
Although ES cell technology is a valuable tool in mice, for nearly all non-model mammalian 
species, embryonic stem cells have not been derived and, therefore, gene drives for real-
world application will likely require a zygotic route for genome engineering. Further 
emphasising the need for new or improved approaches for genome engineering large 
constructs into zygotes with high efficiency. The majority of emerging techniques for 
genome engineer are focused on creating relatively small genome alterations or 
corrections. Examples of these strategies are highlighted in an article I co-authored during 
my PhD, titled “On-Farm Livestock Genome Editing Using Cutting Edge Reproductive 
Technologies”. A copy of this paper can be found in Appendix A.13. Other examples of 
novel molecular genome editing strategies include prime editing, that reverse transcribes 
an RNA repair template (Anzalone et al., 2019); and SpCas9 covalently tethered to a 
ssODN repair template (Aird et al., 2018). The instability of RNA and ssODN templates 
will make it challenging to deliver the large constructs required for CRISPR-based gene 
drives (>5 kb) directly into zygotes using these novel techniques.  
5.4.3  Genotyping 
No matter the genome engineering approach used, genotyping is required and is one of 
the most time consuming aspects of any project. PCR screens offer a good method to 
rapidly determine if the cassette is present and quickly narrow down likely candidate cell 
lines or animals. PCR using homology arm flanking primers, spanning from inside the 
integrated construct to outside the homology arm, were used in this project to identify cell 
lines with the expected band sizes for 5’ and 3’ targeted integration. This approach was 
ideal for shortlisting candidates, but the information gained from standard PCR does not 
fully characterise the clones, offering no insight into the copy number of the integrated 
construct nor the fidelity of the integration. Southern blotting can be used to gain 
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information on the copy number of constructs in the genome and the expected size of the 
integration at the target side (Wang et al., 2015). Southern blotting was not performed in 
this project due to its cost and safety issues with the use of hazardous radioactive probes 
(see section 5.1.5.1). 
5.4.4 Droplet  digital PCR (ddPCR) 
To overcome the drawbacks of Southern blotting, new methods are available and 
becoming routine in genome engineering facilities. One approach for identifying the copy 
number of the construct within a cell line is ddPCR and this was used in this project. Cell 
lines with 5’ and 3’ construct integration at the target site confirmed by PCR were screened 
by ddPCR to determine the copy number of the construct. The PAC gene that is present 
in all construct was probed for copy number. When determining copy number by ddPCR 
it is essential to digest the gDNA prior to analysis. When choosing a restriction enzyme, 
keep in mind that in most cases, the construct will integrate in a head-to-tail tandem array, 
known as a concatemer (Smirnov et al., 2020). If a restriction enzyme that has no sites in 
the construct is selected, the analysis could miss concatemers. In this project, gDNA was 
digested with AluI, which is recognised as an efficient cutter and has cleavage sites within 
the PAC transgene, allowing for identification of concatemers. 
From the ddPCR analysis, clones with one copy of the PAC gene, and PCR confirmed 5’ 
and 3’ integration, were considered to be heterozygous with no additional copies of the 
construct within their genome. The wild-type homologous chromosome in the 
heterozygous clones was PCR amplified and Sanger sequenced within each 
heterozygous cell line to identify any CRISPR-induced indels present on the homologous 
chromosomes (Figures 5.11 to 5.13). Using this genotyping approach clones were 
narrowed down to four OOEP_CAG, four OOEP_VASA and three ROSA_gRNAs clones 
(section 5.3.5). Although one of the initial two ROSA-gRNAs clones (G10) was a polyclone 
and required subcloning for clonal isolation. 
All samples in the ddPCR analysis had more that 10,000 droplets (individual PCR 
reactions) read, however, it would have been beneficial to increase the concentration of 
gDNA in some samples. The protocol was designed to have 0.8 copies of template per 
droplet. Several samples were below this calculation, for instance, ROSA26_gRNAs 
clones H10, one the samples that underwent complete screening, had 13 droplets positive 
for PAC and TRFC, 319 droplets positive for PAC only, 632 droplets positive for TRFC 
only, and 11,925 with no call (Appendix A.12). Only 8% of droplets contained template. 
Although the 95% Poisson confidence limits for this clone are reassuring tight, adding 
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more gDNA template would improve the statistics of this analysis. This variance is gDNA 
template is likely due inaccurate gDNA quantification on the Nanodrop 
spectrophotometer. Using a DNA quantification system with improved accuracy, such as 
a Qubit fluorometer, would likely help in template distribution in the reaction. 
This method of applying PCR and ddPCR can be used to identify heterozygous cell lines, 
although it does not characterise the size or sequence of the integrated construct. This 
approach of using PCR and ddPCR should not be used for identifying homozygous lines. 
It is possible that randomly integrated plasmid accompanied by a large CRISPR-induced 
deletion at one of the targeted alleles, which evades PCR detection, could give a false 
positive result. Full characterisation of homozygous cell lines requires Southern blotting 
or NGS technology. It is also worth noting that plasmid DNA lacking the PAC gene could 
integrate into the genome and go undetected by this screening process. Furthermore, 
within the ROSA26_gRNAs clones, no screening was undertaken for random integration 
of pY094 plasmid that provided the expression of AsCas12a and associated gRNA. A 
rudimentary method for screening for random integration of this plasmid would be a PCR 
specific to the ampicillin gene that is located on the plasmid backbone, however, this is 
liable to false positives due to highly sensitive nature of PCR. If pY094 is integrated into 
the genome, it is possible to breed out in the resulting mice. 
Overall, ddPCR provides an efficient and reliable method for high throughput screening 
of transgene copy number. 
5.4.5 New generation screening technologies 
Next generation sequencing (NGS) technologies are now being applied to genotype 
modified cell lines and animals. These methods can be high throughput and provide 
improved data outputs (Cain-Hom et al., 2017; Nicholls et al., 2019). A good example of 
an NGS based genotyping approach for cell line screening is Targeted Locus 
Amplification (TLA) technology, where gDNA is cross-linked, fragmented and ligated 
before sequencing using outward facing primers complementary to a sequence within the 
transgene construct. Tens to hundreds of kilobases of the transgene and surrounding 
gDNA can be sequenced with TLA. This enables robust detection of SNPs, concatemers 
and random integration sites in the genome (Hottentot et al., 2017). TLA is therefore a 
useful method in genome engineering projects when comprehensive or allele-specific 
genetic information is needed; for instance, gene drive animals for potential real-world 
application. 
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Another NGS technology, Oxford Nanopore Technologies (ONT) sequencing produces 
long reads which can easily cover the entire length of a gene drive construct in one 
molecule (Jain et al., 2018). Although ONT is gaining traction in many biological fields, it 
remains plagued by high error rates. McCabe et al. (2019) showed that the high error 
rates inherent to ONT sequencing can be offset by very deep sequencing coverage. They 
established a workflow analysis of sequencing data to identify the genomic DNA samples 
that include the correct allele for accurate genotyping of genetically modified mice. ONT 
sequencing could also be applied to ES cell clones prior to injection. Several web-based 
online platforms have been developed to analyse the NGS data, including CRISPR-GA, 
BATCH-GE, CRISPResso, Cas-analyzer and CRISPRMatch (Li et al., 2019). However, 
even though effective, NGS-based analysis still requires multi-step operations and are 
costly in both time and money.  
Although not imminent, with the continuing reduction in cost of whole genome sequencing 
(WGS), this NGS technique may become a viable option for validating genome 
engineered cell lines and animals in the future. WGS is the only method to fully 
characterise the genome and is rarely deployed, only in high-value projects, such as 
genome engineered livestock and ex vivo engineered therapeutic cell lines (Ashmore-
Harris & Fruhwirth, 2020; Norris et al., 2020). The main barriers of WGS remain cost of 
the library preparation and downstream analysis, including genome assembly. With 
increases in computation power and the development of user-friendly software pipelines 
for rapid analysis of WGS data, what is now considered ‘overkill’ for most projects may 
soon be the norm. 
5.5.6 Ribonucleoprotein (RNP) 
Within this study, SpCas9 delivered as RNP had significantly better knock-in efficiency 
than plasmid delivered AsCas12a. Although these differences in knock-in efficiency could 
be locus, vector or nuclease dependent, it is worthwhile highlighting some of the reported 
differences in RNP delivered CRISPR-Cas rather than Cas and gRNA expressed from 
plasmid vectors.  
Plasmid delivery approaches are considerable cheaper but can be associated with higher 
levels of unintended edits (Lino et al., 2018). This editing is likely due to the relatively long 
period that plasmid persists inside the cells, continuing to express Cas and gRNA, which 
provides ample opportunity for off-target cleavage to occur. Several studies have 
demonstrated that the frequency of off-target mutations is lower when CRISPR-Cas is 
delivered as RNP rather than plasmid DNA (Kim, Kim, Cho, et al., 2014; Liang et al., 
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2015). For instance, Liang et al. (2015) found that for the gene OT3-18, the ratio of off-
target to on-target mutations was 28-fold lower when using RNPs relative to plasmid 
delivery of SpCas9.  
Another potential problem with plasmid transfection is the random integration of all or part 
of the plasmid DNA into the genome of targeted cells. It is desirable to limit the amount of 
dsDNA entering cells to reduce the likelihood of this occurring. Kim, Kim, Cho, et al. (2014) 
found a prevalence of plasmid-derived insertions at off-target sites, transfection using 
RNPs avoids the risk of the CRISPR-Cas expression system integrating into the genome.  
SpCas9 RNP also has been reported to have increased HDR efficiency, which was 
certainly the case in this project. Differences in efficiency is likely due to the immediate 
activity of the RNP. When RNP is delivered to the nucleus with a donor plasmid, RNP 
stimulates HDR at the target site without delay, when fresh repair template is readily 
available. Published findings show a consist improvement in knock-in efficiencies (Kim, 
Kim, Cho, et al., 2014; Liang et al., 2015; Schumann et al., 2015). These findings align 
with improved levels of HDR seen when using RNP in this project. 
5.4.7 Techniques for increasing HDR efficiency 
HDR was at an acceptable level in this project when using a puromycin selection, 
however, it is unlikely that selection could be implemented when engineering gene drives 
for real world application in wild species, due to the lack of ES cell technology available 
in these species. Therefore, some discussion on strategies aimed at improving HDR 
efficiency in the absence of antibiotic selection is provided here.  
If gene drives are to be engineered directly in embryos, introduction of CRISPR reagents 
at the 2-cell stage of development rather than in zygotes has proven successful at 
increasing HDR (Gu et al., 2018). The rationale for performing the microinjections at the 
2-cell stage is twofold. First, at this developmental time point, the embryo undergoes its 
major genome activation, which is associated with an increased open chromatin state that 
may improve the accessibility of the CRISPR-Cas and the HDR template to the target site. 
Second, HDR is typically restricted to the S and G2 phases of the cell cycle. Embryos 
display an exceptionally long G2 phase of the cell cycle during the 2-cell stage, which 
could provide an extended time for HDR repair to occur (Plaza Reyes & Lanner, 2018). 
Gu et al. (2018) showed that in mice the traditional approach where injection is performed 
in the fertilized zygote generated 1 to 6.5% knock-in efficiencies of both alleles whereas 
2-cell stage injection resulted in 31.5 to 35% targeting efficiencies. 
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One concern related to the 2-cell stage embryo injection might be the plausible increase 
in mosaicism compared to zygote delivery, as there are now two independent 
microinjections and four potential genome editing events that need to be resolved in the 
2-cell embryo (Plaza Reyes & Lanner, 2018). Furthermore, performing the microinjection 
at the 2-cell stage includes an increased technical difficulty, which might make its 
implementation in wild species more challenging when dealing with embryos where little 
embryology is known. Finally, it will be important to explore if this finding extends to other 
species or if this is a particular feature of 2-cell stage mouse embryos. 
An alternate or complementary approach for boosting HDR is the use of chemical and 
biochemical compounds to interfere with the DNA repair machinery. These work either by 
blocking the NHEJ pathway, with siRNA or inhibitors like SCR7, or by stimulating the HDR 
pathway, with HR effectors like RAD51 or with stimulating molecules like RS-1 (Song et 
al., 2016; Wilde et al., 2018), or by delivering the DNA template in a vector designed to 
make use of alternative DNA repair pathways like microhomology-mediated end-joining 
(MMEJ) or single strand annealing (Nakade et al., 2014; Quadros et al., 2017; Sakuma et 
al., 2016). 
One example of a technique that exploits the MMEJ repair pathway is Precise Integration 
into Target Chromosome (PITCh) by Sakuma et al. (2016) that improves efficiency of 
plasmid donor template integration in both ES cell and zygotes or embryos. PITCh uses 
MMEJ-directed repair vectors with short microhomology arms (10–40 bp) flanking the 
construct. Three DSBs are necessary for knock-in a PITCh vector: one on either side of 
the construct to excise it from the carrier plasmid and one in between the 5’ and 3’ 
microhomologies in the genomic locus. The first two breaks can be induced via a generic 
PITCh-gRNA; the third break requires a gRNA specific to the target site in the genome. 
These DSBs allow the microhomology arms (5’ and 3’) to anneal, knocking the construct 
into the locus by a MMEJ repair pathway. Although HDR efficiencies for PITCh are high, 
with a report of 12% knock-in efficiency for a 5 kb construct in mouse zygotes (Aida et al., 
2016), one potential drawback of PITCh is the frequency to which linearized plasmid can 
randomly integrate into the host genome. More data is needed on this. 
5.4.8 Karyotyping 
One of the main concerns with ES cell technology is on injection cells fail to generate 
chimeras or gain germline transmission from the founding chimeras. These failures are 
often attributed to the chromosomal abnormalities (Suzuki et al., 1997). Classically, 
analysis of cell karyotype is by Giemsa stained metaphase spreads (Bakker et al., 2015). 
  157 
This was employed in this project to identify the percentage of aneuploidies in each clone. 
To assist with spreads, the mitotic arrestant colcemid, which greatly increases the 
frequency of mitotic spreads was used; however, this has the concomitant and deleterious 
effect of contracting the chromosomes, thus making detailed karyotyping of the 
chromosomes challenging. Precise G-banding, in the absence of a mitotic arrestant, with 
the resolution to detect inter- and intra-chromosomal abnormalities requires extensive 
training, is instrument and labour intensive, and is therefore often outsourced to 
commercial laboratories (Behringer et al., 2014).  
In this project, 25 metaphase chromosome spreads were counted for each clone under 
60x phase microscope. A threshold of no greater than 50% aneuploidy counts in each 
clone was used. It would be desirable to increase the number of spreads counted to 
improve the statistical power. For instance, previous reports have used 30 metaphase 
spreads per clone, but they reported no difference in outcome when counting either 30 or 
50 spreads. The 50% threshold for acceptable clones for injection was initially proposed 
by Cotton et al. (2015) based on 8 clones in their study with less than 50% euploid cells 
that did not yield germline transmission. Codner et al. (2016) reconfirmed that the 
threshold for efficient germline transmission is acceptable at 50%. In their study of 708 
JM8 ES cells clones, those clones that had >50% euploidy had 80% chance of germline 
transmission, while in clones with less than 50% euploidy, germline transmission drops to 
under 20%. Although, 50% was the predetermined cut-off, the OOEP-CAG H9 clone was 
precautionarily excluded from further screening with 55% euploidy spreads and 44% with 
a 41 chromosome count. 
An additional finding from Codner et al. (2016), which looked at 708 JM8 ES cell clones, 
was that over 99% of total aneuploidy events involved at least one of these four 
chromosomes (1, 8, 11 and Y), with trisomy of chromosome 8 being the most common. 
Clones OOEP_CAG B3 and H9 in this project may carry this trisomy, as 56% and 44% of 
their spreads, respectively, had 41 chromosomes. Codner et al. (2016) devised and 
validated a ddPCR protocol for evaluating chromosome copy number from ES cell-derived 
gDNA. In their protocol, the copy number of a single gene on each aneuploidy-prone 
chromosome (1, 8, 11 or Y) is assayed relative to that of a calibration gene (present on 
either Chr 10 or Chr 17), each shown to be generally maintained at a stable diploid state 
by cytogenetic karyotype analysis. Their technique enables laboratories that are non-
specialist, or work with large numbers of clones, to precisely screen ES cells for the most 
common aneuploidies prior to microinjection. This method would have been valuable to 
use in this project. 
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5.4.9 Morphology and in vitro differentiation 
The indefinite self-renewal ability and plasticity of ES cells allows for in vitro generation of 
an unlimited number of cell types. This ability has caught much interest recently as the 
generation of high-quality specialised cells through robust and reproducible directed 
differentiation protocols is in demand for both research and biomedical applications 
(Zakrzewski et al., 2019). This demand is reliant on protocols that can maintain ES cells 
in a pluripotent state, without unwanted differentiation. Although modern ES cell culturing 
protocols and media formulation substantially improve our ability to maintain pluripotency, 
suboptimal conditions can lead to differentiation and some differentiation can be seen in 
clone OOEP_VASA F8 in Figure 5.17. This could be due to a raft of factors, including lack 
of passaging or poor recovery on thawing. As there are alternative OOEP_VASA clones, 
it is unlikely that the F8 clone will be used for blastocyst injection. 
In this project, this capacity of ES cells to differentiation into specific cell types was used 
to gain further functional insight into the developmental potential of the genome 
engineered ES cell clones that were generated. Each genotyped and karyotyped ES clone 
was differentiated into contracting cardiomyocytes as a method of gauging their 
developmental potential. All clones were differentiated into contracting cardiomyocytes 
via an EB intermediate within 14 days. An alternative method for analysis of the pluripotent 
potential of these ES cells would be to screen for the expression of pluripotent markers, 
such NANOG and OCT4, or alkaline phosphatase staining (Ghimire et al., 2018). 
5.4.10 Functional validation  
Finally, selected clones were screened for functionality of the constructs they harbour. It 
was concerning that eGFP was not visible under an epifluorescence microscope with 
FITC filter in any of the OOEP_CAG or OOEP_VASA clones that should express 
SpCas9–T2A–eGFP. Fortunately, SpCas9 expression in these clones could be tested by 
transfection with a validated gRNA. NLRP5 SpCas9 gRNA 4 was transfected into two 
OOEP_CAG and four OOEP_VASA clones and a T7EI assay performed on the gDNA 
extracted from the cells. All clones cut the NLRP5 target site, indicating that SpCas9 was 
expressed in the two OOEP_CAG and four OOEP_VASA clones tested. In a similar way, 
expression of the gRNAs in ROSA-gRNAs clones was confirmed by transfecting a 
SpCas9-only expressing plasmid followed by a confirmatory T7EI assay at the OOEP 
target site of the endogenously expressed gRNAs. 
LoxP sites were also tested for their ability to excise the floxed PAC cassette. It was 
plausible to remove the floxed PAC cassette in each ES clone prior to injection by 
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transfection of clones with Cre mRNA and isolation of clones with excised floxed 
cassettes. However, to keep the passage number of all clones as low as possible, excision 
was not performed in vitro and only functional testing of LoxP sites were performed. After 
blastocyst injection of the engineered ES cells, it is possible to remove the floxed PAC 
cassette in vivo, by crossing the transgenic lines with VASA-Cre mice that specifically 
express Cre recombinase within their germline.  
Undoubtedly, one of the key benefits that ES cell technology offers is the scrupulous level 
of genotyping and functional testing that can be undertaken before commencing in vivo 
work. Although the ES cell lines generated in this project were well characterised it does 
not guarantee these cells will gain germline transmission. There are a number of factors 
that can prevent germline transmission. The karyotyping assessment in this project was 
basic and the ES cells used were at a high passage at the outset (passage 24). Although 
previous mice have been generated at The Roslin Institute with this parental E14 ES cell 
line at a passage number up to 43, it would be desirable to use ES cells with lower 
passage number and this would certainly be a consideration if I were to utilise ES cell 
technology in future projects. Furthermore, the potential of the ES cells developed in this 
project will be greatly influenced by embryo manipulation and culture conditions during 
microinjection. 
5.4.11 Conclusions 
Although ES cell technology requires significant time and effort for generating genome 
engineered mice, it remains the benchmark and has played a central role in developing 
complex mouse. Accurate genotyping and karyotyping are key hurdles for most genome 
engineering projects and a range for new technologies, including ddPCR and NGS 
technologies are helping to increase throughput and improve data. Despites its time 
consuming nature, ES cell technology provides an excellent path to test and tune gene 
drive strategies in mice but technologies capable of delivering large constructs specifically 
and efficiency into target sites within zygotes will likely be need for real-world application 
of gene drives in wild species. 
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6 Discussion 
This project set out to investigate the potential of gene drive technology as a pest 
management tool in rodents. This involved designing, modelling and developing a 
safeguarded gene drive strategy that could spread female infertility through a laboratory-
contained mouse population. In Chapter 3, gene drive strategies were designed and 
modelled in silico. The reagents for developing the two selected split gene drive (SGD) 
strategies were then generated and validated in Chapter 4. Within Chapter 5, mouse ES 
cells were engineered to harbour the SGD elements, and cell lines are now ready to 
generate two SGD mice models for in vivo assessment. 
6.1 Ambitions and realities 
At the outset of this project, it was my ambition to generate a founding cohort of SGD mice 
for a future in vivo study. This ambition was not realised, although substantial progress 
was made towards achieving this goal in the allotted 3-year timeframe. Being the first 
gene drive project at the University of Edinburgh and the first vertebrate gene drive project 
within the UK, there were significant delays due to intensive, and justified, biosafety and 
ethical scrutiny. The project was evaluated by The Roslin Institute Biosafety Committee, 
the University of Edinburgh Biosafety Committee, the University of Edinburgh Animal 
Welfare and Ethical Review Body (AWERB) committee and the Home Office. This 
involved numerous presentations and volumes of documentation, including nine separate 
risk assessments. Although steps towards obtaining approval for generating SGD mice 
commenced in June 2017, final approval in the form of Project License (PPL) from the 
Home Office was not granted until the 14th of January 2020. As of August 2020, the  
SARS-CoV-2 outbreak had stalled impending animal experiments. 
6.2 Planned in vivo testing 
Because of these delays, there remains significant work to be undertaken in order to test 
the SGDs developed in this project in vivo. Steps that remain to be undertaken include 
generating the SGD mice using the three engineered ES cell lines (OOEP_CAG, 
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OOEP_VASA and ROSA26_gRNAs), and studying the transmission pattern and 
phenotype conferred by the SGD in OOEP_CAGxROSA26_gRNAs and 
OOEP_VASAxROSA26_gRNAs mice. These steps are not trivial, and include blastocyst 
injection of the ES cells, obtaining germline transmission from the F0 chimeras, 
genotyping F1 offspring, potentially crossing ES cell-derived mice with VASA-Cre mouse 
lines to remove the floxed PAC cassette, crossing subsequent lines to establish a cohort 
SGD mice, which will require ongoing genotyping and phenotyping. Figure 6.1 shows a 
schematic overview of the planned in vivo testing. 
 
 
Figure 6.1 Schematic overview of planned in vivo work. a) Blastocyst inject confirmed 
OOEP_CAG, OOEP_VASA (collectively labelled OOEP_Cas9 in figure) and 
ROSA26_gRNAs mouse ES cells. b) Recipient females give birth to three separate 
heterozygous mouse lines: OOEP_CAGPuroR, OOEP_VASAPuroR (collectively represented 
as blue) and ROSA26_gRNAsPuroR (green). All three lines harbour the floxed PAC 
cassette (PuroR). c) Each line will be crossed with Vasa-Cre line (brown) to excise the 
floxed PAC cassette. d) Establish small breeding colonies of each of the three 
OOEP_CAG, OOEP_VASA and ROSA26_gRNAs lines. e) Cross OOEP_CAG and 
OOEP_VASA lines with ROSA_gRNAs line to generate the two split gene drive lines: (1) 
OOEP_CAGxROSA_gRNAs and (2) OOEP_VASAxROSA_gRNAs. f) Breed split gene 
drive male mice with wild-type females (grey) to produce up to 8 litters of pups 
(approximately 48 pups in total for each split gene drive). The transmission frequency of 
the split gene-drive will be assessed by PCR-based genotyping of ear clippings. Once 
split gene-drive female pups reach sexual maturity (6 weeks), a small cohort of pups will 
be mated to establish their fertility status. Females presenting an infertility phenotype will 
be mated up to 4 times to confirm this infertility status. 
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It should be noted that the ES cell lines generated in this project, although well 
characterised, are by no means guaranteed of achieving chimera production or germ line 
transmission of the ES cell-derived genotype. This is an issue that has plagued ES cell 
technology since its inception. If OOEP_CAGxROSA26_gRNAs and 
OOEP_VASAxROSA26_gRNAs mice are successfully generated, male founders will be 
mated with C57BL/6Ncrl (Bl6) wild-type females to produce 8 litters of pups for each of 
the two SGD models. Anticipated in vivo experiments have been well thought out due to 
the rigorous internal and external assessment of this project and details on this can be 
found in section 3.3.7 and within the non-technical summary from the granted PPL in 
Appendix A.9. The AWERB committee approved the inclusion of this redacted non-
technical summary within this thesis.  
The C57BL/6NCrl wild-type mice to be used are genetically compatible with both SGDs, 
having conserved DNA sequences at OOEP gRNA target sites (Section 4.3.3.2). As this 
is a proof-of-concept study, the breeding plan was knowingly underpowered to reduce 
animal numbers. For a gene drive to be successful as a pest management tool, it will be 
required to propagate at a rate much greater than 50%. It is expected that this effect could 
be seen in the selected sample size. Assuming each of the 8 litters contains 6 pups, this 
equates to 48 pups for each SGD strategy. If successful in this initial proof-of-concept 
study, there is potential to undertake an additional study to statistically validate the best 
performing SGD system. 
The SGD approaches developed in this project feature multilayer safeguard design. After 
identifying the two SGD strategies and generating constructs, Grunwald et al. (2019) 
published the first demonstration of a CRISPR-based gene drive in mice. Of the gene 
drive strategies they reported, self-propagation was only observed in the female germline 
when expression of SpCas9 was restricted to the germ cells. In this project, female 
germline homing in OOEP_VASAxROSA26_gRNAs mice may not be detected as all 
females that inherit the SGD should be OOEP knock-out within their germ cells and 
infertile. As female infertility in OOEP knock-out mice results in spontaneous abortion at 
the 2-cell embryo stage, embryos from OOEP_VASAxROSA26_gRNAs cannot be 
genotyped. OOEP_VASAxROSA26_gRNAs females could be phenotypically assessed 
for their fertility status, but it will be unknown if infertility was due to HDR-mediated homing, 
or NHEJ or MMEJ-based indel mutations. This issue is not anticipated with 
OOEP_VASAxROSA26_gRNAs males, which should retain normal fertility, or 
OOEP_CAGxROSA26_gRNAs mice where homing for both sexes is anticipated to occur 
in the zygote or early embryo. 
  163 
Once generated, SGD mice will be maintained at The Roslin Institute, which has a 
modern, well-resourced and environmentally stabilised rodent facility. Husbandry will be 
performed by experienced animal technicians. Careful selection of the targeted female-
fertility gene (OOEP) based on previous studies that have shown OOEP knock-out mice 
are phenotypically normal other than female infertility indicates animals are unlikely to 
suffer in any way. Furthermore, as the embryo in OOEP knock-out females aborts at the 
2-cell stage it is unlikely to be associated with any adverse clinical signs such as uterine 
infection and is unlikely to be physiologically recognised as a pregnancy or influence 
subsequent ovulation cycles. 
6.3 Value of fundamental research 
The research progress made in this in this project and its future objectives can be 
classified as applied science, and like all applied sciences, it relies on fundamental 
research. A wide variety of selfish genetic elements occur naturally in many types of 
organisms and, although fundamental biologists have been studying these elements since 
the 1920s their origins and our understanding of the molecular mechanics remains basic 
(Burt & Trivers, 2006; National Academies of Sciences, 2016). Selfish genetic elements 
are a fascinating and a particularly challenging field of genetics. Continued research into 
this field, along with replenishment of interest and funding due to the publicity surrounding 
gene drive technology will likely identify new classes of naturally occurring selfish genetic 
elements and improve our understanding of how these elements function. This improved 
understanding could guide the development of new more robust synthetic gene drive 
strategies. 
In addition to advancing our fundamental knowledge on naturally occurring selfish genetic 
elements, population genetics and ecosystem dynamics are two fields of study that are 
essential to determining the efficacy of gene drives and their biological and ecological 
outcomes. There are considerable gaps in knowledge regarding the implications of gene 
drives for species fitness, gene flow in and among populations, and the dispersal of 
individuals, and how factors such as mating behaviour, population structure, and 
generation time could influence a gene drive’s effectiveness (National Academies of 
Sciences, 2016). The population simulation performed in this project did not incorporate 
many of these important factors. Addressing these knowledge gaps to gain better 
understanding of the biological and ecological outcomes of gene drivers will require non-
trivial interdisciplinary research. 
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6.4 Interdisciplinary nature of gene drive research 
To emphasise the importance of interdisciplinary research when developing gene drives, 
simple look at the contents of this thesis, written by an emerging biotechnologist, who has 
the skills to design gene drives, without necessarily a deep understanding of population 
genetics or ecosystem dynamics. Yet, these parameters are required to accurately 
understand the effects of gene drives on populations and ecosystems. The power of 
interdisciplinary collaboration was briefly highlighted in Chapter 3 of this document. Within 
this Chapter, collaboration with Dr Gregor Gorjanc and Nicky Faber, both population 
modellers, lead to valuable simulations of gene drive strategies in wild mouse populations. 
Fields that will be required to collaborate for gene drive technology to be realised, include: 
fundamental geneticist, population modellers, molecular biologist, ecologists, ethicists, 
animal technicians, regulators, policymakers, and communication specialists. This 
requirement for interdisciplinary interaction will be both rewarding and challenging. 
6.5 Phased testing pathway 
With the recent successes in developing gene drives in laboratory, there is increasing 
interest in progressing this technology to be ready for real-world applications. However, 
the path towards applying gene drives requires a phased testing approach, such as the 
one developed by the World Health Organization (WHO) for testing genetically modified 
mosquitoes (World Health Organization, 2014). Each step in such a pathway promotes 
careful study and evaluation, includes checkpoints to determine whether research should 
move to the next phase. A phased testing framework can also be adapted to laboratory 
research on gene drive. For example, in this project, experiments aimed to start with by 
developing a SGD in laboratory-contained inbreed mouse strain, to avoid issues 
associated with a failure of containment, before considering the develop and testing of 
any self-sustaining gene drive strategies in wild mice. 
In accordance with the WHO phased testing pathway for genetically modified mosquitoes, 
an idealised pathway to develop of gene drives for real-world applications includes five 
steps: Phase 0 – Research Preparation: includes identification of ideal attributes and 
containment strategies, establish risk assessment needs and plan regulatory 
requirements; Phase 1 – Laboratory-based research: includes using computational 
methods to model gene drives, undertaking risks assessment and obtaining regulatory 
approval, developing containment strategies, optimising gRNA design and enhancing 
HDR efficiency, evaluating effects on animal fitness and measuring gene drive stability 
over multiple generations. The work in this project pertained to Phases 0 and 1. The 
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remaining three phases of WHO testing pathway, include: Phase 2 – Field-based 
research, Phase 3 – Active environmental release and Phase 4 – Post-release 
surveillance.  
6.6 Risk assessment 
A common concern raised with field-trials and active environmental release of gene drives 
is that it will be challenging to accurately predict the consequences that could arise from 
gene drive animals as the environments they will be released into do not exist as 
‘ecological vacuums’ (Webber, Raghu, & Edwards, 2015). Individual species are 
connected to other species in the community through direct trophic links (e.g. native eagle 
preys on introduced mice) and through indirect trophic links (e.g. introduced mice 
competes with native rodent for the same resources). These links create dynamic 
feedbacks that affect the relative abundances of different species (Wootton, 1994). These 
feedback loops can become highly complex and makes accurate prediction difficult 
(Scheffer, 2009). Although prediction is difficult, the theoretical and empirical insights that 
ecological risk assessments can provide will play a critical role as testing progresses 
beyond laboratory-contained research.  
In addition to the assessing likely ecosystem changes from a gene drive release, good 
ecological risk assessment will also make comparisons between alternate strategies, 
incorporate relevant people’s concerns, and can be used to identify sources of 
uncertainty, giving it the ability to quantify the probability of different outcomes. Reliable 
data and robust models are particularly crucial for ecological risk analysis, which is 
challenging to obtain for gene drives. Contained laboratory studies, such as the 
proceeding in vivo study from this project, and in silico modelling currently represents the 
best approaches for providing data to reduce uncertainty. 
Although a significant proportion of this project was dedicated to risk assessment, no in-
depth ecological analysis was undertaken. This project aimed to develop two SGDs in an 
inbreed laboratory mice within a secure rodent facility. The SGD was not self-sustaining 
and, therefore, the risk this project posed to the environment was assessed to be no 
greater than a conventional genetically altered laboratory mouse.  
6.7 Governance and regulations 
With gene drive research moving rapidly, particularly in mosquitoes focused  at controlling 
malaria, it is likely that field trials will soon be undertaken. It is essentially that adequate 
regulations and governance for the environmental release of gene drive organisms are in 
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place before this occurs. The governance of research begins with the personal 
responsibility of investigators, which is formalised in professional guidelines and can be 
legally enforceable. Currently, institutions, funders, and professional societies work to 
encourage professional best practices in research. The research in this project was 
conducted at The Roslin Institute, that receives funding from the BBSRC and is part of 
the University of Edinburgh. The Roslin Institute, therefore, is  subject to University of 
Edinburgh and BBSRC’s Biosafety Policies. Beyond the professional, institutional and 
funding body guidelines, there remains much regulatory uncertainty regarding gene drive 
technology around the global (Brossard et al., 2019). 
In many countries, there are regulations in place to guard against unintended effects of 
releasing genetically engineered organisms into the environment. These regulations were 
developed for animals that have conventional genetic modifications that are typically for 
welfare or human benefit and reduce the fitness of the animal outside a controlled 
environment. Current regulations call for a step-by-step process where the first releases 
are in small numbers in isolated areas (Brossard et al., 2019; National Academies of 
Sciences, 2016). With gene drives, the intention is for the engineered animals genotype 
to spread, to some extent, in the environment, so there is a need to amend established 
regulations. At present, no nation has regulations in place specifically for gene drives and 
no case of release of an organism with a gene drive has been recorded (Brossard et al., 
2019). 
The most broad-ranging and widely accepted international governance system for genetic 
resources and biosafety is the United Nations Convention on Biological Diversity 
(UNCBD), as implemented through the Cartagena and Nagoya Protocols . Many countries 
are now developing regulatory systems in response to the Cartagena Protocol. Many such 
systems are predicated on a strong precautionary, nearly preventative approach (National 
Academies of Sciences, 2016). To cope with the unique aspects of gene drives, existing 
approaches to governance need to be adapted. Integrating new policy and law for gene 
drives into existing international governance poses significant challenges but it is 
necessary, and this need was recently highlighted in April 2020 by a UNCBD Ad Hoc 
Technical Expert Group (AHTEG) Report on Risk Assessment. 
6.8 Engagement 
Gene drives represent a case of post-normal science for which technical expertise alone 
is not enough to address the intricacies surrounding a scientific issue. Consideration 
should be given not only to technical concerns but also social and ethical implications. 
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Unlike normal scientific issues for which risk assessment can be primarily based on 
scientific inputs, post-normal science requires input from a multitude of perspectives when 
assessing risks and benefits (Brossard et al., 2019; Ravetz, 1999). The decision to deploy 
a gene drive to suppress a pest species will involve more than a technical assessment of 
the risks involved, and responsible decision-making regarding their use will require 
consensus from communities, stakeholders and publics (Figure 6.2).  
 
 
Figure 6.2 Communities, publics, and stakeholders. These audiences for engagement 
are based on geographic proximity and interests. Image from National Academies of 
Sciences (2016). 
 
Engaging with communities, stake holders and publics should be considered an essential 
part of any gene drive project. The outcomes of engagement can be as crucial as the 
scientific outcomes for decision making. This project did include media engagement. At 
the start of this project, I outlined the goals and strategy of my PhD research in a press 
conference at the Science Media Centre at Wellcome Centre in London. This press 
conference was linked to an article I co-authored, titled “CRISPR-Based Gene Drives for 
Pest Control” (Appendix A.1), and lead to several press articles, including write ups in the 
Times, Guardian, Financial Times, Telegraph and The Australian, along with significant 
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social media attention. This helped inform publics, stake holders and communities, 
encouraging discussion and debate on the topic. Over the course of my PhD, I have also 
developed publicly available videos on genome engineering technologies and actively 
engaged in scientific discussion on Twitter. 
In addition to engaging through media channels, I contributed to a Wellcome Trust funded 
research project during my PhD on “Talking about gene drive: An exploration of language 
to enable understanding and deliberation in Africa, Europe, North America and 
Australasia.” Decisions involving governance and potential future use of gene drive 
technology will require meaningful and relevant dialogue among and between publics, 
stakeholders and communities. This project looks to identify what language devices, such 
as storytelling or metaphors, are most useful for communicating gene drive technology 
across audiences. 
Following on from my PhD, I am now involved a small pilot project investigating the 
potential of gene drive to manage invasive grey squirrel in UK. This project has been 
promoted through print and digital media, and although it has been largely well received 
it has attracted some criticism in social media channels. Very few emerging technologies 
are realised without first encountering criticism and caution. Caution is warranted with 
early applications of gene drive. In a similar way that genetically modified foods were 
condemned, the way gene drives are used in their first attempts could have a lasting, 
potentially generational impact on society’s view of this technology. All gene drive 
research should include a thoughtful engagement plan from the outset. 
6.9 Human values 
Through my own experiences of engagement, in both social and academic fora, it has 
become clear that not everyone will be affected by gene drive research and applications 
in the same way. The expectation that people should have a voice in fundamental 
decisions that affect their environment is important. The increased power that gene drive 
technology might give scientists and governments to alter, and perhaps remove invasive 
pests, will be intrinsically disagreeable to some people. An increased ability to conserve 
species and ecosystems through gene drive technology may be intrinsically attractive to 
others. Approaches to ensure that communities participate meaningfully in decision 
making about the use of gene drive will be essential for the progression of this technology. 
One consistently uniting force that both sides of the gene drive debate can embrace is the 
strong and widely shared commitment of most to protect human welfare and the 
environment. 
  169 
6.10 Other vertebrate applications 
From an ethical standpoint, some may find the use of gene drive to rescue a species from 
a devastating disease more acceptable than rescuing a native species through the demise 
of a competing invasive species. For instance, chronic wasting disease (CWD) is a form 
of prion disease in cervids that affects primarily deer, elk and moose. The infectious prions 
responsible for CWD are caused by misfolding and aggregation of a prion protein (PrP) 
and are spread through saliva, urine and faeces. Once an animal is infected, misfolded 
PrP builds up in the brain, causing neuronal loss and eventually leading to death 
(Benestad et al., 2016). In some states in northern US, prevalence of CWD in deer is up 
to 30% in free-ranging populations and 90% in captive deer (Williams, 2005; Williams & 
Young, 1992). Studies in rodents and large animals have shown that animals do not 
require PrP (Denning et al., 2001; Weissmann & Flechsig, 2003). Gene drives could be 
used to knock-out the PrP gene to rescue infected cervid populations from this highly 
infectious disease. However, the long generation interval in cervids would mean the gene 
drive spreads very slowly through the population (Whitelaw & McFarlane, 2019). 
Gene drives could also be applied to rescue threatened amphibians from 
chytridiomycosis. Chytridiomycosis is the disease caused by the fungus Batrachochytrium 
dendrobatidis, which has been implicated in mass die-offs and a conservative estimate 
suggests that chytridiomycosis has caused the severe decline or extinction of over 200 
species (Fisher & Garner, 2007). In a study Olson et al. (2013), they detected B. 
dendrobatidis in 516 of 1240 (42%) amphibian species sampled. As the fungus 
reproduces mostly asexually (Fisher, Garner, & Walker, 2009), it cannot be controlled with 
a gene drive itself . However, resistance to B. dendrobatidis infection varies both within 
and among amphibian species. Major histocompatibility complex (MHC) peptides play an 
important role in the innate immune system of vertebrates and a specific MHC allele in 
the lowland leopard frog (Lithobates yavapaiensis) has been shown to increase survival 
of infected individuals (Savage & Zamudio, 2011). Gene drive could be used to spread 
the lowland leopard frog’s resistant MHC allele through threatened amphibian 
populations, rescuing species from this killer fungus and potentially saving them from 
extinction (Whitelaw & McFarlane, 2019).  
For further information on other potential applications of gene drive technology in 
vertebrates, see Appendix A.14, which contains as article titled “Accelerating Evolution”, 
which I co-authored during my PhD for the Royal Society of Biology magazine, The 
Biologist. 
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When looking to apply gene drive in a non-model species there are a number of factors 
to consider, such as the genetic feasibility of engineering the species. A lack of 
reproductive and embryological information on the species may limit genetic engineering 
capabilities. Other issues may be the identification of suitable promoters, establishing 
stable transgene expression, access to a genome sequence data and genetic variation in 
the population that would likely prevent the spread of a gene drive. Evolutionary issues 
should also be strictly scrutinised, such as mating structure and barriers to mating 
between naive and engineered animals. 
6.11 Final remarks 
This project set out on a pioneering path to study gene drive technology as a potential 
tool for rodent pest management. The work encountered regulatory hurdles that slowed 
progression but was ultimately able to design, model, and engineer safeguarded two SGD 
approaches in mouse ES cells. These cells can now be used to generate SGD mouse 
models for in vivo studies. Throughout this journey, it has become clear that technical 
challenges of engineering a gene drive are relatively minor in comparison to the 
ecological, regulatory and ethical questions that remain regarding gene drive technology. 
It is hoped that work undertaken in this project will contribute to answering some of these 
questions and aid in the future development of safe, cost-effective and species-specific 
technologies for humanely managing damaging invasive vertebrate pests.  
The scale of opportunities for gene drive technology and depth of interdisciplinary 
research needed before real-world application of this technology can be justified is truly 
exciting and I hope to continue contributing to this field. If used wisely, I believe synthetic 
selfish genetic elements can help solve many issues in public health, agriculture and 
conservation. 
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(GDs) could be used to spread
desirable genetic elements
through wild populations. With
the imminent development of this
technology in vertebrates, we
believe that it is timely to highlight
two forms of sex-ratio distorting
GDs that show potential as pest
management tools.
In agriculture and wildlife, invasive pests
are well known: rabbits and cane toads in
Australia, mink in the UK, and the omni
present infestation of rodents around the
globe. It is estimated that in the USA,
introduced rats cost the economy more
than US$27 billion per year. [1]. To
counter the impact of vertebrate pests,
control measures are deployed that
include shooting, poison baiting, trapping,
and the release of biological agents
(Figure 1A). These methods are costly
and inadequate, and often lead to
unwanted suffering in both target and non
target species [2]. GDs may offer a more
cost effective, humane, and species spe
ci!c alternative than current approaches.
Gene Drives for Sex-Ratio
Distortion
The GD concept has emerged from
observations that naturally occurring self
ish genetic elements, such as homing
endonuclease genes and transposons,
are preferentially inherited at frequencies
greater than predicted by Mendelian
inheritance. This ‘super Mendelian’ inher
itance allows these elements to drive
through a population even if they reduce
the !tness of an individual organism [3]
(Figure 1B). The recent discovery and
repurposing of RNA guided CRISPR
endonucleases into a set of gene editing
tools (Box 1) allows the development of
synthetic GDs in a standard molecular
biology laboratory [4].
One potential application of GD is to dis
tort the sex ratio of a population. By skew
ing the sex ratio away from the favored
Fisherian ratio of 1:1 male to female, it is
possible to manipulate the reproductive
performance of a population. In most pest
species, female procreative capacity is
responsible for maintaining the overall
population size. Therefore, an ef!cient
means of population suppression is to
bias the sex ratio in favor of males [5].
A grossly male population will result in a
population decline, while an all male pop
ulation will lead to eradication. Here, we
describe two forms of CRISPR based sex
ratio distorting GDs, homing GD and X
shredder (XS), both of which have the
potential to drive maleness. To date,
these GD systems have only been engi
neered in proof of concept studies in
mosquitoes [6,7], with the focus on con
trolling vector borne diseases. After
insects, invasive vertebrate pests are
likely to be the next GD target.
Homing Gene Drive Targeting
Female Fertility
A homing GD works by copying or ‘hom
ing’ itself into a target site in the genome.
To build a CRISPR based homing GD, an
animal is engineered with a GD cassette
that expresses a CRISPR endonuclease,
such as Cas9, and one or more guide
RNAs (gRNAs) (Box 1) from one allele that
can cut at a conserved target site on the
sister allele on the homologous chromo
some (Figure 1C). After CRISPR medi
ated cleavage, homology directed repair
(HDR) results in the CRISPR machinery
and any additional payload included in the
GD cassette being copied onto the
homologous chromosome [4,8]. This pro
cess ensures homozygosity for the GD
cassette.
Targeting a homing GD to a haplosuf!
cient female fertility gene (HFFG) can be
used to disrupt the coding sequence of
the gene, rendering homozygous female
offspring infertile, while males and hetero
zygous females will retain normal fertility.
Importantly, for this strategy to drive
through a population, the homing event
should occur only in germline cells that
are precursors to sperm or eggs. This can
Box 1. CRISPR Cas9
The CRISPR-Cas prokaryotic immune defence system, and its associated proteins (Cas), has been
repurposed into a set of gene-editing tools. Currently, the CRISPR-Cas9 system from Streptococcus
pyogenes is the most widely used CRISPR system for genetic manipulation. The system comprises two
components: a guide RNA (gRNA) and a nonspeci!c endonuclease (Cas9; Figure I). The gRNA includes an
89-nucleotide ‘scaffold’ sequence that Cas9 binds to and a 20-nucleotide user-de!ned ‘targeting’
sequence that delivers the endonuclease to the correct site in the genome by Watson–Crick base pairing
with the target sequence. Provided that the genomic target is immediately adjacent to a protospacer
adjacent motif (PAM; 50-NGG-30 for S. pyogenes Cas9), the endonuclease cuts the DNA generating a
double-stranded DNA break (DSB). The natural DNA repair machinery of the cell then recognizes that the
DNA is damaged and repairs the DSB by one of two pathways: (i) in the presence of a DNA repair template,
such as the homologous chromosome or an exogenous DNA template, the DSB is repaired through high-
!delity homology-directed repair (HDR). HDR can be used to make accurate repairs or precisely edit the
DNA sequence; or (ii) in the absence of a DNA repair template, a DSB is repaired by the error-prone
nonhomologous end-joining (NHEJ) pathway. Repair by NHEJ yields deletion or insertion mutations (indels)
[12].
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be achieved by using a germline speci!c
promoter to express Cas9. By restricting
homing to the germline, this will initially
allow rapid spread of the GD and accu
mulation of fertile heterozygous GD ani
mals that produce mostly GD gametes
[7,9] (Figure 1C). As mating between het
erozygous GD carriers becomes increas
ingly likely, the population will decline due
to infertility of the homozygous GD female
offspring, which are homozygous null for
the HFFG [9]. With every generation, the
sex ratio will become more biased
towards males, eventually resulting in a
population crash. Hammond and col
leagues [7] developed this system in mos
quitoes and achieved transmission rates
of 91.4 99.6% in caged populations. In
theory, homing GDs could be adapted to
control most vertebrate pests and several
groups are currently undertaking pilot
studies in mouse models.
X-Shredder
In XY heterogametic species, an XS is a
type of sex ratio distorting GD that cuts
the X chromosome at multiple sites dur
ing spermatogenesis, thus shredding the
X chromosome beyond repair [8]. To
engineer a CRISPR based XS, an XS cas
sette is inserted within a neutral intergenic
region of the Y chromosome. The cas
sette encodes Cas9, which is expressed
under the control of a spermatogenesis
speci!c promoter, and one or more
gRNAs that target conserved repetitive
sequences unique to the X chromosome.
Given that most X chromosomes are
destroyed during spermatogenesis, most
sperm that mature and reach the oocyte
are Y bearing, resulting in a biased sex
ratio in favor of males. By placing the XS
cassette on the Y chromosome, all male
offspring will inherit the cassette and con
tinue transmitting the XS to subsequent
generations.
A CRISPR based XS has been engi
neered in mosquitoes, although the sys
tem was commendably safeguarded by
expressing the XS cassette from an auto
some instead of the Y chromosome. With
this approach, Galizi and colleagues [6]
achieved male bias among progeny rang
ing from 86.1% to 94.8% in laboratory
contained mosquito populations.
Although successful in mosquito, techni
cal challenges facing the adaption of an
XS into vertebrates include identifying
appropriate spermatogenesis speci!c
promoters in target species and the tran
scriptional silencing of mammalian sex
chromosomes during meiosis. The latter
may hinder expression of Cas9 from the
Y chromosome, as well as the accessibil
ity of the endonuclease to shred the X
chromosome.
Drive Resistance and Inactivation
Strategies
The two forms of GDs described above
are self perpetuating and, in theory,
would only require the release of a small
number of engineered animals to initiate
drive. The duration and extent of spread
would be limited by naturally arising resis
tant alleles that prevent CRISPR medi
ated cleavage. Resistant alleles could
exist in the population before release or
originate from indels generated when
CRISPR mediated cleavage is repaired
by the error prone nonhomologous
end joining (NHEJ) pathway and alters
the gRNA recognition sequence [8]. The
rate of NHEJ mediated repair will be
dependent on the species, target site,
and the stage of development that DNA
cleavage occurs. Given that natural selec
tion tends to favor equal sex ratios, resis
tant alleles that restore function would
spread rapidly through the population
[10].
Of the two strategies presented here, XS
should be less prone to inactivation by
resistant alleles because it targets multi
ple sites and, therefore, would require an
animal to simultaneously acquire multiple
resistant alleles to incapacitate the drive.
Following a similar approach, it has been
suggested that the evolutionary stability of
homing GDs could be improved by using
multiple gRNAs closely spaced along the








Precise repair or edi!ng 
Figure I. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Cas9 Gene Editing.
The Cas9 endonuclease is guided to the target sequence in the genome by the guide RNA (gRNA). At the target
site, Cas9 cleaves the DNA, creating a double-stranded DNA break (DSB). A DSB induced by Cas9 can be
repaired by homology-directed repair (HDR) or nonhomologous end joining (NHEJ). HDR can precisely repair
or edit the DNA sequence. NHEJ-mediated repair produces insertion or deletion mutations (indels).





Prowse and colleagues [9] used in silico
modeling to demonstrate that multiple
gRNAs are necessary for homing GDs
to evade drive resistance and success
fully suppress vertebrate pest popula
tions. Even if drive resistance were to
prevail, it would be possible to release a
second GD targeting a different gene to
continue suppressing the population.
Conversely, if a GD were not limited by
naturally arising resistance, it would have
the potential to spread inde!nitely through
a species. Therefore, it is essential to have
strategies in place that could deliberately
inactivate a GD that escaped contain
ment or was causing unforeseen impacts.
Fortunately, both homing GD and XS sys
tems can be inactivated by the release of
animals bearing engineered functionally
resistant alleles or a reversal gene drive
that immunizes the animal against the
original drive [4,8]. However, it is impor
tant to recognize that, with the current
technology, once either of these systems
is released, complete reversion to a wild
type genotype would not be possible
because residual Cas9 and gRNA would
still be present.
Risks and Bene!ts
Genetically engineered animals normally
come with few ecological risks. Most
engineered traits are for human bene!t
and will not be favored by natural
selection. By contrast, GDs can spread
through populations even if they reduce
the !tness of each carrier animal [4]. This
gives GDs more scope to escape the
target population and unintentionally
affect extraneous ecosystems. However,
the potential bene!ts of GDs are equally
as impactful as the risks. GDs could rev
olutionize public health, agriculture, and,
as discussed here, could be applied for
pest control and ecological restoration. In
line with the recent decision at the United
Nations Convention on Biodiversity, we
believe that the potential bene!ts of
GDs warrant further investigation.
Concluding Remarks
For the !rst time, we have the makings of
a technology that could reduce or elimi
nate a pest population in a humane and
species speci!c manner. If proven effec
tive, the decision to deploy a GD should
be based on substantiated research and
involve public engagement to ensure
there is societal consensus. With the
rapid progress in this space, the risks
associated with current GD architectures
are likely to be reduced with the realization
of self limiting GD strategies [11].
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Inheritance of a GD. (C) A homing GD targeting female fertility. In the !rst generation, heterozygous (Het) GD animals are released carrying a GD cassette (purple), which
disrupts the coding sequence of a haplosuf!cient female-fertility gene (HFFG; yellow). Within the germ cells, the GD cassette expresses Cas9 and one or more guide
RNAs (gRNAs) that cut the HFFG on the wild-type (WT) chromosome. The germ cells then repair the cut by homology-direct repair (HDR), using the GD chromosome as
the repair template. This process copies the GD cassette onto the WT chromosome and ensures that most sperm or eggs carry the GD cassette. Matings between Het
GD and WT animals will give rise to an increasing number Het GD animals. In subsequent generations, as mating between Het GD animals becomes increasingly likely,
the population will decline through infertility of homozygous (Hom) GD female offspring, which are homozygous null for the HFFG. (D) X-Shredder (XS). During
spermatogenesis, Cas9 and gRNA(s) are expressed from the XS cassette (orange) located on the Y-chromosome (Y) and shred the X-chromosome (X) beyond repair.
Most sperm that mature and reach the oocyte are Y-bearing, resulting in most offspring being XS males.







A.8  crRNAs for SpCas9 ribonucleoprotein  
Table A.8 crRNAs and tracrRNA used for SpCas9 ribonucleoprotein. 
crRNA Sequence crRNA type 
crRNA OOEP 1 GACUUCGCACUCGGCCCUGGGUUUUAGAGCUAUGCU Alt-R CRISPR-SpCas9 crRNA, 2 nmol 
crRNA OOEP 4 GCUUCCAUGUAGAGCACCAGGUUUUAGAGCUAUGCU Alt-R CRISPR-SpCas9 crRNA, 2 nmol 
crRNA NLRP5 4 AUAGUGUCAUAUCAUCAUGUGUUUUAGAGCUAUGCU Alt-R CRISPR-SpCas9 crRNA, 2 nmol 




A.9  Project License for animal work 
The following pages contain the cover page from the Project License (PPL) that was 
granted by the Home Office during my PhD. This PPL will be used for the subsequent 
generation, breeding and analysis of split gene drive mice. The non-technical summary 
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Non-technical summary 
Aim and duration 
What's the aim of this project? 
Keep this to a short one or two sentence summary. 
This proof-of-concept project aims to test a safeguarded genetic system known as a 
split gene-drive to spread female infertility through a laboratory-contained mouse 
population. If successful, this approach may find future application as a pest 
management tool as after several generations the population would humanely 
decline due to the lack of fertile females available as breeding partners. 
___________________________________________________________________ 
Why is it important to undertake this work? 
In agriculture and wildlife, invasive pests are well known: rabbits in Australia, grey 
squirrel in the UK, and the omnipresent infestation of rodents around the globe. 
Invasive vertebrate pests impact the environment, economy and society. Current 
control methods include shooting, poisoning and trapping, which are costly and 
largely inadequate, and they often lead to unwanted suffering in target and non-
target species. A gene drive spreading female infertility may offer a humane, 
species-specific and cost-effective alternative to current control methods. 
___________________________________________________________________ 
What will be the duration of this project? 
2 Years 0 Months 
Benefits 
What outputs do you think you will see at the end of this project? 
Outputs can include new information, publications, or products. 
The outputs of this project will help assess the feasibility of using genetic approaches 
to pest management. The findings will assist with technical development of gene 
drive technology as a potential humane alternative to current pest management 
tools. Dissemination of the project through mainstream media will encourage public 
and political discussion on genetic pest control approaches. 
___________________________________________________________________ 
Who or what will benefit from these outputs, and how? 
The impact of these outputs may be seen in the short-term, or they may not be fully realised 
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Invasive mammalian pests are a global concern that impact the environment, 
economy and society. Current control methods include shooting, poisoning and 
trapping, which are costly and largely inadequate, and they often lead to unwanted 
suffering in target and non-target species.  Therefore, the outputs from this project 
have the potential to benefit environmental conservation efforts, support native 
predated species, the economy and those within our society that are impacted by 
mammalian pest, such as farmers and foresters. The outputs also have the potential 
to reduce suffering in pest species and non-pest species that are affected by 
currently deployed control methods. This is a proof-of-concept study and these 
beneficial outputs would likely not be seen for 10 years or more as this technology 
would require subsequent scientific investigation and a political and public 
consensus reached before application. 
 
___________________________________________________________________ 
Will this work be offered as a service to others? 
No 
___________________________________________________________________ 
How will you look to maximise the outputs of this work? 
For example, collaboration, dissemination of new knowledge, or publication of unsuccessful 
approaches. 
This project contributes to collaborative research efforts to assess the feasibility of 
genetic pest control tools in vertebrate species. The outputs of this work will play a 
key role in this growing pool of knowledge and many within this collaborative 
research community are eagerly awaiting the results from this project. We will 
disseminate outputs through the research community via personal communication, 
invited talks, workshops, conference presentations and scientific publication. Outputs 
will be disseminated through mainstream media channels to encourage public and 
political discussion on the potential use of genetic pest control approaches. 
___________________________________________________________________ 
Anticipated harms 
Explain why you are using these types of animals and your choice of life 
stages. 
The mouse is the preferred mammalian model for genetic research. Mice are cost 
effective because they are relatively cheap and easy to look care for. The mouse 
also benefits from a fast generation interval and is small in size, so convenient to 
house. It is relatively easy to manipulate the mouse genome compared to other 
mammalian species and this is why it is the preferred animal to study gene drive 
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As gene drives transmit through sexual reproduction, the mice used in this project 
will be sexually mature adults 
 
___________________________________________________________________ 
Typically, what will be done to an animal used in your project? 
For example, injections and surgical procedures. Include any relevant information about the 
duration of experiments and the number of procedures. 
The gene drive mice used in this project will be mated to generate 16 litters of pups. 
Within those litters, the percentage of offspring that inherit the gene drive will be 
quantified. Once the female offspring reach sexual maturity, we will check the fertility 





What are the expected impacts and/or adverse effects for the animals during 
your project? 
Examples can include pain, weight loss, tumours, or abnormal behaviour. State the estimated 
duration of these effects on an animal. 
This study is expected to have no impact or adverse effects on animal health other 
than infertility of the female offspring that inherit the split gene-drive system. 
___________________________________________________________________ 
What are the expected severities and the proportion of animals in each 
category (per animal type)? 
Infertility of some female offspring is expected to be of mild severity. Loss of 
pregnancy will occur shortly after conception, at the 2-cell embryo stage. We 
anticipate no other impact from this study on animal health or wellbeing. 
___________________________________________________________________ 
Fate of animals 
Will any animals not be killed at the end of this project? 
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Why do you need to use animals to achieve the aim of your project? 
Gene drives transmit through sexually reproduction, therefore, the only way to 
investigate the potential of the safeguarded split gene drives in this project is in 
sexually mature animals. This project will use the mouse to study the potential of 
gene drive in mammalian animals. 
___________________________________________________________________ 
Which non-animal alternatives did you consider for use in this project? 
No non-animal systems were considered, as gene drives transmit through sexual 
reproduction the assessment of these genetic systems is only possible in animal 
systems. 
___________________________________________________________________ 
Why were they not suitable? 
Gene drives can't be tested in non-animal alternatives as they transmit through 
sexual reproduction. At present, there are no non-animal systems for studying the 




Enter the estimated number of animals of each type used in this project. 
Mice: 128 
___________________________________________________________________ 
How have you estimated the numbers of animals you will use? 
For example, you may have made some power calculations or carried out some statistical 
modelling. 
The only previously reported study on gene drive in mice used a significant different 
genetic strategy and, therefore, we can not predict the efficiency of the split gene-
drive approach in this study based on their findings. The previous study reported up 
to 5 successful born litters for the gene drive systems tested. 
This proof-of-concept study aims to generate 8 litters of pups for each of the two 
gene drive systems tested.  
If we estimate an average litter size of 6 pups, we will generate a total of 96 pups 
whilst screening offspring. To generate these litters, the project will require 
approximately 8 split gene-drive breeding males (4 of each genetic system) and the 
16 wild type female breeding partners. An additional 8 males will be required to 
confirm the fertile status of the split gene-drive female offspring once they reach 
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___________________________________________________________________ 
What steps did you take during the experimental design phase to reduce the 
number of animals being used in this project? 
Include advice taken from local statisticians, online tools (such as the NC3Rs' Experimental 
Design Assistant), or regulatory requirements. 
As this is a proof-of-concept study we have knowing underpowered the project to 
reduce animal numbers. For a gene drive to be successful as a pest management 
tool it will be required to propagate at a rate much greater than 50% (at least 75% 
based on our computer simulations). We expect to see this effect in the selected 
sample size. If successful in this initial underpowered study, we will look to undertake 
additional study to statistically validate the most efficient of the best performing split 
gene-drive system being tested in this initial project. 
___________________________________________________________________ 
What measures, apart from good experimental design, will you use to optimise 
the number of animals you plan to use in your project. 
This may include efficient breeding, pilot studies, computer modelling, or sharing of tissue. 
This is a proof-of-concept (pilot) study. We have chosen to perform an initial small-
scale study before considering a larger-scale study that would offer statistical 




Which animal models and methods will you use during this project? 
Explain why these models and methods cause the least pain, suffering, distress, or lasting 
harm to the animals. 
This project will breed and maintain lines of genetically altered mice. Breeding of 
animals is a natural behaviour and this is anticipated to have no negative impact of 
animal health or wellbeing.  Females may inherit a female infertility trait, which is 
expected to have minimal impact of animal wellbeing as loss of pregnancy will occur 
very shortly after conception. 
___________________________________________________________________ 
Why can’t you use animals that are less sentient? 
For example, animals at a more immature life stage, species that are less sentient, or animals 
that have been terminally anaesthetised? 
This project examines the potential of gene drive technology in mammalian pest 
species. The is the most accessible, genetically sophisticated and cost-effective 
mammalian model. As gene drives propagate through sexual reproduction it is 
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How will you stay informed about advances in the 3Rs, and implement these 
advances effectively, during the project? 
The Roslin Institute is located within the The Easter Bush Campus, which hosts the 
largest concentration of animal science and animal welfare related expertise 
anywhere in Europe. The Easter Bush Campus and researchers involved in this 
project are active participants in 3Rs research and stay informed on the latest 
advances through scientific publications, social media channels and discussion 
amongst colleagues and peers. The Roslin Institute is a state-of-the-art facility with 
the expertise to implement advances in the 3Rs as they evolve. 
___________________________________________________________________ 
How will you refine the procedures you're using to minimise the welfare costs 
(harms) for the animals? 
Potential refinements include increased monitoring, post-operative care, pain management, 
and training of animals. 
We anticipate minimal animal suffering during this project. Animals are checked 
regularly checked (typically daily) and any animal identified to be suffering at a level 
greater than anticipated will be managed accordingly by experienced staff. 
___________________________________________________________________ 
What published best practice guidance will you follow to ensure experiments 
are conducted in the most refined way? 
We will design and carry out our experiments in accordance with the PREPARE and 
the ARRIVE guidelines. If required, we will consult the Experimental Design 












A.12 ddPCR quality control data 
Figure A.12.1 Quality control for ddPCR calls in genome edited cell lines. Each plot represents an overlay of all samples 






























A.13 Publication: On-farm genome editing of livestock  
The following pages contain a paper I co-authored during my PhD project and has been 







McFarlane et al. On-Farm Livestock Genome Editing
and introduce polymorphisms that are not present in the
gene pool of elite brood stock, or even create novel changes
predicted to result in improved gain (Laible et al., 2014). This
powerful technology allows animal breeders to specifically and
e!ciently alter an animal’s DNA. Precise genetic alterations to
remove deleterious mutations, such as recessive lethal genetic
variants, or introduce desirable traits, such as hornlessness, heat
tolerance and disease resistance; without a"ecting other genetic
characteristics of their herd (Davis et al., 2017; Mueller et al.,
2019; Proudfoot et al., 2019).
The genome editor toolbox currently contains variants
of ZFNs, TALENs and CRISPR-Cas, and these have been
successfully used in livestock species such as pigs, cattle,
sheep, goats, and chickens (Tait-Burkard et al., 2019). These
genome editors all work on the principle of introducing double
strand DNA breaks (DSBs) at a user-defined target site in the
genome, stimulating endogenous cellular DNA repair pathways
to make modifications. DSBs will most frequently be repaired
by non-homologous end joining (NHEJ), which is error prone
and can result in the introduction of nucleotide insertions
or deletions. However, if a homologous DNA repair template
(HDRT) is provided, then the repair can then occur via the
homology-directed repair (HDR) pathway. In this manner, DNA
sequences can be precisely modified or introduced into the
genome (Fernandez et al., 2017).
Of the genome editing tools currently available, CRISPR-Cas
has quickly become the “go to” technology due to its ease-of-use,
high e!ciency and low cost. Since it’s repurposing into a genome
editor in 2012, there has been a flurry of research activity around
the technology and an ever expanding toolbox of CRISPR-Cas
reagents, including base-editors and nickase systems, which can
drive editing without the need for introducing DSBs (Pickar-
Oliver and Gersbach, 2019). Due to the simplicity and range of
CRISPR-Cas tools now available, it is foreseeable that a significant
number of genome edited livestock will be produced over the
next decade. Within this article, we describe livestock genome
editing strategies based on CRISPR-Cas, although ZFNs and
TALENs could also achieve the same results.
A precondition for applying CRISPR-Cas in livestock
are reproductive technologies that enable e!cient delivery
of CRISPR-Cas reagents into zygotes or reproductive
cells. Although genome editors have rapidly developed,
the reproductive technologies for delivering CRISPR-Cas
remain complex and ine!cient at a large scale. Somatic cell
nuclear transfer (SCNT) and zygote microinjection are the
conventional techniques. Both are technically challenging,
costly, labor-intensive, and require expert skills with bulky
micromanipulation equipment; restricting their use to a small
number of specialized laboratories (Sheets et al., 2016).
New reproductive technologies that simplify the delivery
of CRISPR-Cas reagents into livestock reproductive cells
are needed to disseminate the benefits of genome editing
beyond research institutes and corporate biotechnology
enterprises. The emergence of three cutting-edge reproductive
technologies—(i) zygote electroporation, (ii) zygote
transduction with recombinant adeno-associated virus
(rAAV), and (iii) surrogate sire technology (SST)—will
provide animal breeders with a new toolkit for delivering
CRISPR-Cas to reproductive cells. The simplicity of
these approaches will allow livestock genome editing to
occur on-farm.
We believe it is timely to highlight these three cutting-
edge reproductive technologies and have outlined pipelines for
their implementation in on-farm settings. It is hoped these
cutting-edge reproductive technologies will disperse the capacity
to genome edit farm animals, fast-tracking genetic gains and
helping to secure a sustainable future for livestock agriculture.
ZYGOTE ELECTROPORATION
Zygote electroporation is a recently developed method that
overcomes many of the shortcomings of conventional SCNT
and microinjection delivery approaches. This technique
allows direct introduction of genome editing tools into
zygotes by application of voltage to zygotes suspended in
a medium containing CRISPR-Cas reagents. The pulses of
electricity cause pores to form in the zygote membrane,
allowing the genome editing tools in the suspension to
pass through the pores in the zygote membrane and into
the nucleus where CRISPR-Cas can begin genome editing
activity (Miao et al., 2019).
Electroporation is a well-established method for introducing
reagents into mammalian cells but has only recently been
refined for application to zygotes. Initial e"orts required the
enzymatic removal of the zona pellucida, a protective membrane
surrounding the zygote. However, the removal of the zona
pellucida makes zygotes sticky and di!cult to work with, which
restricted adoption of zygote electroporation. Optimization of
the technique now makes it possible to introduce CRISPR-Cas
into zona-intact zygotes, making it significantly more attractive
to users.
Several livestock genome editing facilities have now employed
zona-intact zygote electroporation to successfully edit the
genomes of pigs and cattle (Laible, 2018; Miao et al., 2019;
Namula et al., 2019). The simplicity of this approach allows for
zygote electroporation to be incorporated into on-farm embryo
transfer (ET) programs, which are increasingly common in
commercial livestock farming.
In on-farm settings, we foresee a pipeline where donor females
are super-ovulated and oocytes collected for in vitro fertilization -
as per a conventional ET program. After fertilization, the zygotes
undergo electroporation to introduce CRISPR-Cas reagents. The
genome edited embryos are then matured in vitro and the editing
of each zygote is confirmed by portable biopsy sequencing.
Validated embryos are then transferred into recipient females to
give birth to genetically superior animals (Figure 1).
Equipment, expertise, throughput and e!ciency inhibits
SCNT or zygote microinjection from being routinely
applied on-farm. One of the key benefits of electroporation
is that CRISPR-Cas reagents and HDRTs can be designed
on a basic computer, ordered online and supplied ready-
to-use in a short time frame. Compared to conventional
microinjection-based approaches, electroporation is compatible
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FIGURE 1 | On-farm genome editing by zygote electroporation or zygote transduction of recombinant adeno-associated viruses (rAAV). Oocytes are collected from
donor females using ovum pick up. Collected oocytes are matured and fertilized in vitro. Validated genome editing reagents are introduced into the zygote using
electroporation or transduction. Embryos are cultured in vitro to blastocyst stage. A biopsy is taken from each blastocyst, DNA is extracted and sequenced on-farm
using a portable DNA sequencer. Embryos with the desired edits are transferred into recipient females, who give birth to genome edited offspring. Animals with
confirmed genotypes are added into the breeding program to disseminate their superior genetics.
with high throughput, potentially editing hundreds of
zygotes simultaneously with reduced physical damage and
improved embryo survival rates. The portable equipment
and minimum training requirements would allow zygote
electroporation to be integrated into established ET programs
with little disruption.
Although electroporation has many benefits over SCNT and
zygote microinjection, there are still several limitations (Laible,
2018). Primarily, only short HDRTs have been successfully used
in zygote electroporation. This limits the genetic alterations
to <1 kb in length. Secondly, like zygote microinjection,
electroporation can be associated with mosaicism in the
genome edited o!spring. This occurs when the genome
editing does not occur prior to the first zygotic cleavage
but when the embryo has progressed to the 2 cell stage
or beyond. Optimization of the timing of genome editor
delivery following fertilization will likely result in a reduction
in the frequency of mosaic o!spring. Although mosaicism is
undesirable, it is not a major concern as it can be bred out in a
single generation.









Due to its non-pathogenic nature, rAAVs can be used as
vehicles to deliver CRISPR-Cas and HDRTs. This strategy has
proven e!ective in editing the genome of mice zygotes but
like electroporation it has been used on other mammalian cell
types for many years (Kaulich and Dowdy, 2015). To generate
genome edited livestock using rAAV, oocytes are collected from
donor mothers and fertilized. The fertilized zygotes are then
bathed in a solution containing rAAVs that enter the zygote and
drive genome editing by expressing CRISPR-Cas and providing
HDRT. Once validated by biopsy sequencing, edited embryos are
then transferred to recipient females to develop into genetically
superior livestock (Figure 1).
Many of the benefits of rAAV transduction are similar
to zygote electroporation when compared to SCNT and
microinjection. Transduction with rAAV does not require
physical damage to the zygotes which significantly improves
embryo survival rates. The technique increases throughput and
does not require any additional equipment or skills within
on-farm ET programs. Furthermore, as rAAV is non-pathogenic,
it can be handled safely at biosafety level 1, making it suitable for
most on-farm settings.
Although this approach is yet to be applied to livestock,
in mice, rAAV has been applied to zona-intact zygotes to
successfully generate genome edited pups. It has very high
embryo survival rates with editing in up to 100% of o!spring
(Yoon et al., 2018). One rAAV vector can comfortably
accommodate a 3.25 kb HDRT, and even larger DNA sequences
could be integrated if multiple rAAV vectors are designed to
sequentially integrate HDRTs (Bak and Porteus, 2017). No other
technique exhibits such simplicity for precise integration of large
DNA sequences, and this is likely where rAAV transduction will
be of most value in livestock genome editing.
The single stranded DNA genome of rAAV integrates into
non-homologous host genomic sites at very low frequencies
(!0.1%). rAAV is also quickly diluted as the cells undergoes
multiple rounds of division, making it ideally suited for
manipulating the genome of zygotes (Yoon et al., 2018).
However, like most genome editing delivery approaches,
mosaicism has been observed in rAAV genome edited mice. We
expect optimization of embryo collection and the timing of rAAV
transduction will reduce the frequency of mosaicism in rAAV
edited o!spring.
Customized rAAV vectors can be ordered from commercial
suppliers as ready-to-use reagents (Sandoval et al., 2019). The
design does require knowledge of viral genetics and is time-
consuming, however online tools are available to assist and
standardized rAAV kits could be developed for specific breeds
and traits. Genome editing zygotes by rAAV transduction would
not require the purchase of any additional equipment over a
standard ET program and adding rAAV to zygotes in culture is a
relatively straightforward procedure. The low cost and skill-level
required by operators could see this technology widely adopted
in on-farm settings in the near future.
SURROGATE SIRE TECHNOLOGY
Surrogate sire technology (SST) describes the creation of male
animals lacking endemic germline stem cells, and therefore
their ability to produce mature sperm. Spermatogonial stem
cells (SSCs) from a donor male can then be transplanted
into recipient testes of a surrogate sire, providing a source of
self-propagating stem cells which can produce mature sperm
containing the genetic information of the donor (Giasetti et al.,
2019). The recipientmale can then disseminate the genetics of the
donor by natural breeding, operating as an ambulatory artificial
insemination system.
Commercial application of SST relies on a supply of males
lacking their own germline stem cells. To achieve this, researchers
have generated male mice and pigs lacking a functional copy
of NANOS2, a highly-conserved mammalian gene that plays an
essential role in the maintenance of SSCs (Park et al., 2017).
The resulting animals are physiologically healthy, displaying
no abnormal phenotypes other than a complete lack of native
SSCs. The transplantation of donor SSCs into the otherwise
physiologically normal testicular environment of these animals
leads to the establishment of the donor cell SSC population
and eventually to the production of donor-derived sperm.
Researchers are now working to establish NANOS2 knockout
cattle, sheep and goats.
To integrate genome editing into established SST procedures,
CRISPR-Cas and HDRTs can be delivered whilst donor SSCs are
expanded during ex vivo cell culturing. CRISPR-Cas has been
used to successfully edit the genome of mouse SSCs during ex
vivo cell culture. The edited mouse SSCs were then transplanted
into the testes of recipient males and lead to the generation
of o!spring harboring the edited donor genetics (Wang et al.,
2017). These findings suggest the same will be achievable for
mammalian livestock species, enabling the dissemination of
genome-edited livestock genetics through surrogate sires.
Genome editing with SST would be particularly valuable
for disseminating beneficial traits through expansive ranch-style
operations or in developing regions where other genome editing
approaches are limited by equipment and expertise availability
or the scale of the operation. For on-farm settings, a vet could
collect a needle testicular biopsy from a donor animal and
ship the sample to a laboratory. SSCs would be expanded from
the biopsy, with the desired genome edits introduced during
the cell culture process. The cells would then be transplanted
into juvenile sire recipients, and delivered to the farmer for
integration into their breeding operation (Figure 2). With this
genome editing pipeline, SST keeps on-farm equipment and
expertise requirements to a minimum and empowers the farmer
to maintain their own herd blood lines whilst benefiting from
the technology.
In regions such as Africa and South America, robust bulls
of indigenous breeds could be used as surrogate sires to carry
elite genome edited semen. Within the pig industry, SST boars
could rapidly disseminate advantageous genome edited traits.
This technology allows livestock breeders to achieve breeding
objectives in less time. Using genomic prediction tools, elite SSCs
from sexually immature males could be obtained, genome edited
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FIGURE 2 | Genome editing with surrogate sire technology (SST). A spermatogonial stem cell (SSC) sample is collected on-farm by needle testicular biopsy from a
donor male with suitable genetic merit. SSC sample is shipped to a laboratory that cultures and expands the cells in vitro. Genome editing tools are added into SSCs
in culture to introduce trait/s of interest. Gene edited SSCs are validated and transplanted into the testis of germline ablated recipient male. SSC colonization of the
testis and fertility of recipient male is confirmed before delivering surrogate sires to the farmer. Surrogate sires are then introduced into the breeding program to
disseminate the superior germline genetics.
and transplanted into maturing germline ablated recipients
within months. Instead of waiting until breeding maturity for
each animal, generation intervals could be skipped, accelerating
the rate of genetic gain.
RISKS ASSOCIATED WITH UNINTENDED
OR OFF-TARGET EDITING
Until recently, genome editing approaches in livestock were
commonly performed using an editor to introduce a DSB at
the target site, with a double-stranded DNA (dsDNA) molecule,
typically a plasmid, supplied as a repair template. Although this
approach has seen success, it is not uncommon for the plasmid
repair template to insert elsewhere in the genome. This issue was
recently highlighted when the US Food and Drug Administration
(FDA) found additional plasmid sequence proximal to the target
site in genome edited hornless bulls (Norris et al., 2019). There
are straightforward methods available to screen for unintended
repair template integration and once identified the unwanted
integration can be bred out using standard breeding strategies.
This was the approach taken with the genome edited hornless
bulls (Young et al., 2019). Most livestock genome editing e!orts
have now transitioned to using single stranded DNA (ssDNA)
repair templates, which have a significantly reduced frequency of
unintended genomic integration. Despite the reduced risks with
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ssDNA repair templates, comprehensive screening of founder
livestock is important to maintain public and political trust in
the technology.
O!-target editing occurs when a genome editor cuts at an
unplanned site in the genome. It was a significant concern
with early genome editing experiments as the impact of
o!-target e!ects remained contentious. However, the latest
genome editing technologies have improved and quantified
specificity, reducing o!-target e!ects, and concerns. The goal
of improving CRISPR-Cas reagents and increasing genome
editing specificity has been primarily driven through biomedical
research looking to apply genome editing to treat or cure
human disease. The work done in the biomedical arena has
significantly expanded the toolkit of CRISPR-Cas reagents
available, which now includes base editors that can edit single
nucleotides in the genome without the need to induce DSBs
(Eid et al., 2018). Although current CRISPR-Cas reagents are
adequate for on-farm application, further improvements in the
specificity and e"ciency of CRISPR-Cas will deliver reagents
that carry a risk of o!-target e!ect substantially lower than
the frequency of spontaneous mutations naturally occurring in
animal genomes.
REGULATIONS
The science is clear: genome editing could improve animal
welfare and performance while reducing the environmental
footprint of livestock production. Furthermore, dietary
DNA is generally regarded as safe to consume, as naturally
occurring DNA variations are a routine ingredient in the
food products we consume. What remains unclear is the
regulatory pathway to bring genome edited animal-derived
foods to market (Zhou et al., 2019). Currently, regulations vary
substantially between geo-political regions. Harmonizing the
regulations associated with genome editing in food species
is imperative to allow livestock farmers access to genome
editing tools that could increase global food security in a
sustainable manner.
Genome editing provides an opportunity to align the interests
of producers and consumers. Despite the foreseeable benefits, the
EU applies an inhibitory regulatory framework on genome edited
foods and the US currently mandates premarket new animal drug
regulatory evaluation for all genome edited food animals (Van
Eenennaam et al., 2019). Although the EU and the US have an
oversupply of food, the prohibitive regulatory frameworks they
currently implement may have detrimental knock-on e!ects in
developing countries who stand to benefit the most from genome
editing technology.
As the tide of public acknowledgment to the benefits and
safety of genome editing appears to be turning, the technology
will continue to gain media attention and public debate. In the
US and EU there are movements from within government and
the scientific community to modernize regulatory frameworks.
In the US, President Trump recently signed an “Executive Order
on Modernizing the Regulatory Framework for Agricultural
Biotechnology Products,” while in the EU a report by the
European Academies’ Science Advisory Council on “Genome
Editing: Scientific opportunities, public interests, and policy
options in the EU” was delivered to the European Parliament
and European Commission to prompt a rethink of EU’s stance
on genome edited foods.
Outside of the EU and US, countries such as Japan, Argentina,
Brazil, Canada, and Australia have to varying extents deregulated
genome editing of livestock. These proactive countries are
likely to gain a competitive advantage and leave other non-
subscribing nations scrambling to prevent genome edited
foods entering their supply chain. Unlike previous transgenic
technologies, the genetic alteration in genome edited foods
are often “scarless,” in that they contain no foreign DNA.
Without any plausible methodology for discriminating “naturally
occurring” from intentionally edited DNA variations, regulators
will have di"culty enforcing importation restrictions on genome
edited foods.
CONCLUDING REMARKS
The amalgamation of genome editing and cutting-edge
reproductive technologies o!ers a powerful tool for improving
the livestock breeding landscape. Success in creating precise
and heritable germline edits in diverse livestock species for
a plethora of traits has demonstrated the potential benefits
of this technology. However, to spread the beneficial impacts
across economies, geographic regions and societies, strategies of
translating established genome editing protocols into livestock
breeding systems are necessary. Zygote electroporation and
rAAV transduction of genome-editing reagents evades the
associated, costs, labor, and facilities required by traditional
methods. SST converged with genome editing could o!er a
commercially valuable tool to farmers with natural breeding
programs. This array of cutting-edge reproductive technologies
makes it technically plausible to apply genome editing in on-farm
settings to rapidly improve productivity, fertility, sustainability,
and animal welfare with minimal infrastructure and moderate
fiscal inputs. The key to unlocking these benefits now lays in the
hands of regulators.
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